Compositions and methods related to profiling a plurality of cells based on peptide binding

ABSTRACT

Methods and compositions are described for classifying cells and/or peptides that associate or bind with a particular characteristic pattern to a plurality of cells or cell lines. Aspects of the invention also include the use of peptide(s) having an appropriate binding characteristic to deliver a drug to a cell or cell population.

The present application is a divisional of co-pending U.S. application Ser. No. 12/826,327, filed Jun. 29, 2010, which is a continuation of U.S. application Ser. No. 11/684,379, filed Mar. 9, 2007, which claims the benfit of U.S. Provisional Patent Application No. 60/780,893, filed Mar. 9, 2006, the entire contents of each of which are incorporated herein by reference in their entirety.

This invention was made with government support under grant number DAMD17-03-1-0638 awarded by the Department of Defense, and grant number CA103056 awarded by the National Institutes of Health. The government has certain rights in the invention.

TECHNICAL FIELD

The present invention is directed generally to method and compositions related to molecular biology, virology, and oncology. In certain aspects it is directed to compositions comprising and methods of profiling and/or classifying a plurality of cells or cell lines based on peptide binding characteristics.

BRIEF SUMMARY OF THE INVENTION

An embodiment of the invention includes methods of profiling cell lines and/or identifying peptide sequences or structures that bind a target population or family of cells. The methods include providing a plurality of cell lines; contacting each cell line with a library of phage displaying random heterologous peptides on their surface; obtaining phage that bind each of the cell lines; identifying peptides that bind each cell line; and classifying each cell line based on the identified peptides. The method can further comprise classifying each identified peptide based on the cell lines that bind each identified peptide. In one aspect, the cell lines include cancer cell lines. Cancer cell lines may include, but are not limited to kidney, breast, colon, lung, prostate, brain, liver, pancreatic, uterine, neuronal, skin, head and neck, leukemic, lymphocytic, or ovarian cancer cell lines. In another aspect, the panel is cancer cell lines. In a particular aspect, the panel is a NCI 60 panel of cancer cell lines. The methods further include identifying a peptide that binds to a majority of the cancer cell lines or cancer cells of common origin. Furthermore, methods can also include analyzing the identified peptides to identify similarities with known receptor ligands.

In certain aspects, classifying the cell line is performed by clustering analysis. Clustering analysis can be used to construct a clustered image map (CIM). In a particular aspect, classifying the identified peptide is performed by clustering analysis. Clustering analysis can be used to construct a clustered image map. In another aspect, the methods may also include identifying receptors for at least one of the identified peptides comprising the steps of providing an identified peptide; labeling the identified peptide; contacting an appropriate cell line with the labeled peptide; isolating a receptor-peptide complex; and identifying the receptor bound to the labeled peptide.

In another embodiment, a group of peptides comprising five or more peptides can be classified or identified as selectively bind to a sub-population of cell lines, wherein the peptides include, but are not limited to those listed in Table 3 and described herein. In certain aspects, a sub sequence of the peptide may be identified as conferring to the peptide a certain binding characteristic.

In still further embodiments, methods of the invention can be used to classify a cell or cell line. Methods of classifying a cell line include, but are not limited to steps comprising: contacting a cell with a group of selected peptides or polypeptides that differentially bind cells of a known origin; detecting the peptides that bind the cell line; and assessing the classification of the cell line based on the peptide(s) that bind the cell line. Thus, in certain aspects, classifying a cell may comprise determining whether as cell expresses a certain receptor polypeptide, is susceptible to a particular therapy or determining the tissue of origin for the cell. In certain aspects of the invention, a group of selected peptide for use according to the invention are further defined as cyclic or partially peptides, such as peptides comprising a disulfide bond. In certain cases, a group of selected peptides or polypeptides may comprise at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30 or more distinct peptides or polypeptides.

Thus, in a further specific embodiment there is provided a method for classifying a cell comprising obtaining or having a sample comprising a cell; contacting the cell with a group of peptides or polypeptides that differentially bind cells of a known origin or type; detecting the peptides that bind to the cell and classifying the cell based on the peptide binding. As described supra, in certain aspects, a group of selected peptides or polypeptides comprise amino acid sequences selected from those provided in Table 3. Thus, in certain cases a group of selected peptides or polypeptides comprise 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30 or more members that comprising an amino acid sequence according to Table 3. The skilled artisan will recognize that selected peptide or polypeptides of the invention may in some aspects be labeled for example with an enzyme, a fluorophor or a radio isotope.

In some aspects, a selected peptide or polypeptide may be a cyclic or partially polypeptide such as a peptide or polypeptide comprising a disulfide bond. In some preffered aspects, the cyclic region of a peptide or polypeptide comprises 5, 6, 7, 8, 9, 10 or more amino acids. For example, in certain aspects, a selected peptide or polypeptide comprises an amino acid sequence provided in Table 3 wherein the given amino acid sequence is comprised in the cyclic region of the polypeptide. Thus, it is contemplated that a selected peptide or polypeptide may comprise an amino acid sequence of Table 3 wherein the sequence is flanked by cysteine residues such that the cysteine residues may be linked by a disulfide bond.

In some aspects of the invention a method for classifying a cell according to the invention may comprise comparing the binding profile of a group of selected peptides or polypeptides to a cell to a similar binding profile from a cell with a known classification. Such a comparison may be performed directly or may performed by consulting a chart or database of binding profiles. For example, a chart or database of binding profiles may comprise binding profiles from cells of 5, 10, 15, 20, 25 or more different classifications. In certain aspects, a chart or database of binding profiles may comprise clustering analysis of the binding of selected peptides or polypeptide to cells of different classification. Thus, in some cases a chart or database of binding profiles may comprise a clustered image map (CIM). Thus, classifying a cell may be performed by for example clustering analysis.

In still further aspects of the invention there is provided a method for treating a subject comprising obtaining or having a sample from the subject comprising a cell; classifying the cell (e.g., by the methods described supra); and treating the subject with a therapeutic based upon the classification of the cell. For example, in some cases a subject may be defined as a cancer patient. In this case a cancer cell from the subject may be classified. Classification of the cell may for example comprising determining the tissue of origin, receptor status or susceptibility of the cell to particular anticancer therapy. Thus, based upon the classification of the cell the subject may be treated with an appropriate anticancer therapy. For example, methods of the invention may be used to classify a cell as susceptible or resistant to radiation therapy, immunotherapy, surgical therapy or chemotherapy. Furthermore, methods of the invention may be used to classify the cell as susceptible or resistant to a particular chemotherapeutic agent or class of chemotherapeutic agents. Thus, methods of the invention may involve classifying a cancer cell from a subject as susceptible or resistant to an anticancer therapy and treating the subject with one or more anticancer therapies that the cell is susceptible to.

In certain aspects the invention concerns obtaining or having a sample such as a cell. It is contemplated that in cases where a sample is from a subject the sample may be directly obtained or may be obtained by a third party and subsequently subjected to methods described herein. Furthermore, in certain aspects it is contemplated that methods of the invention may be defined as a method for aiding in the therapy of a subject comprising classify a cell from the subject (e.g., as having certain protein receptor expression or being from a tissue of a particular origin) and providing the classification information to a third party such as a medical professional to aid in the therapy of the subject.

In yet another embodiment of the invention includes a method of classifying a peptide(s). Methods of peptide classification include, but are not limited to steps comprising: contacting a plurality of cell lines with a library of peptides that differentially bind the cells; detecting the peptides that bind the cell line; and classifying the peptides based on the cells that bind the peptide.

In certain aspects an EphA5 receptor can be targeted by using a composition comprising a peptide sequence of CSGIGSGGC (SEQ ID NO:2) or CRFESSGGC (SEQ ID NO:3). The skilled artisan will further recognize that in certain aspects a peptide targeting sequence of the invention is cyclic. Thus, there is provided EphA5 receptor targeting composition comprising a cyclic polypeptide wherein the cyclic polypeptide comprises the amino acid sequence SGIGSGG (SEQ ID NO:4) or RFESSGG (SEQ ID NO:5). As exemplified herein in certain aspects an cyclic EphA5 targeting composition may comprise a peptide sequence according to SEQ ID NO:4 or SEQ ID NO:5 flanked by cysteine residues thereby forming a cyclic targeting agent via disulfide bonds between the cysteine residues. As used herein the termed flanked means that the indicated amino acid sequence are between two cysteine residues however it is contemplated that in some cases additional amino acids may also be comprised between the two cysteine residues.

A composition of the invention can be coupled (either non-covalently or covalently, or indirectly via an intermediate such as a liposome or directly) to a therapeutic or imaging agent. The therapeutic can include, but is not limited to a small molecule, a drug, or a therapeutic peptide. For example, in certain aspects, a therapeutic composition of the invention comprises a polypeptide. In these aspects the therapeutic Eph5A receptor targeting composition may comprise a fusion protein. Thus, in some very specific cases the therapeutic polypeptide may be a toxin or other cytotoxic molecule capable of inducing cell death in Eph5A receptor expressing cells. Imaging agents for use in the invention include but are not limited to MRI contrast agents, radio isotopes, fluorophors and mass tags (e.g., for detection via mass spectrometry).

In certain aspects there is provided an EphA5 receptor agonist comprising the amino acid sequence SGIGSGG (SEQ ID NO:4) or RFESSGG (SEQ ID NO:5). As described above in some cases the EphA5 receptor agonist is a cyclic peptide or polypeptide wherein the cyclic region comprises the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:5. Thus, in some case the agonist is a cyclic peptide or polypeptide comprising a disulfide bond such as a peptide or polypeptide wherein the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:5 are flanked by cysteine residues (e.g., as in SEQ ID NO:2 or SEQ ID NO:3).

Thus, in still further aspects of the invention there is provided a method for treating an Eph5A receptor positive cell comprising administering to the cell an EphA5 receptor targeting therapeutic as described supra. Thus, in some aspects a method of the invention may be further defined as a methods for treating a subject comprising an EphA5 receptor positive cell by administering an effective amount of an EphA5 receptor targeting therapeutic. For example, in certain cases a subject may be a cancer patient comprising an EphA5 receptor positive positive cancer such as a lung cancer or neuronal cancer. In still further aspects there is provided a method for treating a subject with a an EphA5 receptor positive cancer by administering an EphA5 receptor targeting therapeutic wherein the therapeutic comprising a cytotoxic agent or an anticancer agent.

The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”

The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternative are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.”

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

For a more complete understanding of the present invention, reference is now made to the following descriptions taken in conjunction with the accompanying drawing, in which:

FIG. 1: Selectivity of broad-specificity tripeptides for clusters of NCI-60 cell lines. Two-dimensional hierarchical clustering was applied to the frequencies of 38 tripeptides (rows) encountered in CX₇C peptides selected on NCI-60 cell lines (columns). Tripeptides selected on all but one cell line of common origin were clustered based on their correlations with cell lines; cell lines were clustered based on their correlations with the tripeptides. Tripeptide frequencies were mean subtracted and average linkage clustered with correlation metric. Amino acid color code: red, hydrophobic; green, neutral and polar; purple, basic. The color in each CIM segment ranges from blue (negative correlation) to red (positive correlation), as indicated by the scale bar. Cell lines are color-coded based on previously defined histologic tumor origin (Monks et al., 1991, Weinstein et al., 1997. Bars underneath dendrogram, clusters of cells of similar tumor tissue origin (one exception allowed). Boxed, cluster of lung cancer-derived cell lines and associated/dissociated tripeptides.

FIGS. 2A-B: Identification of peptides mimicking EGFR ligands. FIG. 2A, EGFR-binding peptide sequences isolated from the SKOV-3 selected phage pool were matched in each orientation to protein sequences of biological human EGFR ligands (leader peptide sequence underlined). Matches displayed are peptides with three or more amino acids being identical (red) and one or more being from the same class (green) as the correspondingly positioned protein amino acids. Tripeptides listed in Table 1 (yellow). FIG. 2B, isolation of peptides targeting EGFR. Binding of SKOV3-selected phage pool to immobilized EGFR compared with BSA in rounds 1 and 2 of biopanning of SKOV3-selected phage pool on immobilized human EGFR.

FIGS. 3A-3B: Phage selection on immobilized EphA5 receptor. FIG. 3A, Ephrin-mimic phage displaying the enriched motif GGS were selected on EphA5-coated microtiter wells. Phage showing specific binding to EphA5 was analyzed for its distinctive binding to EphA5 compared to EphA4 receptor (FIG. 3B). BSA and fd-tet insertless phage were used as negative controls.

FIG. 4: EphA5 receptor expression in the NCI-60. From microarray analysis reported at dtp.nci.nih.gov/mtweb/servlet/moltidsearch?moltid=MT894.

FIG. 5: EphA5 and EphA4 receptor expression by the lung cancer cell lines Hop92 and H460. The OVCAR3 cell line was used as negative control. 10× magnification.

FIG. 6: Specific binding of the CSGIGSGGC (SEQ ID NO:2) and CRFESSGGC (SEQ ID NO:3)-phage to lung cancer cells Hop92 and H460 but not to the ovarian cancer cell line OVCAR-3. Insertless phage (fd-tet) was used as negative control.

FIGS. 7A-B: A. Clustered image map relating all isolated NCI-60-binding tripeptides to NCI-60 cell lines. FIG. 7A, Two-dimensional hierarchical clustering was applied to the frequencies of 3,280 unique tripeptides (rows) found in cell-binding CX7C peptides selected on the NCI-60 cells (columns). Tripeptides were clustered based on their correlations with cell lines; cell lines were clustered based on their correlations with tripeptides. Tripeptide frequencies were mean-subtracted and average-linkage clustered with correlation metric (the data were transformed to the mean of 0; variance of 1). The color in each CIM segment ranges from blue (high negative correlation) to red (high positive correlation), as indicated by the scale bar. Cell lines are color-coded based on previously defined histological tumor origin. FIG. 7B, A control two-dimensional hierarchical clustering applied under the Poisson assumption to 3,280 randomly simulated tripeptide frequencies (rows) showed no obvious pattern, thus indicating that clusters in A were not generated at random.

FIG. 8: Targeted peptides mediate ligand-receptor cell internalization. CSGIGSGGC (SEQ ID NO:2) and CRFESSGGC (SEQ ID NO:3)-phage were permeabilized into A549 cells. No internalization was observed when cells were incubated with insertless phage

FIG. 9A-B: Biological effects of the peptides CSGIGSGGC (SEQ ID NO:2) and CRFESSGGC (SEQ ID NO:3 on lung cancer cells. Promotion of cell survivial and proliferative response of starved lung cancer cells to the ephrin mimic peptides, control peptide and complete culture medium (A549 (FIG. 9A), H460 cells (FIG. 9B)). Concentrations of peptide were optimized. Values in the Y-axis correspond to the number of viable cells under each experimental condition evaluated after a 72 h incubation period. Data bars represent the mean and corresponding standard error of the mean.

DETAILED DESCRIPTION OF THE INVENTION

A collection of 60 cell lines derived from human tumors (NCI-60) has been widely explored as a tool for anticancer drug discovery. In one aspect of the invention, the cell surface of the NCI-60 was profiled by high-throughput screening of a phage-displayed random peptide library and classified the cell lines according to the binding selectivity of 26,031 recovered tripeptide motifs. By analyzing selected cell-homing peptide motifs and their NCI-60 recognition patterns, the inventors established that some of these motifs (a) are similar to domains of human proteins known as ligands for tumor cell receptors and (b) segregate among the NCI-60 in a pattern correlating with expression profiles of the corresponding receptors. The inventors biochemically validated some of the motifs as mimic peptides of native ligands for the epidermal growth factor receptor. The results indicate that ligand-directed profiling of tumor cell lines can select functional peptides from combinatorial libraries based on the expression of tumor cell surface molecules, which in turn could be exploited as “druggable” receptors in specific types of cancer (Kolonin et al., 2006).

The National Cancer Institute panel of human cancer cell lines from different histologic origins and grades (NCI-60) has been extensively used to screen compounds for anticancer activity (Monks et al., 1991; Weinstein et al., 1997). The NCI-60 includes carcinomas of several origins (kidney, breast, colon, lung, prostate, and ovarian), tumors of the central nervous system, malignant melanomas, leukemias, and lymphomas. Gene expression determined by high-throughput microarrays has been used to survey the variation in abundance of thousands of distinct transcripts in the NCI-60; such data provided functional insights about the corresponding gene products in tumor cell transformation (Weinstein et al., 1997; Scherf et al., 2000; Nishizuka et al., 2003). This information-intensive genomic approach has yielded candidate diagnostic tumor markers to be validated at the protein level in prospective studies (Nishizuka et al., 2003). Moreover, systematic proteomic studies based on two-dimensional PAGE (Myers et al., 1997) and protein microarrays (Nishizuka et al., 2003) have also been implemented. Finally, in parallel with the NCI-60 transcriptome and proteome initiatives, pharmacologic sensitivity of the cells to >10⁵ different chemical compounds has been registered (Monks et al., 1991; Weinstein et al., 1997). Indeed, for some genes, correlation of expression data to drug sensitivity profiles has uncovered the mechanistic basis for the drug activity (Scherf et al., 2000; Zaharevitz et al., 2002; Blower et al., 2002; Rabow et al., 2002; Wallqvist et al., 2002; Szakacs et al., 2004). Thus, conventional genomic and proteomic approaches have identified several potential tumor markers and drug targets. However, despite such advances, correlation between drug activity and gene expression profiles has not as yet been established for most of the compounds tested (Wallqvist et al., 2002; Brown, 1997; Walloyist et al., 2003). This suggests the likely existence of unknown factors and the need to develop alternative methodology to discover “druggable” molecular targets.

Over the past few years, it has been proposed that (a) characterization of molecular diversity at the tumor cell surface level (represented primarily by membrane-associated proteins that are often modified by lipids and carbohydrates) is required for the development of ligand-directed anticancer therapies, and that (Zaharevitz et al., 2002) peptides binding to surface receptors preferentially expressed on tumor cells may be used to ligand-direct therapeutics to sites of disease with potential for increased therapeutic windows (Arap et al., 1998; Kolonin et al., 2001). It has become increasingly clear that selective cell surface features can be mapped by screening libraries of peptides (Kolonin et al., 2001; Pasqualini and Ruoslahti, 1996; Giordano et al., 2001; Arap et al., 2002). In fact, combinatorial peptide libraries displayed from pIII protein of an M13-derived phage have now been successfully screened on intact cells and in vivo (Arap et al., 1998; Kolonin et al., 2001; Pasqualini and Ruoslahti, 1996). Peptide ligands selected from unbiased screens without any predetermined notions about the nature of the cellular receptor repertoire have been used for the subsequent identification of the corresponding target cell surface receptors (Giordano et al., 2001; Arap et al., 2002; Pasqualini et al., 2000; Kolonin et al., 2002; Kolonin et al., 2004; Pasqualini et al., 2001). In addition, novel techniques, such as the biopanning and rapid analysis of selective interactive ligands (BRASIL), have enabled high-throughput phage library screening on cells (Giordano et al., 2001). Here, the BRASIL method is used to systematically screen combinatorial libraries on tumor cells of the NCI-60 panel. Results of this feasibility study suggest that tumor cells can be grouped by profiles of their peptide ligands directed to differentially expressed cell surface receptors. The data support the notion that many tumor cell surface-exposed receptors are expressed irrespective of tumor origin, thus suggesting they could be developed as broad tumor targets. Integration of ligand-directed surface profiling with other approaches related to the NCI-60 may uncover functional ligand-receptor pairs for the targeted drug delivery.

I. CELL TARGETING MOLECULES

Modified cell targeting molecules of the present invention may be produced by chemical synthetic methods, by chemical linkage between the two moieties or in some cases by fusion of a second polypeptide coding sequence to the targeting moiety. It is contemplated that modified cell targeting molecules of the invention may be used as therapeutics and/or as imaging agents to target specific classes of cells.

As mentioned above, in certain aspects of the invention, a modified cell targeting moiety may comprise a second polypeptide wherein the two polypeptides together comprise a fusion protein. For example, in certain aspects the second polypeptide may be a therapeutic or cytotoxic (e.g., a toxin) polypeptide as exemplified below. A fusion of two polypeptide coding sequences can be achieved by methods well known in the art of molecular biology. It is preferred that a fusion polynucleotide contain only the AUG translation initiation codon at the 5′ end of the first coding sequence without the initiation codon of the second coding sequence to avoid the production of two separate encoded products. In addition, a leader sequence may be placed at the 5′ end of the polynucleotide in order to target the expressed product to a specific site or compartment within a host cell to facilitate secretion or subsequent purification after gene expression. The two coding sequences can be fused directly without any linker or by using a flexible polylinker.

A. Cell Targeting Moieties

Cell targeting moities as provided here may, in some aspects, comprise peptides or polypeptides that exhibit binding to a specific class of cells. For example, in some cases the cell targeting moiety is selected from one of the polypeptide sequences provided in Table 3. The skilled artisan will understand that such sequences may comprise additional amino acids or other covalent modifications. For instance, in preferred embodiments a polypeptide sequence from Table 3 is provided a cyclic polypeptide. Thus, in some specific examples, an amino acid sequence from Table 3 is flanked by cysteine residues that may form a disulfide bond thereby providing a cyclic polypeptide. Thus, in some aspects the invention provides compositions and methods for targeting any of the classes of cells that bind to the peptides and polypeptides provided herein (e.g., as indicated in Table 3) such as leukemia cells, lung cancer cells, colon cancer cells, CNS cancer cells, melanoma cells, ovarian cancer cells, prostate cancer cells, renal cancer cells or breast cancer cells.

B. Therapeutic Moieties

As mentioned above in certain aspects, a therapeutic moiety may be a toxin such as radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, cytotoxins (cytotoxic agents), or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNAse, alpha toxin, ricin, abrin, Pseudomonas exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. “Toxin” also includes a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example, ²¹³Bi, or other radioisotopes such as, for example, ¹⁰³Pd, ¹³³Xe, ¹³¹I, ⁶⁸Ge, ⁵⁷Co, ⁶⁵Zn, ⁸⁵Sr, ³²P, ³⁵S, ⁹⁰Y, ¹⁵³Sm, ¹⁵³Gd, ¹⁶⁹Yb, ⁵¹Cr, ⁵⁴Mn, ⁷⁵Se, ¹¹³Sn, ⁹⁰Yttrium, ¹¹⁷Tin, ¹⁸⁶Rhenium, ¹⁶⁶Holmium, and ¹⁸⁸Rhenium; luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin. Furthermore, a therapeutic moiety may be a pro-apoptotic protein such as a BCL2 family member, a caspase or a granzyme.

II. CANCER THERAPIES

A variety of conventional cancer therapies are currently used in the treatment of cancer. Thus, in some aspects of the invention there are provided methods for classifying cancer cells such as cells that are sensitive or resistant to an anticancer therapy. Some examples of conventional cancer therapies discussed below. It is contemplated that methods according to the invention may be used to identify cells that are sensitive or resistant to any particular cancer treatment. Furthermore, some aspects of the invention concern compositions and methods for cell targeted anticancer therapy. Thus, it is contemplated that any anticancer method known to those in the art (as exemplified below) may be used in combination or conjunction with compositions and methods provided herein.

A. Chemotherapy

Cancer therapies also include a variety of combination therapies with both chemical and radiation based treatments. Combination chemotherapies include, for example, cisplatin (CDDP), carboplatin, procarbazine, mechlorethamine, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, busulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP16), tamoxifen, raloxifene, estrogen receptor binding agents, taxol, gemcitabien, navelbine, farnesyl-protein tansferase inhibitors, transplatinum, 5-fluorouracil, vincristin, vinblastin and methotrexate, or any analog or derivative variant of the foregoing.

B. Radiotherapy

Other factors that cause DNA damage and have been used extensively include what are commonly known as γ-rays, X-rays, and/or the directed delivery of radioisotopes to tumor cells. Other forms of DNA damaging factors are also contemplated such as microwaves and UV-irradiation. It is most likely that all of these factors effect a broad range of damage on DNA, on the precursors of DNA, on the replication and repair of DNA, and on the assembly and maintenance of chromosomes. Dosage ranges for X-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 wk), to single doses of 2000 to 6000 roentgens. Dosage ranges for radioisotopes vary widely, and depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells.

The terms “contacted” and “exposed,” when applied to a cell, are used herein to describe the process by which a therapeutic construct and a chemotherapeutic or radiotherapeutic agent are delivered to a target cell or are placed in direct juxtaposition with the target cell. To achieve cell killing or stasis, both agents are delivered to a cell in a combined amount effective to kill the cell or prevent it from dividing.

C. Immunotherapy

Immunotherapeutics, generally, rely on the use of immune effector cells and molecules to target and destroy cancer cells. The immune effector may be, for example, an antibody specific for some marker on the surface of a tumor cell. The antibody alone may serve as an effector of therapy or it may recruit other cells to actually effect cell killing. The antibody also may be conjugated to a drug or toxin (chemotherapeutic, radionuclide, ricin A chain, cholera toxin, pertussis toxin, etc.) and serve merely as a targeting agent. Alternatively, the effector may be a lymphocyte carrying a surface molecule that interacts, either directly or indirectly, with a tumor cell target. Various effector cells include cytotoxic T cells and NK cells.

Immunotherapy, thus, could be used as part of a combined therapy, in conjunction with gene therapy. The general approach for combined therapy is discussed below. Generally, the tumor cell must bear some marker that is amenable to targeting, i.e., is not present on the majority of other cells. Many tumor markers exist and any of these may be suitable for targeting in the context of the present invention. Common tumor markers include carcinoembryonic antigen, prostate specific antigen, urinary tumor associated antigen, fetal antigen, tyrosinase (p97), gp68, TAG-72, HMFG, Sialyl Lewis Antigen, MucA, MucB, PLAP, estrogen receptor, laminin receptor, erb B and p155.

III. EXAMPLES Example 1 Combinatorial Library Screening on Cells

All the NCI-60 cell lines (1), except MDA-N (unavailable), were grown in RPMI 1640 supplemented with 5% fetal bovine serum (FBS) and 5 mmol/L L-glutamine. A phage display random peptide library based on the vector fUSE5 displaying the insert CX₇C (SEQ ID NO:1) was screened by using BRASIL as described (Giordano et al., 2001). Exponentially growing cells were harvested with 0.5 mmol/L EDTA, 0.4 g/L KCl, 8 g/L NaCl, and 1 g/L dextrose, washed once with phosphate buffer saline (PBS), and resuspended in RPMI containing 1% bovine serum albumin (BSA) and 1 mmol/L HEPES. Cells (˜10⁶) were incubated for 2 hours on ice with 10⁹ transduction units (T.U.) of CX₇C phage in 200-μL suspension, transferred to the top of a nonmiscible organic lower phase (dibutyl phtalate/cyclohexane, 9:1), and centrifuged at 10,000×g for 10 minutes. The phage-bound cell pellet was incubated with 200 μL of K91 bacterial culture, and the bound phages were amplified and used in the following round. To prevent preferential isolation of peptides containing the RGD motif, which is selected on tissue-cultured cells due to expression of cell adhesion molecules binding to vitronectin, library screening was done in the presence of 1 mg/mL of the synthetic peptide RGD-4C (AnaSpec, San Diego, Calif.) in each round. After three rounds of selection, phage peptide-encoding inserts were sequenced as described (Pasqualini and Ruoslahti, 1996; Arap et al., 2002; Pasqualini et al., 2001).

Example 2 Hierarchical Cluster Analysis of Peptide Motif/Cell Line Association

The inventors created an interactive sequence management database of all peptide sequences isolated in the screen. Calculation of tripeptide motif frequencies in CX₇C peptides (in both directions) was done by using a character pattern recognition program based on SAS (version 8.1.2, SAS Institute, Cary, N.C.) and Perl (version 5.6.1) as described (Arap et al., 2002). To identify the most closely related tripeptides and cell lines, clustered image maps (CIM) were generated by using online software CIMminer available at discover.nci.nih.gov/tools.jsp. Data were centered (mean subtracted and divided by SD) on both cell lines and tripeptide motifs; correlation coefficient metric with average linkage algorithm was used as distance measurement. The tripeptide motif frequencies across the NCI-60 cell lines formed a two-dimensional data matrix that was used to correlate motif enrichment with groups of cell lines. To evaluate whether CIMMiner algorithm is appropriate for clustering analysis of peptide frequency data, a simulation test was devised assuming that the frequencies of tripeptide motifs in a given data set follow an independent Poisson distribution. The inventors simulated a random 3,280×59 data matrix of the dimension identical to that of tripeptide motif frequency data matrix (corresponding to the set of 3,280 tripeptides and 59 cell lines). These simulated data were centered the same way as the experimental data by transforming to mean of 0, variance of 1. For CIM in FIG. 1, tripeptides selected on all but one cell line of common origin (Arap et al., 2002) were used. Specificity of five tripeptides selectively overrepresented or underrepresented in lung tumor cell binding peptides for the 11 boxed cell lines (against the other 48 cell lines) was evaluated by using the R Package, version 2.0.0 (www.r-project.org) by performing two-sample t test (one tailed), as well as using Wilcoxon rank sum test (one tailed) and Fisher exact test (one tailed) as described (Arap et al., 2002).

Example 3 Identification of Candidate Targeted Receptors

To identify lead receptors targeted by tripeptide motifs, the Molecular Target Database (found on the world wide web at dtp.nci.nih.gov) was screened to identify proteins, expression levels of which in individual cell lines of the NCI-60 correlated with frequencies of individual tripeptides from FIG. 1 in the corresponding cell lines. The inventors used the COMPARE software (found on the world wide web at dtp.nci.nih.gov/docs/compare/compare.html) to calculate pairwise Pearson correlations between tripeptide frequencies in cell lines and the protein expression patterns in the database. Minimum Pearson correlation coefficient of 0.2 served as cutoff for the selection of lead receptors, as it provided a reasonable number of candidate molecular targets for which NCI-60 expression profiles and tripeptide frequency distribution profiles correlated. To initially restrict the candidate targets analyzed to broad-specificity receptors, only putative cell surface molecules (Table 1) were included, expression of which in the NCI-60 was found to correlate with the frequency profile of at least 25% of the tripeptides.

Example 4 Protein Database Screening for Peptide Motif Similarity

To identify natural prototype ligands of candidate receptors that are mimicked by selected peptides, the inventors screened all 7-mer peptides selected in the screen by using online ClustalW software (www.ebi.ac.uk/clustalw/) to identify extended (four or longer amino acids) motifs shared between multiple peptides containing the broad-specificity tripeptides (FIG. 1). Nonredundant databases of human proteins were searched by the BLAST software (www.ncbi.nlm.nih.gov/BLAST/) for proteins containing the cell-targeting 4-mers under the condition that at least the tripeptide part of the motif is identical to the part of the BLAST match.

Example 5 Validation of Epidermal Growth Factor Receptor as One of the Peptide Targets

To isolate peptides binding to epidermal growth factor receptor (EGFR), phage clones selected on SKOV3 in rounds 2 and 3 of the screening were individually amplified and pooled, and 10⁹ transduction units of the mixed phage were incubated overnight at 4° C. with 10 μg of purified human EGFR (Sigma, St. Louis, Mo.), or BSA control immobilized on plastic. Unbound phages were extensively washed off with PBS, and then the bound phages were recovered by infecting host K91 Escherichia coli directly on the plate, and tetracycline-resistant clones were selected, quantified, and sequenced. To identify EGFR ligand-matching motifs among phage-displayed SKOV3-binding peptides, custom-designed Perl 5.8.1-based software was used to run peptide sequences against biological EGFR ligand sequences. Each 7-mer peptide sequence was aligned in each orientation against the EGFR ligand sequences from the NH₂ to COOH terminus in one-amino-acid shifts. The peptide/protein similarity scores for each residue were calculated based on a BLOSUM62 matrix modified to identify peptide matches of at least three amino acids in any position being identical and one being similar to the corresponding amino acid positions in the EGFR ligands (FIG. 2A).

Example 6 Isolation of Peptides Binding to Surface of the NCI-60 Cancer Cells

As an initial attempt to profile cell surface of the tumor cell panel, a large (2×10⁸ unique sequences) cyclic random peptide library was screened with the basic structure CX₇C (C, cysteine; X any residue) on every cell line of the NCI-60. Phage selection was done in the excess of a competing Arg-Gly-Asp (RGD) synthetic integrin-binding peptide (Arap et al., 1009) to minimize the recovery of RGD-containing peptides. This strategy was designed to facilitate the recovery of ligands binding to nonintegrin families of cell surface receptors because RGD tends to become dominant in the screening due to the high levels of integrin expression in adherent cells (unpublished observation). Preferential cell binding of specific cell-targeting peptides results in enrichment, defined by the increased recovery frequency of these peptide motifs in each subsequent round of the screen (Kolonin et al., 2001; Pasqualini et al., 2001). Thus, the inventors set out to profile the expression of nonintegrin cell surface molecules among the cell lines of the NCI-60 according to the differential selection of motifs enriched in the screen.

Example 7 Hierarchical Cluster Analysis of Peptides Binding to the NCI-60 Cells

To analyze the spectrum of the peptides resulting from the screening and compare those among different cell lines of the panel, a combinatorial statistical approach was adopted based on the premise that three residue motifs (tripeptides) provide a sufficient structure for protein-peptide interactions in the context of phage display (Arap et al., 2002). For each NCI-60 cell line, CX₇C peptide-encoding DNA inserts from 96 phage clones recovered after three rounds of selection were sequenced. A computer-assisted survey of all tripeptides within the library-derived sequences selected on each cell line by analyzing a database of 26,031 tripeptides contained within the 5,270 CX₇C-encoded 7-mer peptides isolated (an average of eighty-nine 7-mer peptide sequences analyzed per each NCI-60 cell line) was performed. Thus, each cell line was assigned a unique set of tripeptides that was identified during the selection for cell surface binders, and the frequencies of each motif among all peptides for a given cell line were calculated.

To classify cell lines according to their association with particular motifs, which might provide inference on the targeted surface molecules, a hierarchical clustering analysis of the 3,280 nonredundant tripeptides was done based on the frequency of association with the NCI-60 cell lines. For the construction of a CIM, the inventors adapted a hierarchical clustering algorithm and a pseudo-color visualization matrix initially designed to address differential gene expression among the cells of the panel (Scherf et al., 2000; Zaharevitz et al., 2002; Blower et al., 2002; Rabow et al., 2002). CIMMiner (Weinstein et al., 1997) was used for inference of the variation in peptide binding specificity across the cell lines by comparing relative frequencies of tripeptides found in 7-mer peptides binding to each cell. Clustering of peptide motifs with similar cell selectivity revealed that the peptide distribution of the combinatorial library within the NCI-60 set was nonrandom. Computer simulations of the permutated data set show that the observed pattern could not be generated by random chance, thus indicating that the discontinuous tripeptide frequency data is applicable for cluster analysis.

The selective spectra of peptide motifs interacting with the clustered cell lines suggest the existence of shared targeted surface receptor(s) expressed in these lines. In this study, the inventors chose to focus on putative peptide-targeted receptors with broad cell line specificity, which would be more informative for an initial peptide binding/receptor expression correlation analysis. the inventors therefore excluded from the data set motifs selected only on a single or few cell lines. Instead, the inventors focused on 38 tripeptides that showed a semiubiquitous distribution among the NCI-60 lines (FIG. 1). A CIM constructed according to the isolation frequency of these broader-specificity tripeptides from each cell line revealed several apparent clusters of cell lines that displayed distinct profiles of association with certain classes of peptide motifs. For example, the majority of lung cancer-derived cell lines segregated as a separate group, suggesting that some of the receptors targeted may be conserved among cell lines derived from a common origin (FIG. 1). Thus, although the analysis was severely restricted by limiting it to semiubiquitous tripeptides, clustering of some of them (predominantly with cell lines derived from the same tumor type) is consistent with their relative tissue specificity. To evaluate individual motifs for selectivity, a distinct cluster of five tripeptides associated with lung tumor-derived cell lines (FIG. 1, boxed) were identified. The inventors compared tripeptide frequencies for the 11 cell lines within this cluster with their frequencies for the rest of NCI-60 lines by using statistical tests (Fisher exact, Wilcoxon rank-sum, and t test). Consistently, the GGS motif was isolated for the clustered lines significantly (P<0.05) more frequently than for the other NCI-60 cell lines.

Notably, the distribution of cell lines in the dendrogram (FIG. 1) was partially consistent with the reported association of cells derived from tumors with common tissue origin (Scherf et al., 2000; Nishizuka et al., 2003). This suggests that some of the receptors, such as the one presumably recognized by the lung tumor-specific tripeptide GGS (FIG. 1), may be up-regulated only in certain cancer origins. However, the tumor cell phylogeny was recapitulated only to an extent; the majority of the observed clusters contained cell lines derived from unrelated tumor types (FIG. 1). The limited grouping of lines derived from tumors of common origin is perhaps not surprising: the relationship between different cell lines in the study is based on peptide binding to putative cell surface molecules, many of which may be tumor induced rather than characteristic of the tissue of origin. If so, the analysis of broad-specificity motif distribution may be well suitable for identification of specific surface molecules that are generally up-regulated by tumors and thus may constitute broad drug targets against cancer.

Example 8 Identification of Candidate Receptor Targets for Peptide Motifs

The inventors proceeded to identify the targets for the 38 broad-specificity tripeptides, most of which presumably bind to receptors expressed by multiple NCI-60 cell lines. The NCI Molecular Targets Database that contains detailed information on the expression and activity of 1,218 human proteins measured by nonarray methods was used (Holbeck, 2004). By using the COMPARE algorithm (Zaharevitz et al., 2002), the inventors correlated the selectivity profiles of the 38 tripeptide motifs with the expression profiles of the characterized molecular targets. It was observed that several of the qualifying proteins, expression of which correlated with enrichment profiles of certain motifs, represented tyrosine kinase receptors, such as those for ligands belonging to families of EGFs, fibroblast growth factors (FGF), nerve growth factors (NGF), and ephrins (Table 1). When transferred to molecular target correlation data, the order of the 38-tripeptide motif set in the dendrogram (FIG. 1) revealed clusters of tripeptides for which cell line association profile correlated with expression profiles of EGF, FGF, NGF, or ephrin receptors (Table 1).

The peptide distribution-correlating tyrosine kinase receptors, belonging to EGFR, FGFR, NGFR, and ephrin receptor families (Table 1), are often up-regulated in many types of cancer (Vogelstein and Kinzler, 2004). To determine if the cell-binding peptides may target these tyrosine kinases, the inventors employed the notion that receptor-binding peptide motifs often mimic natural ligands for these receptors (Giordano et al., 2001; Arap et al., 2002; Kolonin et al., 2002). Thus, the selected motifs mimic ligands for the candidate tyrosine kinases were tested by determining whether tripeptides listed in Table 1 are embedded into longer peptides that may be responsible for cell surface binding. The inventors analyzed the CX₇C (SEQ ID NO:1) phage inserts containing the 38 tripeptides by using the ClustalW software and compiled extended motifs containing the tripeptides shared among multiple peptides selected during the screen (data not shown). To identify candidate prototype human ligands, epitopes of which could be mimicked, each of the ClustalW-extended motifs were screened against the nonredundant database of human proteins by using the BLAST software (National Center for Biotechnology Information). As a result of this analysis, the inventors found the motifs containing 34 of 38 tripeptides (89%) to be identical or very similar to segments of proven or putative ligands for the tyrosine kinase receptors listed (Table 1).

Example 9 Validation of EGFR as a Targeted Receptor

To show that the approach taken can lead to actual targetable tumor cell surface proteins, the inventors chose to test if the EGFR is bound by any of the tripeptide motifs distributed in the panel in a profile correlating with EGFR expression. Consistently, 24 of 38 tripeptides surveyed displayed NCI-60 cell line association pattern consistent with that of EGFR expression (Table 1). Of these tripeptides, 22 were isolated in the screens on ovarian cancer cell lines SKOV3 and OVCAR4 (data not shown). Because EGFR is well known to be associated with ovarian cancer (Vogelstein and Kinzler, 2004), the inventors deemed these cell lines to be likely expressers of targetable EGFR, which would account for the selection of EGFR ligand-mimicking motifs. To validate EGFR binding by the selected motifs, the SKOV3-binding phage sublibrary (pooled clones recovered in rounds 2 and 3) were screened against immobilized human EGFR. After two rounds of selection, phage displaying the EGFR-binding peptides were analyzed: the majority were comprised by different 7-mer peptides (FIG. 2A) that contained 17 of 22 SKOV3-selected tripeptide motifs distributed in the panel in a profile correlating with EGFR expression (Table 1). Phage displaying these peptides had specific affinity to EGFR, as determined by subjecting the same sublibrary to immobilized BSA control binding (FIG. 2B). Remarkably, computer-assisted analysis of sequences (FIG. 2A) revealed that 12 of the 7-mer EGFR-binding peptides contained amino acid motifs similar to those present in some of the biological EGFR ligands (Vogelstein and Kinzler, 2004). These peptides, containing eight of the candidate tripeptides (RVS, AGS, AGL, GVR, GGR, GGL, GSV, and GVS), were found highly similar to fragments of EGF, amphiregulin, heparin-binding EGF-like growth factor, and epiregulin (FIG. 2A). Similarity search using the same algorithm on the same twelve 7-mers did not reveal any matches to two other EGFR ligands, transforming growth factor-α and β-cellulin, or randomly chosen control ligands of tyrosine kinase receptors from the three other candidate families listed in Table 1: ephrin A, NGF-β, and FGF6 (data not shown). Taken together, these data suggest that at least some of the peptides selected on the NCI-60 cells target EGFR, whereas others may bind to different tyrosine kinases, possibly including those from TRK, ephrin, or FGF receptor families.

Expression profiles of the candidate receptor targets for peptides identified in the screen illustrate the concept that in cancer, at least some tumor-associated cell surface molecules seem up-regulated regardless of cancer tissue origin. As such, this is the case for the EGFR and other tyrosine kinases possibly targeted by peptide ligands selected on the NCI-60 cell panel. This may also be the case for many other receptors with a role in tumorigenesis, expression profiles of which may not correlate with the overall proteomic profile of the original tumor tissue. In fact, these observations may account for the relatively limited success in correlating drug toxicity profiles with the genomic and/or proteomic profiles of the NCI-60 panel (Walloyist et al., 2003). On the other hand, some of the receptors, such as EphA5 presumably targeted by GGS tripeptide and its derivatives predominantly selective for lung tumor-derived cell lines (FIG. 1), seem to be at least partially specific for the progenitor cancer type.

The candidate ligand-receptor leads identified in this study can be characterized further for the development of targeted agents selective for tumors. Moreover, the peptides identified by the approach described here may map receptor interaction domains of biological (native) ligands. Similarity of peptides to the corresponding receptor-binding ligands has already been used for validation of the IL-11Rα receptor as a target of an interleukin-11 mimic peptide homing to blood vessels in the prostate (Arap et al., 2002; Zurita et al., 2004). The inventors and others have modeled the usage of peptides homing to receptors expressed by tumors (Pasqualini et al., 2000) or non-malignant tissues (Kolonin et al., 2002; Kolonin et al., 2004) for directing the delivery of cytotoxics, proapoptotic peptides, metalloprotease inhibitors, cytokines, fluorophores, and genes (Arap et al., 1998; Kolonin et al., 2001). Thus, the approach provides a straightforward way to identify drug-accessible tumor cell surface receptors and to discover peptide ligands that can serve as mimetic prototype drugs. Unlike genomic or proteomic-based approaches that rely on differential expression levels of transcripts or protein products, this discovery platform directly addresses functional protein-protein interactions at the level of physical binding. In contrast to protein array systems, it is possible to select binding peptides even if the ligand-receptor interaction is mediated by conformational (rather than linear) epitopes. Ligand-directed screening of combinatorial libraries on tumor cell surfaces can lead to improved selection of functionally relevant peptides that can be developed for targeting “druggable” molecular targets.

TABLE 1 Candidate ligand-receptor interactions mimicked* RLS ErbB2, ErbB4 FGF2, 4 EGF-TM7 RGV RGS ErbB4 FGF2 EphA2, A3, A4, A8, B1 EGF-TM7, FGF-12b, FGF-5, NGF-beta RAV ErbB2 MEGF7, NGF-beta. NTF 6 alpha RAS TRKA FGF-20, NRG-3 GAG EGFR FGF1, 2, 3 MEGF4, FGF6, NGF-beta AVS EGFR, ErbB2, FGF1 TRKB, C EphA2, A3, A4, A7, TRK1 ErbB4 B1, B2, B3, B5 LLS Amphlregulin LLR TRKA EphA4 LRV EGFR, ErbB2, FGF3 TRKA, B, C EphA2, A3, A7 FGF-12b, Eph-B3 ErbB4 LRS ErbB3 MEGF4, MEGF5, MEGFS, NRG-3, NGF-beta RVS EGFR, ErbB2, FGF1, 2 TRKB EphA7 MEGF10, amphiregulin ErbB4 RSS FGF3 TRKA EphAS EGF-TM7, FGF-S, NRG-3 AGS EGFR TRKA MEGF6, brain NGF AGR MEGF2, MEGF4, FGF6, NTF-5, NTF-6 AGL EGFR, ErbB2, FGF1, 3 EphAS, A6, A8 MEGF12 ErbB3 AGG EphA5 HB-EGF, Ephr-B3 GVR EGFR, ErbB2, FGF1, 2 TRKB EphA7 MEGF4, MEGF6, MEGF8, FGF-5, bFGF, ErbB4 brain NGF GVL FGF1, 2 EphA2, A3, A5, A6, B3 NGF2, Ephrin-B3, GAV MEGFS, MEGF6, NGF-beta GLV ErbB4 FGF4 EphA5 ESF-TM7, betaceilulin, NTF 3, Eph-B3, GLR ErbB4 MEGF5, EGFL5, FGF-12b, FGF-16, NRG-3 LVS FGF1, 4 EphA5, A6 EGFL5, FGF23, GDNF, Eph-B3 ARG ErbB2 FGF2, 4 TRKA EphAI FGF-12b, FGF23, NGF-beta, GDNF, NTF 6 ASL FGF1, 2 TRKC EGF-TM7, FGFR1 AAV TRKB EphA2, A3, A4, A7, • B3, B5 AAS FGF1, 2 TRKC • GGS EphA5 Eph-B3, Eph A4 GGR EGFR · ErbB2 FGF2 EGF-TM7, HB-EGF, FGF23, Ephrin-B3 GLG ErbB2, ErbB3 FGF2, 3, 4 EphA1, A6 heparin binding growth factor 8 GGL ErbB2 HB-EGF, MEGF5, EGFL5, NRG-3 GSS EGFR, ErbB2 FGF3 TRKA, C EphA5 MEGFS GSG EGFR EphA5 GSV EGFR, ErbB2, FGF4 TRKB EphA7, B2 MEGF5, NRG-3, Ephrin-B3 ErbB4 GRV EGFR MEGFS, EGF-TM7, FGF23, NTF5 GRL EGFR · ErbB2 EphAS, B1, B2, B4 betacellulin, EGFL5, NGF2, NTF5, EphB3, EphA4 GPS EGFR, ErbB2, FGF3 TRKB EpnA2, A3, A4, A7, MEGFS, EGFL5, EGF-like EMR3, SPGF ERB4 B2, B5 GVS EGFR FGF4 TRKA MEGF-1, MEGF5, NRG-3, NTF-6, NTF-5 *NOTE: Candidate peptide motif receptors are the human cell surface proteins (identified by COMPARE) expressed in profiles correlating with the selectivity of the corresponding tripeptides. Candidate peptide-mimicked receptor ligands are human proteins (identified by automated BLAST) that contained the corresponding tripeptides. Tripeptides in the column are ordered as in FIG. 1. Receptors of the same family and their corresponding candidate biological ligands identified based on tripeptide similarity are coded by the same color [EGFR, blue; FGFR, green; TRK receptor (NGFR), purple; ephrin receptor, red]. Tripeptides that both have a selectivity correlating with EGFR family receptor expression and are found within EGFR ligands (boldface). Tripeptides that were confirmed to reside within EGFR-binding SKOV3-slected peptides (FIG. 2; blue).

Example 10 Molecular Fingerprinting of Cancer Cell Lines

Proteomics can be defined as the systematic analysis of the proteins in biological samples that aims to document the overall distribution of proteins in tumor cells or tumor-associated cells, identify and characterize individual proteins of interest and to elucidate their relationships and functional roles. Ultimately, high-throughput profiling of protein expression will lead to the “proteome”, a protein-based fingerprint, for each tissue in humans and other species. As technologies related to proteomics advance, new approaches for systematic molecular analysis of cancer at the protein level are surfacing. However, methods for systematic protein expression profiling may also easily overlook potential targets for intervention. These methods often do not take anatomical context into account. Therefore, for the generation of molecular map of accessible receptors that can be used for targeting therapeutics, information derived from conventional protein profiling approaches should be enhanced by integration with data from functional screenings ex vivo and in vivo. Studies by the inventors and others have advanced the concept of cancer proteomics: the molecular phenotyping of tumor cells and cells forming blood vessels at the protein-protein interaction level. Exploiting the molecular diversity of cell surface receptors expressed in cancer will eventually result in a ligand-receptor functional map for targeted delivery.

A major goal in drug development has long been to generate targeted therapies. This approach would improve drug therapeutic indexes by limiting the systemic exposure of other tissues to untoward or toxic effects. Thus, the promise for the identification of selectively expressed tumor-associated receptors and the ligands that home to these receptors is translation of this knowledge into the development of targeted therapeutics. Generally, coupling of homing peptides yields targeted compounds that are more effective and less toxic than the parental compound. So far, peptides selected by homing to tumor vasculature have been used as carriers to guide the delivery of cytotoxic drugs, pro-apoptotic peptides, metalloprotease inhibitors, cytokines, fluorofores, and genes in transgenic and xenograft mouse models of human disease.

Recognition of molecular diversity in human cancer is essential for the development of targeted therapies. The methods developed have two main applications. First, they may identify ligands targeting human cancer. Second, the determination of molecular profiles of biomarkers in specific types of tumors may enable identification of differentially expressed cancer markers. Thus, the approach may lead to construction of a molecular profile of human tumors. Early identification of targets, optimized regimens tailored to molecular profile of individual cancer patients, combined with the identification of new vascular addresses may result in revisiting or salvaging of drug candidates that are ineffective or too toxic. Ultimately, it may be possible to guide imaging or therapeutic compounds to tumor targets in cancer patients.

By fingerprinting lung cancer cells the inventors have confirmed the expression of a previously characterized molecular target, EGFR, in multiple cancer origins, which demonstrates the power of the approach. Recently, the inventors used this approach to identify a new cancer origin-selective molecular target, Ephrin A5 receptor, which the inventors have preliminary validated in the context of human lung cancer cell lines and tissues.

Example 11 Motifs Targeting NCI-60 Cells in Correlation with EGFR Expression Pattern are Found within Peptides Similar to Domains of Biological EGFR Ligands and Bind to EGFR

To show that the approach taken can lead to actual targetable tumor cell surface proteins, the inventors chose to test if the EGF receptor (EGFR) is bound by any of the tripeptide motifs distributed in the panel in a profile correlating with EGFR expression. Consistently, 24 out of 38 tripeptides surveyed displayed NCI-60 cell line association pattern consistent with that of EGFR expression (Kolonin et al., 2001). Of these, tripeptides, 22 were isolated in the screens on ovarian cancer cell lines SKOV3 and OVCAR4 (data not shown). Since EGFR is well known to be associated with ovarian cancer (Vogelstein, 2004; Maihle and Lafky, 2002), the inventors deemed these cell lines to be likely expressers of targetable EGFR, which would account for the selection of EGFR ligand-mimicking motifs. To validate EGFR binding by the selected motifs, the SKOV3-binding phage sub-library (pooled clones recovered in rounds 2 and 3) were screened against immobilized human EGFR. After 2 rounds of selection, phage displaying the EGFR-binding peptides were analyzed: the majority were comprised by different seven-mer peptides (FIG. 3A) that contained 17 out of 22 SKOV3-selected tripeptide motifs distributed in the panel in a profile correlating with EGFR expression.

Phage displaying these peptides had specific affinity to EGFR, as determined by subjecting the same sub-library to immobilized bovine serum albumin (BSA) control binding (FIG. 2B). Remarkably, computer-assisted analysis of sequences (FIG. 2A) revealed that 12 of the seven-mer EGFR-binding peptides contained amino acid motifs similar to those present in some of the biological EGFR ligands. These peptides, containing eight of the candidate tripeptides (RVS, AGS, AGL, GVR, GGR, GGL, GSV, and GVS) were found highly similar to fragments of EGF, Amphiregulin, heparin-binding EGF-like growth factor, and Epiregulin (FIG. 2A). Similarity search using the same algorithm on the same 12 seven-mers did not reveal any matches to two other EGFR ligands, TGF-α and betacellulin, or randomly chosen control ligands of tyrosine kinase receptors from the three other candidate families listed in Table 2 (Kolonin et al. 2001): Ephrin A, NGF-β, and FGF6. Taken together, these data suggest that at least some of the peptides selected on the NCI-60 cells target EGFR, while others may bind to different tyrosine kinases, possibly including those from TRK, Ephrin, or FGF receptor families.

A phage-displayed combinatorial library was systematically screened for peptides capable of targeting the cell lines in the NCI-60 panel. By statistical analysis of peptide motif sequences, each NCI-60 cell line was assigned a unique set of peptide motifs that were isolated during the selection for cell surface binders. It was shown that tumor cells can be grouped by profiles of their phage display-derived peptide ligands directed to differentially expressed cell surface receptors.

An approach for peptide-targeted receptor identification was designed. Profiles of peptide motif preference for specific lines of the NCI-60 were correlated with expression profiles of known breast cancer-related targets. Some of the peptide motifs were found within proteins known to bind the receptors that had NCI-60 expression profiles matching cell line recognition profiles of the peptides, and that are implicated in cancer.

Candidate targeted cell surface molecules were identified, which included a number of tyrosine kinase receptors. As a proof of principle, EGFR, a receptor known to be upregulated in various cancers, was validated as a target of tripeptides RVS, AGS, AGL, GVR, GGR, GGL, GSV, and GVS, which were The results described uncover a previously overlooked phenomenon. The data support the notion that many tumor cell surface-exposed receptors are expressed irrespective of tumor origin, thus suggesting they could be explored as broad tumor targets.

Example 12 Ephrin A5 Receptor as a Lung Cancer Cell Surface Marker

The peptide distribution-correlating tyrosine kinase receptors, belonging to EGFR, FGFR, NGFR and Ephrin receptor families are often up-regulated in many types of cancer. On the other hand, some of the receptors, such as EphA5 presumably targeted by GGS tripeptide and its derivatives predominantly selective for lung tumor-derived cell lines appear to be at least partially specific for the progenitor cancer type. Since this approach clearly allowed identification of cell surface receptors ubiquitously upregulated in various cancers, the inventors took a step further to attempt identification of cancer type-specific receptors.

Having chosen lung cancer for the initial procedure establishment, the inventors identified a distinct cluster of five tripeptides associated with lung tumor-derived cell lines. The inventors compared tripeptide frequencies for the 11 cell lines within this cluster with their frequencies for the rest of NCI-60 lines by using statistical tests (Fisher exact, Wilcoxon rank-sum, and t-test). Consistently, the inventors observed that motif GGS was isolated for the clustered lines significantly (P<0.05) more frequently than for the other NCI-60 cell lines (Table 2).

TABLE 2 Association of specific tripeptides with lung cancer-derived cell lines: P value Mean motif count P value Wilcoxon P value (±SEM) inside vs. t-test, rank-sum Fisher exact Motif outside cluster 1-sided test, 1-sided test, 1-sided GGS 2.2 (±0.5) vs. 1.2 (±0.2) 0.0422 0.0407 0.0043 GGR 1.3 (±0.3) vs. 1.5 (±0.2) 0.6991 0.6466 0.6739 GLG 0.7 (±0.4) vs. 0.7 (±0.2) 0.5375 0.6888 0.5150 GGL 1.2 (±0.2) vs. 1.3 (±0.2) 0.6457 0.4174 0.5485 GSS 2.2 (±0.4) vs. 1.1 (±0.2) 0.0422 0.0026 0.0008

To determine statistical significance of association or dissociation between exemplary tripeptides and cell lines, normalized frequencies of five tripeptides predominantly associated (GGS, GGR, GLG, and GGL) or dissociated (GSS) with the cluster containing the majority of lung tumor-derived cell lines (FIG. 1, boxed) were compared for cell lines inside the cluster and outside the cluster. Selective association of tripeptide GGS with the clustered cell lines was found significant according to t-test, Fisher exact test and Wilcoxon rank-sum test (all tests one-tailed).

Based on the automated BLAST analysis (Table 2) the inventors identified proteins of the ephrin family candidate prototypes of the GGS-containing peptides: ephrins -B3 and A4 contain the GGS, consistent with a functional mimickry. Ephrins (A and B) and their receptors (EphA and EphB) represent a large class of cell-cell communication molecules with well-defined developmental functions. Their role in healthy adult tissues and in human disease is still largely unknown, although diverse roles in carcinogenesis have been postulated and a number of Eph receptors have been found overexpressed by various cancers (Hafner et al., 2004). Based on the COMPARE analysis of GGS distribution within NCI-60 (Kolonin et al., 2001, Table 2), the receptor expressed in the corresponding pattern is EphA5. The EphA5 expression (FIG. 4 has been explored using cDNA microarray analysis and is reported at the DTP server (dtp.nci.nih.gov/mtweb/servlet/moltidsearch?moltid=MT894), however, no studies of EphA5 function in cancer have been published. Intriguingly EphA5 is not expressed in normal lung and normally is only thought to have brain-specific functions.

Example 13 Validation of Ephrin-Mimic Peptides in Lung Cancer

To validate phage containing the motif GGS as a ligand of Eph receptors, the inventors tested phage binding to the EphA5 immobilized receptor. The inventors started testing eight peptides (CAGLSGGTC (SEQ ID NO:2133), CSGIGSGGC (SEQ ID NO:2134), CSSGGVLGC (SEQ ID NO:2135), CSWGSGGSC (SEQ ID NO:2136), CTLVLGGSC (SEQ ID NO:2137), CRFESSGGC (SEQ ID NO:2138), CHVSGGSGC (SEQ ID NO:2139), CTGGSLGAC (SEQ ID NO:2140)) containing the enriched motif GGS, all of them displayed by phage clones obtained from the screening on different cell lines known to express the EphA5 receptor (FIG. 3A). From this first round of selection, 5 clones (CAGLSGGTC (SEQ ID NO:2133), CSGIGSGGC (SEQ ID NO:2134), CSSGGVLGC (SEQ ID NO:2135), CRFESSGGC (SEQ ID NO:2138) and CSWGSGGSC (SEQ ID NO:2136) showed good binding to the receptor relative to the control (BSA) and were further analyzed by their ability to specifically bind to EphA5 but not to the control EphA4 receptor (FIG. 3B). Phage displaying the peptide sequences CSGIGSGGC (SEQ ID NO:2134) and CRFESSGGC (SEQ ID NO:2138) showed binding specificity and were chosen for characterization. The inventors investigated the binding of the selected phage to the lung cancer cells Hop92 and H460. These cells are known to express EphA5 receptor on its surface, as confirmed by immunofluorescence analysis (FIG. 5). The ovarian cancer cell line OVCAR-3, negative for EphA5 expression, was used as control.

Next, the inventors used the BRASIL method (biopanning and rapid analysis of selective interactive ligands) to analyze binding of selected phage to lung cancer cells. The inventors observed specific binding of phage displaying the sequences CSGIGSGGC and CRFESSGGC to Hop92 and H460, confirming the data obtained from the screening on the immobilized EphA5 receptor (FIG. 6).

Finally, by using banked sections or patient tissues from the MD Anderson Cancer Center, the inventors showed that EphA5 protein is overexpressed by human lung adenocarcinoma epithelium.

Immunohistochemistry (polyclonal anti-prohibitin antibody) on formalin-fixed paraffin sections of human non-small cell lung cancer (NSLC) or normal prostate with EphA5 or EphA4-specific antibodies. Immunostaining demonstrates selective EphA5 upregulation of EphA5 protein expression in NSLC lung adenocarcinoma epithelium, but not stroma, as compared with the control prostate tissue.

Taken together, these data suggest that the two selected phage displaying the motif GGS are ligands of EphA5 receptor. Upregulation of EphA5 in gliomas has been reported, without any functional connections, and, up to date, there has been no reports of investigation of this tyrosine kinase receptor in lung cancer. Therefore, EphA5 protein overexpression in lung cancer cells (FIG. 4) in light of candidate ephrin mimics (GGS peptides) targeting these cells provides an original evidence for EphA5 being a lung cancer marker and has potential functional implications.

It is contemplated by the inventors that the cancer-associated motifs identified here can be used for the development of approaches for targeted imaging or therapy of breast tumors in patients. Their receptors, including EGFR, EphA5, and other cell surface molecules, can be further explored for their oncogenic properties and the potential to serve as universal or origin/grade-selective targets of cancer.

Example 14 Cell Internalization of Ephrin-Mimic Peptides

The ability of ephrin-mimic peptides to mediate cell internaization was assessed. The A549 cell line was used as a representative human lung cancer-derived cells expressing the EphA5 receptor on the cell surface. Each phage clone or control insertless phage was incubated with cells for 4 h at 37° C. Both CSGIGSGGC (SEQ ID NO:2) and CRFESSGGC (SEQ ID NO:3)-phage were internalized into A549 cells while only background fluorescence was obtained when nontargeted control phage was used (see FIG. 8).

Example 15 Activation of Cells by Ephrin-Mimic Peptide

Activation of the EphA5 receptor by the peptides CSGIGSGGC (SEQ ID NO: 2) and CRFESSGGC (SEQ ID NO:3) lead to proliferation and/or survival of lung cancer cells. In the absence of sera, this peptides increased lung cancer cells proliferation by 4-fold (FIG. 9A-B). This effect was confirmed in two different human cell lines, which express the EphA5 receptor.

TABLE 3 Peptides and Motifs Associated with NCI-60 cell lines. Peptide Motif w/Seq ID: No. Cell Line RLS LRLSSIP (6) CCRF-CEM Leukemia RGV ARGVLLM (7) CCRF-CEM Leukemia RGS RGSHLVP (8) CCRF-CEM Leukemia DVETRGS (9) CCRF-CEM Leukemia RAV SRAVIDM (10) CCRF-CEM Leukemia RAS CCRF-CEM Leukemia GAG CCRF-CEM Leukemia AVS CCRF-CEM Leukemia LLS GLLSLXL (11) CCRF-CEM Leukemia TSLLSFR (12) CCRF-CEM Leukemia LLR CCRF-CEM Leukemia LRV CCRF-CEM Leukemia LRS CCRF-CEM Leukemia RVS RRVSLVA (13) CCRF-CEM Leukemia SRFRVSI (14) CCRF-CEM Leukemia RSS CCRF-CEM Leukemia AGS AGSLSVF (15) CCRF-CEM Leukemia AGR AGRICEG (16) CCRF-CEM Leukemia QVAGRER (17) CCRF-CEM Leukemia VEYAAGR (18) CCRF-CEM Leukemia AGL YNRSAGL (19) CCRF-CEM Leukemia AGG AVLVAGG (20) CCRF-CEM Leukemia LAGGVPG (21) CCRF-CEM Leukemia GVR DWWAGVR (22) CCRF-CEM Leukemia EPDGVRS (23) CCRF-CEM Leukemia EQLSGVR (24) CCRF-CEM Leukemia GVL GVLARVT (25) CCRF-CEM Leukemia ARGVLLM (26) CCRF-CEM Leukemia GAV GGAVLVA (27) CCRF-CEM Leukemia RERGAVQ (28) CCRF-CEM Leukemia GLV RALGLVS (29) CCRF-CEM Leukemia GLR SLGLRNQ (30) CCRF-CEM Leukemia LVS RALGLVS (31) CCRF-CEM Leukemia GAYRLVS (32) CCRF-CEM Leukemia ARG FDARGGL (33) CCRF-CEM Leukemia MFARGWE (34) CCRF-CEM Leukemia ARGVLLM (35) CCRF-CEM Leukemia ASL CCRF-CEM Leukemia AAV CCRF-CEM Leukemia AAS CCRF-CEM Leukemia GGS GGGSDGV (36) CCRF-CEM Leukemia GGR LGGRADF (37) CCRF-CEM Leukemia CCRF-CEM Leukemia GLG CCRF-CEM Leukemia GGL EVGGGLT (38) CCRF-CEM Leukemia FDARGGL (39) CCRF-CEM Leukemia GSS CCRF-CEM Leukemia GSG CCRF-CEM Leukemia GSV CCRF-CEM Leukemia GRV TGRVVRR (40) CCRF-CEM Leukemia GRL CCRF-CEM Leukemia GPS MGMSGPS (41) CCRF-CEM Leukemia GVS CCRF-CEM Leukemia RLS HL-60-Leukemia RGV AVRGVAR (42) HL-60-Leukemia DRGVPGL (43) HL-60-Leukemia RGS LSFSRGS (44) HL-60-Leukemia RGSVRVL (45) HL-60-Leukemia PVRGSVD (46) HL-60-Leukemia QVMMRGS (47) HL-60-Leukemia NGRGSGW (48) HL-60-Leukemia RAV RAVGRVA (49) HL-60-Leukemia RAS RASCALT (50) HL-60-Leukemia GAG ADIGAGG (51) HL-60-Leukemia FMGAGFA (52) HL-60-Leukemia AVS AGVFAVS (53) HL-60-Leukemia LLS HL-60-Leukemia LLR VMLLRPE (54) HL-60-Leukemia LLRGLEL (55) HL-60-Leukemia LPLLRGI (56) HL-60-Leukemia LRV DPRGLRV (57) HL-60-Leukemia LRS HL-60-Leukemia RVS LVRVSGR (58) HL-60-Leukemia SGSRVSL (59) HL-60-Leukemia RSS HL-60-Leukemia AGS AGSIALR (60) HL-60-Leukemia AGR MLASAGR (61) HL-60-Leukemia AGL HL-60-Leukemia AGG ADIGAGG (62) HL-60-Leukemia FAGGSTD (63) HL-60-Leukemia GVR HL-60-Leukemia GVL HL-60-Leukemia GAV TGFGAVG (64) HL-60-Leukemia HL-60-Leukemia GLV HL-60-Leukemia GLR FGLRNSR (65) HL-60-Leukemia DPRGLRV (66) HL-60-Leukemia LVS LVSSGSK (67) HL-60-Leukemia LVSSSEP (68) HL-60-Leukemia ARG HL-60-Leukemia ASL HL-60-Leukemia AAV AAVWAAD (69) HL-60-Leukemia AAS HL-60-Leukemia GGS FAGGSTD (70) HL-60-Leukemia GGR HL-60-Leukemia GLG HL-60-Leukemia GGL TFGKGGL (71) HL-60-Leukemia GSS KSGSSVL (72) HL-60-Leukemia HL-60-Leukemia GSG WGSGRGN (73) HL-60-Leukemia GSV RGSVRVL (74) HL-60-Leukemia PVRGSVD (75) HL-60-Leukemia TEGSVTV (76) HL-60-Leukemia GRV RAVGRVA (77) HL-60-Leukemia DVSGRVP (78) HL-60-Leukemia LGQCGRV (79) HL-60-Leukemia GRL GRLRLTD (80) HL-60-Leukemia LELGRLL (81) HL-60-Leukemia IGRLLPL (82) HL-60-Leukemia SDENGRL (83) HL-60-Leukemia GPS HL-60-Leukemia GVS HL-60-Leukemia RLS K-562-Leukemia RGV ELHPRGV (84) K-562-Leukemia FDRGVEA (85) K-562-Leukemia RGS EAVSRGS (86) K-562-Leukemia WTKRGSV (87) K-562-Leukemia RAV K-562-Leukemia RAS ERASQTA (88) K-562-Leukemia GAG K-562-Leukemia AVS EAVSRGS (89) K-562-Leukemia LLS AATLLSF (90) K-562-Leukemia LLSASLV (91) K-562-Leukemia RRHGLLS (92) K-562-Leukemia LLR RYSTLLR (93) K-562-Leukemia LRV FTLRVDK (94) K-562-Leukemia LRS K-562-Leukemia RVS SHRVSDS (95) K-562-Leukemia K-562-Leukemia RSS NRSSAKF (96) K-562-Leukemia LRRSSFS (97) K-562-Leukemia AGS AIRAGSD (98) K-562-Leukemia VLFSAGS (99) K-562-Leukemia AGR K-562-Leukemia AGL K-562-Leukemia AGG K-562-Leukemia GVR K-562-Leukemia GVL GVLHSIA (100) K-562-Leukemia GAV RQTTGAV (101) K-562-Leukemia GLV CQGLVLQ (102) K-562-Leukemia GLR PPPWGLR (103) K-562-Leukemia LVS K-562-Leukemia ARG SNARGPR (104) K-562-Leukemia ASL LLSASLV (105) K-562-Leukemia AAV AAVFVRS (106) K-562-Leukemia AAS K-562-Leukemia GGS FFGGSRA (107) K-562-Leukemia GGSQCDT (108) K-562-Leukemia VWGVGGS (109) K-562-Leukemia GGR FAWGGRG (110) K-562-Leukemia GLG GLGIMGP (111) K-562-Leukemia GGL K-562-Leukemia GSS SSGSSNG (112) K-562-Leukemia GSG K-562-Leukemia GSV WTKRGSV (113) K-562-Leukemia GRV K-562-Leukemia GRL K-562-Leukemia GPS K-562-Leukemia GVS GVSTGFT (114) K-562-Leukemia RLS Molt-4-Leukemia RGV CHARGVT (115) Molt-4-Leukemia RGS WGRGSVA (116) Molt-4-Leukemia RAV Molt-4-Leukemia RAS Molt-4-Leukemia GAG LRSGAGS (117) Molt-4-Leukemia AVS RAAVSAI (118) Molt-4-Leukemia AVSGRGW (119) Molt-4-Leukemia LLS LLSFLGR (120) Molt-4-Leukemia LLR Molt-4-Leukemia LRV Molt-4-Leukemia LRS GFYWLRS (121) Molt-4-Leukemia RVS RGARVSA (122) Molt-4-Leukemia RSS GGRSSHP (123) Molt-4-Leukemia RSSIAPS (124) Molt-4-Leukemia AGS LAGSGSH (125) Molt-4-Leukemia LRSGAGS (126) Molt-4-Leukemia AGR ASVRAGR (127) Molt-4-Leukemia AGL Molt-4-Leukemia AGG Molt-4-Leukemia GVR IGVRGFF (128) Molt-4-Leukemia GVL ANGVLEL (129) Molt-4-Leukemia Molt-4-Leukemia GAV WFGAVGL (130) Molt-4-Leukemia GLV GLVRGTA (131) Molt-4-Leukemia GLVRGTA Molt-4-Leukemia EGLVSVV (132) Molt-4-Leukemia GLR DLGLRPV (133) Molt-4-Leukemia LVS ALVSRRG (134) Molt-4-Leukemia EVLVSGD (135) Molt-4-Leukemia EGLVSVV (136) Molt-4-Leukemia ARG CHARGVT (137) Molt-4-Leukemia ASL Molt-4-Leukemia AAV RAAVSAI (138) Molt-4-Leukemia AAS Molt-4-Leukemia GGS HRGGSQS (139) Molt-4-Leukemia GGR GGRSSHP (140) Molt-4-Leukemia SQSGGRH (141) Molt-4-Leukemia GLG ARAIGLG (142) Molt-4-Leukemia GGL STEGGGL (143) Molt-4-Leukemia GSS Molt-4-Leukemia GSG LAGSGSH (144) Molt-4-Leukemia GSV DGSVLVE (145) Molt-4-Leukemia WGRGSVA (146) Molt-4-Leukemia GRV ATGRVLG (147) Molt-4-Leukemia ATGRVLG (148) Molt-4-Leukemia FFGRVGI (149) Molt-4-Leukemia RIGRVWA (150) Molt-4-Leukemia GRL RGRLEVP (151) Molt-4-Leukemia GPS Molt-4-Leukemia GVS Molt-4-Leukemia RLS RRLSYRD (152) RPMI-8226-Leukemia SRLSYRG (153) RPMI-8226-Leukemia RGV FSSKRGV (154) RPMI-8226-Leukemia RGS RGSAQNF (155) RPMI-8226-Leukemia LRSGRGS (156) RPMI-8226-Leukemia LRSGRGS RPMI-8226-Leukemia LRSGRGS RPMI-8226-Leukemia YRGSSGK (157) RPMI-8226-Leukemia RAV RPMI-8226-Leukemia RAS FWISRAS (158) RPMI-8226-Leukemia GAG GAGSISD (159) RPMI-8226-Leukemia RAMGGAG (160) RPMI-8226-Leukemia AVS RPMI-8226-Leukemia LLS LLSTSIR (161) RPMI-8226-Leukemia LLR LLLRSGG (162) RPMI-8226-Leukemia LLRSAAP (163) RPMI-8226-Leukemia LRV RPMI-8226-Leukemia LRS LLLRSGG (164) RPMI-8226-Leukemia GRYSLRS (165) RPMI-8226-Leukemia LRSGRGS (166) RPMI-8226-Leukemia LRYDLRS (167) RPMI-8226-Leukemia LRYNLRS (168) RPMI-8226-Leukemia LLRSAAP (169) RPMI-8226-Leukemia SKYRLRS (170) RPMI-8226-Leukemia RVS VHRVSGG (171) RPMI-8226-Leukemia RSS RPMI-8226-Leukemia AGS GAGSISD (172) RPMI-8226-Leukemia AGR FAGRVPS (173) RPMI-8226-Leukemia AGL AGLSGSQ (174) RPMI-8226-Leukemia TDLAGLH (175) RPMI-8226-Leukemia AGG LAAGGEL (176) RPMI-8226-Leukemia GAGGMAR (177) RPMI-8226-Leukemia RAAGGSR (178) RPMI-8226-Leukemia GVR LYGVRYG (179) RPMI-8226-Leukemia PRYGVRA (180) RPMI-8226-Leukemia GVL RPMI-8226-Leukemia GAV GAVDGSR (181) RPMI-8226-Leukemia GLV ADFFGLV (182) RPMI-8226-Leukemia GLR KYYGLRR (183) RPMI-8226-Leukemia SRYGLRR (184) RPMI-8226-Leukemia LVS RPMI-8226-Leukemia ARG RPMI-8226-Leukemia ASL RPMI-8226-Leukemia AAV RPMI-8226-Leukemia AAS PAASRLL (185) RPMI-8226-Leukemia RLRAASY (186) RPMI-8226-Leukemia RPMI-8226-Leukemia GGS GGSRLLL (187) RPMI-8226-Leukemia RAAGGSR (188) RPMI-8226-Leukemia GGSVRHV (189) RPMI-8226-Leukemia GGR GGRSWVN (190) RPMI-8226-Leukemia GLG GLGNRPT (191) RPMI-8226-Leukemia HGLGSGT (192) RPMI-8226-Leukemia GGL RPMI-8226-Leukemia GSS GSSLHLL (193) RPMI-8226-Leukemia YRGSSGK (194) RPMI-8226-Leukemia GSG EGSGVDC (195) RPMI-8226-Leukemia HGLGSGT (196) RPMI-8226-Leukemia GSV SGSVNRG (197) RPMI-8226-Leukemia GGSVRHV (198) RPMI-8226-Leukemia GRV FAGRVPS (199) RPMI-8226-Leukemia GRL AMRPGRL (200) RPMI-8226-Leukemia GRLYYYR (201) RPMI-8226-Leukemia GPS PAFGPSR (202) RPMI-8226-Leukemia GVS HSGVSHG (203) RPMI-8226-Leukemia RLS VYYRLSA (204) SR Leukemia RGV SR Leukemia RGS GRGSFES (205) SR Leukemia RRGSSRN (206) SR Leukemia RAV HSRAVAP (207) SR Leukemia RAS RASFRAG (208) SR Leukemia LMGRASG (209) SR Leukemia WRASAFT (210) SR Leukemia GAG GAGRTVM (211) SR Leukemia AVS PLAVSMV (212) SR Leukemia LLS SR Leukemia LLR FLLRSSF (213) SR Leukemia WRLLRRQ (214) SR Leukemia LRS FLLRSSF (215) SR Leukemia LRSRLGF (216) SR Leukemia RVS GRRVSLV (217) SR Leukemia RSS FLLRSSF (218) SR Leukemia NRSSGRR (219) SR Leukemia VLGMRSS (220) SR Leukemia THRNRSS (221) SR Leukemia AGS LAGSTRR (222) SR Leukemia AGR AGRTGVG (223) SR Leukemia EFAVAGR (224) SR Leukemia GAGRTVM (225) SR Leukemia REEFAGR (226) SR Leukemia AGL SR Leukemia AGG AGGPTKY (227) SR Leukemia FHVAGGS (228) SR Leukemia WSAGGPH (229) SR Leukemia GVR SR Leukemia GVL SR Leukemia GAV RGAVAFE (230) SR Leukemia SGGAVHF (231) SR Leukemia GAVRARL (232) SR Leukemia GLV GLVRGFP (233) SR Leukemia GAHGLVR (234) SR Leukemia SSRMGLV (235) SR Leukemia YVGLVVS (236) SR Leukemia GLR GLRKAGF (237) SR Leukemia AVDGLRL (238) SR Leukemia FGLRSRL (239) SR Leukemia LVS SR Leukemia ARG SR Leukemia ERARGYP (240) SR Leukemia GSARGML (241) SR Leukemia ASL ASLRYYV (242) SR Leukemia NAASLPS (243) SR Leukemia WLDASLM (244) SR Leukemia AAV SR Leukemia AAS NAASLPS (245) SR Leukemia GGS FHVAGGS (246) SR Leukemia GEHLGGS (247) SR Leukemia GGR SR Leukemia GLG SR Leukemia GGL SGGLHEG (248) SR Leukemia LRV SR Leukemia RLS SRLSYRS (249) A549-Lung RGV GGLRGVR (250) A549-Lung VAWRGVS (251) A549-Lung SVEGRGV (252) A549-Lung RGS FWRGSVP (253) A549-Lung RAV A549-Lung RAS EFTRRAS (254) A549-Lung WGWRASS (255) A549-Lung GAG A549-Lung AVS A549-Lung LLS A549-Lung LLR A549-Lung LRV A549-Lung LRS RFYHLRS (256) A549-Lung SRYSLRS (257) A549-Lung RVS A549-Lung RSS RRSSKQA (258) A549-Lung DWGRSSF (259) A549-Lung RFTRSSG (260) A549-Lung VFQRSSG (261) A549-Lung AGS AGSQSWE (262) A549-Lung AGR A549-Lung AGL A549-Lung AGG EHPAGGM (263) A549-Lung GVR GVRTAGP (264) A549-Lung GGLRGVR (265) A549-Lung LYGGVRY (266) A549-Lung GVL PVGGVLL (267) A549-Lung GAV GAVVKPI (268) A549-Lung SVGAVGG (269) A549-Lung GLV GLVSVEA (270) A549-Lung GLR GGLRGVR (271) A549-Lung LVS DIALVSP (272) A549-Lung GLVSVEA (273) A549-Lung ARG A549-Lung ASL A549-Lung AAV A549-Lung AAS ARNAASP (274) A549-Lung GGS AEGGSGH (275) A549-Lung GGSFSGL (276) A549-Lung GGR VTGGRVD (277) A549-Lung GLG A549-Lung GGL GGLRGVR (278) A549-Lung A549-Lung GSS GSSWVVD (279) A549-Lung GSSRTFR (280) A549-Lung GSSRQFV (281) A549-Lung WVGSSKF (282) A549-Lung GSG AEGGSGH (283) A549-Lung EVIGSGI (284) A549-Lung GSV FWRGSVP (285) A549-Lung VGSVSVN (286) A549-Lung GRV VTGGRVD (287) A549-Lung GRVTVAV (288) A549-Lung GRL RVGRLGG (289) A549-Lung GPS NYMGPSA (290) A549-Lung GWHGPSH (291) A549-Lung GVS GGVSPVD (292) A549-Lung GVSKVRA (293) A549-Lung GGVAGVS (294) A549-Lung VAWRGVS (295) A549-Lung RLS VIGSRLS (296) EKVX-Lung RGV HLRGRGV (297) EKVX-Lung RGS EVRSRGS (298) EKVX-Lung RGSRLPA (299) EKVX-Lung RAV DVRAVSS (300) EKVX-Lung RAS EKVX-Lung GAG EKVX-Lung AVS DVRAVSS (301) EKVX-Lung LLS EKVX-Lung LLR EKVX-Lung LRV EKVX-Lung LRS APLRSGR (302) EKVX-Lung SLRSGIV (303) EKVX-Lung RVS EKVX-Lung RSS DGGRRSS (304) EKVX-Lung AGS QAGSFLR (305) EKVX-Lung DAGSDRR (306) EKVX-Lung AGR AGRRFGG (307) EKVX-Lung AGL AGLSGGT (308) EKVX-Lung AGG AGGGPPA (309) EKVX-Lung AGGGPPA (310) EKVX-Lung FFPAGGP (311) EKVX-Lung PRAGGRW (312) EKVX-Lung GVR DVPGVRF (313) EKVX-Lung GVL FGVLFRS (314) EKVX-Lung SRYGVLV (315) EKVX-Lung GAV EKVX-Lung GLV LRGGLVS (316) EKVX-Lung GLR KSGLRPA (317) EKVX-Lung LVS ALVSFSV (318) EKVX-Lung LRGGLVS (319) EKVX-Lung ARG HKLARGR (320) EKVX-Lung ASL ASLPPRA (321) EKVX-Lung AAV EKVX-Lung AAS EKVX-Lung GGS TGGSLGA (322) EKVX-Lung GGGSWLI (323) EKVX-Lung GGR DGGRRSS (324) EKVX-Lung SVLGGRL (325) EKVX-Lung PRAGGRW (326) EKVX-Lung GLG YWFIGLG (327) EKVX-Lung GGL GGLSVDL (328) EKVX-Lung LRGGLVS (329) EKVX-Lung GSS SGVGSSL (330) EKVX-Lung GSG GSGILDL (331) EKVX-Lung GSV SLGSVGS (332) EKVX-Lung GRV EKVX-Lung GRL VGRGRLH (333) EKVX-Lung SVLGGRL (334) EKVX-Lung MSAFGRL (335) EKVX-Lung GPS EKVX-Lung GVS SGVSGLS (336) EKVX-Lung RLS Hop-62-Lung RGV GDSRRGV (337) Hop-62-Lung GKALRGV (338) Hop-62-Lung RGS PKAGRGS (339) Hop-62-Lung RAV FDRAVAN (340) Hop-62-Lung LLRRAVF (341) Hop-62-Lung RAS FRASSEV (342) Hop-62-Lung PDRASDG (343) Hop-62-Lung FRASLQY (344) Hop-62-Lung GAG Hop-62-Lung AVS Hop-62-Lung LLS Hop-62-Lung LLR HVGLLRA (345) Hop-62-Lung QVLLRSF (346) Hop-62-Lung LLRRAVF (347) Hop-62-Lung LRV FLRVGEL (348) Hop-62-Lung LRS QVLLRSF (349) Hop-62-Lung RVS RRVSCDL (350) Hop-62-Lung RSS RSSGLGF (351) Hop-62-Lung SSGPRSS (352) Hop-62-Lung YSQRSSL (353) Hop-62-Lung Hop-62-Lung AGS Hop-62-Lung AGR DAGRTID (354) Hop-62-Lung AAGREFR (355) Hop-62-Lung PKAGRGS (356) Hop-62-Lung VRAAGRV (357) Hop-62-Lung Hop-62-Lung AGL Hop-62-Lung AGG HGYRAGG (358) Hop-62-Lung WGATAGG (359) Hop-62-Lung YYAGGLK (360) Hop-62-Lung GVR LEGVRLF (361) Hop-62-Lung GVRPFPR (362) Hop-62-Lung GVL GTFGVLG (363) Hop-62-Lung VWAGVLL (364) Hop-62-Lung GAV GAVLFRV (365) Hop-62-Lung GLV GLVGFTG (366) Hop-62-Lung GLVSAFY (367) Hop-62-Lung GLR ARAMGLR (368) Hop-62-Lung LVS GLVSAFY (369) Hop-62-Lung SWRPLVS (370) Hop-62-Lung ARG Hop-62-Lung ASL FRASLQY (371) Hop-62-Lung AAV HSESAAV (372) Hop-62-Lung LFAVAAV (373) Hop-62-Lung AAS VAASESH (374) Hop-62-Lung GGS Hop-62-Lung GGR HPSMGGR (375) Hop-62-Lung GLG GLGVSGV (376) Hop-62-Lung KRESGLG (377) Hop-62-Lung RSSGLGF (378) Hop-62-Lung VGLGHWP (379) Hop-62-Lung GGL YYAGGLK (380) Hop-62-Lung GSS NYGSSFH (381) Hop-62-Lung FGLGSSR (382) Hop-62-Lung SSRPGSS (383) Hop-62-Lung GSG Hop-62-Lung GSV VGSVGLG (384) Hop-62-Lung GRV VRAAGRV (385) Hop-62-Lung GRL HNGRLEV (386) Hop-62-Lung VGRLAKG (387) Hop-62-Lung GPS VMGGPSL (388) Hop-62-Lung GVS GLGVSGV (389) Hop-62-Lung SGVSVEG (390) Hop-62-Lung RLS GESGRLS (391) Hop-92-Lung RGV GSGRGVA (392) Hop-92-Lung RGVVSAK (393) Hop-92-Lung RGVVSGV (394) Hop-92-Lung RGS AVGRGSG (395) Hop-92-Lung SLRGSEG (396) Hop-92-Lung PATRGSV (397) Hop-92-Lung RAV SLTRAVR (398) Hop-92-Lung VARAVPC (399) Hop-92-Lung RAS EGARASD (400) Hop-92-Lung GAG Hop-92-Lung AVS MGSAVSL (401) Hop-92-Lung LLS Hop-92-Lung LLR GGALLRG (402) Hop-92-Lung LRV Hop-92-Lung LRS Hop-92-Lung RVS PNRRVSA (403) Hop-92-Lung QDRVSRS (404) Hop-92-Lung RSS SERSSLG (405) Hop-92-Lung LVRSSGL (406) Hop-92-Lung AGS Hop-92-Lung AGR Hop-92-Lung AGL INWAGLS (407) Hop-92-Lung WAGLSPS (408) Hop-92-Lung AGG GRLLAGG (409) Hop-92-Lung GVR Hop-92-Lung GVL Hop-92-Lung GAV Hop-92-Lung GLV SYGLVLP (410) Hop-92-Lung SGGLVLT (411) Hop-92-Lung HAAHGLV (412) Hop-92-Lung GLR GLRTRQV (413) Hop-92-Lung LVS LVSGYNG (414) Hop-92-Lung ARG AGIARGG (415) Hop-92-Lung ASL Hop-92-Lung AAV Hop-92-Lung AAS Hop-92-Lung GGS HVSGGSG (416) Hop-92-Lung GGSSEFR (417) Hop-92-Lung GGSGIGS (418) Hop-92-Lung SWGSGGS (419) Hop-92-Lung TLVLGGS (420) Hop-92-Lung GGR AVRGGRP (421) Hop-92-Lung GGRAIGA (422) Hop-92-Lung GLG Hop-92-Lung GGL SGGLVLT (423) Hop-92-Lung GSS RTGSSDL (424) Hop-92-Lung LGSSRVL (425) Hop-92-Lung GGSSEFR (426) Hop-92-Lung GSG AVGRGSG (427) Hop-92-Lung HVSGGSG (428) Hop-92-Lung SGIGSGG (429) Hop-92-Lung SWGSGGS (430) Hop-92-Lung WVGSGSP (431) Hop-92-Lung GSV GSGGSVH (432) Hop-92-Lung GNYGSVL (433) Hop-92-Lung VGSVVGR (434) Hop-92-Lung PATRGSV (435) Hop-92-Lung GRV PRGGRVA (436) Hop-92-Lung GRVHLMP (437) Hop-92-Lung GRL GESGRLS (438) Hop-92-Lung GRLLAGG (439) Hop-92-Lung GRLWWHT (440) Hop-92-Lung GRLWSRV (441) Hop-92-Lung GPS AGPSAWL (442) Hop-92-Lung GVS SGVSRGQ (443) Hop-92-Lung RLS H226-Lung RGV RGVSLKG (444) H226-Lung RGS H226-Lung RAV QMQGRAV (445) H226-Lung RAS H226-Lung GAG H226-Lung AVS H226-Lung LLS H226-Lung LLR H226-Lung LRV H226-Lung LRS RGLRSVN (446) H226-Lung RVS H226-Lung RSS RSSLGLP (447) H226-Lung AGS LEAGSQL (448) H226-Lung AGR H226-Lung AGL H226-Lung AGG AGGQSER (449) H226-Lung GVR H226-Lung GVL GGVLYLE (450) H226-Lung GAV H226-Lung GLV H226-Lung GLR RGLRSVN (451) H226-Lung LVS H226-Lung ARG VARGQMQ (452) H226-Lung ASL H226-Lung AAV H226-Lung AAS H226-Lung GGS GGSRNRW (453) H226-Lung GGR GGGRSGV (454) H226-Lung GLG GLGGWVA (455) H226-Lung GGL AVWGGLG (456) H226-Lung GGLSECV (457) H226-Lung GSS H226-Lung GSG H226-Lung GSV AKLGSVY (458) H226-Lung GRV QGRVNVK (459) H226-Lung GRL GRLWGFW (460) H226-Lung GPS H226-Lung GVS RGVSLKG (461) H226-Lung GSLGVSL (462) H226-Lung RLS LLRLSLA (463) H23-Lung RGV H23-Lung RGS RRGSGGL (464) H23-Lung VRGSVRA (465) H23-Lung RAV H23-Lung RAS H23-Lung GAG H23-Lung AVS H23-Lung LLS H23-Lung LLR LLRLSLA (466) H23-Lung LRV PLRVDNL (467) H23-Lung LRVGIGY (468) H23-Lung QGYALRV (469) H23-Lung LRS PLRSFDS (470) H23-Lung RVS ARVSGRV (471) H23-Lung RSS PFPARSS (472) H23-Lung AGS AGSPLAK (473) H23-Lung FVDIAGS (474) H23-Lung AGR SYFRAGR (475) H23-Lung AGL AGLGHEG (476) H23-Lung AGG AGGSLGS (477) H23-Lung GVR YGIGVRL (478) H23-Lung GVL RANGVLV (479) H23-Lung GAV H23-Lung GLV H23-Lung GLR H23-Lung LVS H23-Lung ARG H23-Lung ASL LASLGVG (480) H23-Lung AAV RAAVGAR (481) H23-Lung AAS H23-Lung GGS GCDGGSA (482) H23-Lung GGSGELG (483) H23-Lung LGGSGRR (484) H23-Lung AGGSLGS (485) H23-Lung GGR IGGREIT (486) H23-Lung GLG GEHGLGA (487) H23-Lung GGL RRGSGGL (488) H23-Lung GSS RSGSSVY (489) H23-Lung GSG GLEGSGG (490) H23-Lung LGGSGRR (491) H23-Lung GSV TTGSVIV (492) H23-Lung VRGSVRA (493) H23-Lung GRV HGRVHRL (494) H23-Lung ARVSGRV (495) H23-Lung GRL H23-Lung GPS H23-Lung GVS SGHGVSA (496) H23-Lung RLS AVWRLSH (497) H322-Lung RGV RGVFYGK (498) H322-Lung RGVGWAK (499) H322-Lung RGS SRGSTAG (500) H322-Lung RAV H322-Lung RAS H322-Lung GAG SEDEGAG (501) H322-Lung STSLGAG (502) H322-Lung AVS H322-Lung LLS H322-Lung LLR DLLRYLA (503) H322-Lung LRV LRVRYAV (504) H322-Lung LRS LRSSGAT (505) H322-Lung LSMLRSA (506) H322-Lung RVS REAERVS (507) H322-Lung RSS LRSSGAT (508) H322-Lung AGS TAGSSRL (509) H322-Lung AGR AAGRAGC (510) H322-Lung AGL GAGLSTS (511) H322-Lung AGG H322-Lung GVR PSVGVRA (512) H322-Lung GVL H322-Lung GAV VGAVYFL (513) H322-Lung GLV H322-Lung GLR LGLRAFV (514) H322-Lung LVS TELVSWS (515) H322-Lung ARG CGARGAA (516) H322-Lung ASL H322-Lung AAV H322-Lung AAS H322-Lung GGS GGSRAAE (517) H322-Lung VNLGGSW (518) H322-Lung GGR LIGPGGR (519) H322-Lung GLG H322-Lung GGL LGGLSPH (520) H322-Lung WSGGLNV (521) H322-Lung GSS TAGSSRL (522) H322-Lung SDVSGSS (523) H322-Lung WGSSTVR (524) H322-Lung GSG H322-Lung GSV NLADGSV (525) H322-Lung SSGSVDS (526) H322-Lung GRV GRVPGFE (527) H322-Lung GRVVGEA (528) H322-Lung GRL H322-Lung GPS SRFGPSV (529) H322-Lung GVS ARVGVSP (530) H322-Lung RLS H460-Lung RGV PGKRGVQ (531) H460-Lung RGVASRS (532) H460-Lung RGS ERGSPSR (533) H460-Lung RAV LIRAVSA (534) H460-Lung RAVEMGT (535) H460-Lung RAS H460-Lung GAG WGAGFWM (536) H460-Lung AVS LIRAVSA (537) H460-Lung LLS H460-Lung LLR H460-Lung LRV H460-Lung LRS DRYMLRS (538) H460-Lung RVS H460-Lung RSS PRSSYNE (539) H460-Lung PRSSLVV (540) H460-Lung AGS H460-Lung AGR H460-Lung AGL RRFWAGL (541) H460-Lung AGG PVHSAGG (542) H460-Lung GVR H460-Lung GVL FGGSGVL (543) H460-Lung SSGGVLG (544) H460-Lung GAV H460-Lung GLV GLVGGSS (545) H460-Lung LSSGLVS (546) H460-Lung GLR H460-Lung LVS LSSGLVS (547) H460-Lung WFSWLVS (548) H460-Lung ARG H460-Lung ASL GASLTGD (549) H460-Lung WSSTASL (550) H460-Lung AAV H460-Lung AAS H460-Lung GGS FGGSGVL (551) H460-Lung GLVGGSS (552) H460-Lung GGR H460-Lung GLG H460-Lung GGL GGLSPHR (553) H460-Lung GSS GLVGGSS (554) H460-Lung SVLGSSL (555) H460-Lung GSG FGGSGVL (556) H460-Lung GSV H460-Lung GRV DVRGRVW (557) H460-Lung AEPRGRV (558) H460-Lung GRL H460-Lung GPS SIGPSTN (559) H460-Lung GVS GVSIRQL (560) H460-Lung RLS H522-Lung RGV H522-Lung RGS H522-Lung RAV H522-Lung RAS H522-Lung GAG H522-Lung AVS AVSKRLP (561) H522-Lung RLAVSGY (562) H522-Lung H522-Lung LLS H522-Lung LLR H522-Lung LRV H522-Lung LRS RREGLRS (563) H522-Lung SRYWLRS (564) H522-Lung H522-Lung RVS H522-Lung RSS H522-Lung AGS H522-Lung AGR AVYRAGR (565) H522-Lung H522-Lung AGL H522-Lung AGG H522-Lung GVR H522-Lung GVL H522-Lung GAV H522-Lung GLV H522-Lung GLR RHFGLRE (566) H522-Lung RREGLRS (567) H522-Lung H522-Lung LVS H522-Lung ARG H522-Lung ASL GQGAASL (568) H522-Lung AAV H522-Lung AAS GQGAASL (569) H522-Lung H522-Lung GGS H522-Lung GGR H522-Lung GLG H522-Lung GGL H522-Lung GSS H522-Lung GSG H522-Lung GSV YGSVALR (570) H522-Lung H522-Lung GRV H522-Lung GRL H522-Lung GPS H522-Lung GVS H522-Lung RLS COLO-205-Colon RGV ARRGVLG (571) COLO-205-Colon LRIARGV (572) COLO-205-Colon RGS YRGSMVG (573) COLO-205-Colon GLRGSVW (574) COLO-205-Colon RAV GPFRAVP (575) COLO-205-Colon RAS COLO-205-Colon GAG COLO-205-Colon AVS COLO-205-Colon LLS COLO-205-Colon LLR COLO-205-Colon LRV COLO-205-Colon LRS AHYTLRS (576) COLO-205-Colon SELRSIR (577) COLO-205-Colon SVYALRS (578) COLO-205-Colon RVS COLO-205-Colon RSS COLO-205-Colon AGS COLO-205-Colon AGR COLO-205-Colon AGL COLO-205-Colon AGG COLO-205-Colon GVR COLO-205-Colon GVL ARRGVLG (579) COLO-205-Colon GAV PGAVLTV (580) COLO-205-Colon GLV GLVGRRA (581) COLO-205-Colon GLVRCVL (582) COLO-205-Colon YDGLVSG (583) COLO-205-Colon GLVTAPL (584) COLO-205-Colon RGLVRVV (585) COLO-205-Colon GLR GLRGSVW (586) COLO-205-Colon NSFGLRY (587) COLO-205-Colon LVS YDGLVSG (588) COLO-205-Colon ARG AARGLEA (589) COLO-205-Colon DNDGARG (590) COLO-205-Colon LRIARGV (591) COLO-205-Colon ASL COLO-205-Colon AAV MSNLAAV (592) COLO-205-Colon AAS COLO-205-Colon GGS COLO-205-Colon GGR COLO-205-Colon GLG COLO-205-Colon GGL COLO-205-Colon GSS YSGSSDF (593) COLO-205-Colon GSG COLO-205-Colon GSV GSVLGDY (594) COLO-205-Colon GLRGSVW (595) COLO-205-Colon GRV DLDGRVV (596) COLO-205-Colon GRL WVSGRLG (597) COLO-205-Colon GPS GPSSMTF (598) COLO-205-Colon GVS DGVSSDY (599) COLO-205-Colon FTSGVSW (600) COLO-205-Colon RLS HCC-2998-Colon RGV HCC-2998-Colon RGS HCC-2998-Colon RAV HCC-2998-Colon RAS VLTRAST (601) HCC-2998-Colon LRASLLW (602) HCC-2998-Colon GAG HCC-2998-Colon AVS HCC-2998-Colon LLS WLLSARL (603) HCC-2998-Colon LLR LLRPGTV (604) HCC-2998-Colon LRV HCC-2998-Colon LRS HCC-2998-Colon RVS HCC-2998-Colon RSS HCC-2998-Colon AGS HCC-2998-Colon AGR HCC-2998-Colon AGL HCC-2998-Colon AGG AAGGLLV (605) HCC-2998-Colon GVR HCC-2998-Colon GVL HCC-2998-Colon GAV HCC-2998-Colon GLV HCC-2998-Colon GLR HCC-2998-Colon LVS HCC-2998-Colon ARG HCC-2998-Colon ASL LRASLLW (606) HCC-2998-Colon AAV HCC-2998-Colon AAS HCC-2998-Colon GGS HCC-2998-Colon GGR HCC-2998-Colon GLG LWGLGWL (607) HCC-2998-Colon RRSGLGD (608) HCC-2998-Colon WWGLGWL (609) HCC-2998-Colon GGL AAGGLLV (610) HCC-2998-Colon GSS HCC-2998-Colon GSG HCC-2998-Colon GSV HCC-2998-Colon GRV HCC-2998-Colon GRL HCC-2998-Colon GPS HCC-2998-Colon GVS HCC-2998-Colon RLS HCT-116 Colon RGV GLRGVVK (611) HCT-116 Colon RGS AVEGRGS (612) HCT-116 Colon NAVRGSA (613) HCT-116 Colon RAV HCT-116 Colon RAS HCT-116 Colon GAG HCT-116 Colon AVS HCT-116 Colon LLS HCT-116 Colon LLR LLRSSLG (614) HCT-116 Colon MYLRLLR (615) HCT-116 Colon LRV HCT-116 Colon LRS LLRSSLG (616) HCT-116 Colon DEGLRSR (617) HCT-116 Colon RVS YWQHRVS (618) HCT-116 Colon RSS ARSSHRA (619) HCT-116 Colon LLRSSLG (620) HCT-116 Colon AGS HCT-116 Colon AGR AGRSCNL (621) HCT-116 Colon AGRPRAT (622) HCT-116 Colon AGL HCT-116 Colon AGG HCT-116 Colon GVR GGVRIAA (623) HCT-116 Colon GVRYLRT (624) HCT-116 Colon GVL HCT-116 Colon GAV HCT-116 Colon GLV PLAVGLV (625) HCT-116 Colon GLR GLRGVVK (626) HCT-ll6 Colon DEGLRSR (627) HCT-116 Colon LVS QLVSGSL (628) HCT-116 Colon ARG HCT-116 Colon ASL GWSASLG (629) HCT-116 Colon AAV IAAVWRS (630) HCT-116 Colon AAS HCT-116 Colon GGS GGSSLDA (631) HCT-116 Colon LGGSRDL (632) HCT-116 Colon GGR LIGGRNA (633) HCT-116 Colon GLG HCT-116 Colon GGL LDRSGGL (634) HCT-116 Colon GSS GGSSLDA (635) HCT-116 Colon GSSYSGP (636) HCT-116 Colon GSG TVGSGCL (637) HCT-116 Colon GSV LSGSVLQ (638) HCT-116 Colon GRV ASGRVAN (639) HCT-116 Colon GRL KVVGRLG (640) HCT-116 Colon GRLVWGL (641) HCT-116 Colon NEFLGRL (642) HCT-116 Colon GPS LCDAGPS (643) HCT-116 Colon GVS FRAGVSH (644) HCT-116 Colon RLS AGDSRLS (645) HCT-15 Colon RGV HCT-15 Colon RGS HCT-15 Colon RAV DWRRRAV (646) HCT-15 Colon RAS WTERASA (647) HCT-15 Colon GAG HCT-15 Colon AVS HCT-15 Colon LLS RLLSAFG (648) HCT-15 Colon LLR GFASLLR (649) HCT-15 Colon LRV GALRVPW (650) HCT-15 Colon GALRVPW HCT-15 Colon GALRVPW HCT-15 Colon LRS SLRSDGA (651) HCT-15 Colon DTLRSQW (652) HCT-15 Colon LRSVGSW (653) HCT-15 Colon RVS HCT-15 Colon RSS ISPRSSG (654) HCT-15 Colon WRVRSSG (655) HCT-15 Colon AGS HCT-15 Colon AGR AAGRIRP (656) HCT-15 Colon RAAGRVG (657) HCT-15 Colon AGL AGLQHAV (658) HCT-15 Colon AGG AGGWWVG (659) HCT-15 Colon GVR GVRGAAR (660) HCT-15 Colon GVL GVLPVVT (661) HCT-15 Colon GVLPVVT HCT-15 Colon GAV HCT-15 Colon GLV GLVSSLP (662) HCT-15 Colon SRHGLVR (663) HCT-15 Colon SDRGLVV (664) HCT-15 Colon SDRGLVV (665) HCT-15 Colon GLR HCT-15 Colon LVS GLVSSLP (666) HCT-15 Colon LVSVWSR (667) HCT-15 Colon ARG GSWARGY (668) HCT-15 Colon ASL GFASLLR (669) HCT-15 Colon AAV HAAVMSL (670) HCT-15 Colon AAS HCT-15 Colon GGS HCT-15 Colon GGR DGGRRTD (671) HCT-15 Colon GRPLGGR (672) HCT-15 Colon GRVTGGR (673) HCT-15 Colon GLG HCT-15 Colon GGL RGGLPRG (674) HCT-15 Colon YGQYGGL (675) HCT-15 Colon GSS GSSRPSI (676) HCT-15 Colon PGSSFVG (677) HCT-15 Colon GSSRVRW (678) HCT-15 Colon GSG HCT-15 Colon GSV HCT-15 Colon GRV RAAGRVG (679) HCT-15 Colon GRVTGGR (680) HCT-15 Colon YVRIGRV (681) HCT-15 Colon GRL MITRGRL (682) HCT-15 Colon GPS HCT-15 Colon GVS SVVGVST (683) HCT-15 Colon WSGVSRL (684) HCT-15 Colon RLS RRLSYFH (685) HT-29 Colon PRLSWVL (686) HT-29 Colon RLSALTD (687) HT-29 Colon RGV GRGVGTD (688) HT-29 Colon LKVRGVL (689) HT-29 Colon SSTRGVY (690) HT-29 Colon QVRRGVV (691) HT-29 Colon GRGVTIW (692) HT-29 Colon RGS RGSVASA (693) HT-29 Colon HFIRGSV (694) HT-29 Colon RGSWAGV (695) HT-29 Colon VRGSRWR (696) HT-29 Colon RAV LERAVRT (697) HT-29 Colon RAS GYSRASD (698) HT-29 Colon SRASGHG (699) HT-29 Colon GHYRASV (700) HT-29 Colon DWVCRAS (701) HT-29 Colon GAG GAGRGTP (702) HT-29 Colon LSLAGAG (703) HT-29 Colon AVS ASAVSGR (704) HT-29 Colon FSGDAVS (705) HT-29 Colon LLS LKLLSVP (706) HT-29 Colon LLR HT-29 Colon LRV GTLRVGS (707) HT-29 Colon LRS EHYRLRS (708) HT-29 Colon LRSWLLF (709) HT-29 Colon RRPGLRS (710) HT-29 Colon SKYNLRS (711) HT-29 Colon WQVALRS (712) HT-29 Colon LRSDPRS (713) HT-29 Colon VPLRSSA (714) HT-29 Colon RVS HT-29 Colon RSS GRSSGME (715) HT-29 Colon VPLRSSA (716) HT-29 Colon AGS AGSGFPF (717) HT-29 Colon AGR GAGRGTP (718) HT-29 Colon AGRIASK (719) HT-29 Colon AGL WGVAGLG (720) HT-29 Colon LAGLVSG (721) HT-29 Colon AGG DAGGMDL (722) HT-29 Colon AGGRWNL (723) HT-29 Colon GVR GCGGVRD (724) HT-29 Colon SGVRLTG (725) HT-29 Colon GVL LKVRGVL (726) HT-29 Colon GAV GLGAVGW (727) HT-29 Colon PGAVPGA (728) HT-29 Colon RIGAVWY (729) HT-29 Colon GLV FSGLVVA (730) HT-29 Colon PGGLVPG (731) HT-29 Colon LAGLVSG (732) HT-29 Colon LGLVSTT (733) HT-29 Colon GLR GLRLGVT (734) HT-29 Colon RRPGLRS (735) HT-29 Colon LVS LAGLVSG (736) HT-29 Colon LGLVSTT (737) HT-29 Colon RQLVSPA (738) HT-29 Colon ARG LRARGGH (739) HT-29 Colon ASL ELWASLG (740) HT-29 Colon DTLASLR (741) HT-29 Colon VVASLPH (742) HT-29 Colon AAV HT-29 Colon AAS VLRAASR (743) HT-29 Colon AASGSYY (744) HT-29 Colon GGS GGSALFG (745) HT-29 Colon GRGGSGY (746) HT-29 Colon GGR YGSGGRG (747) HT-29 Colon GTLGGRV (748) HT-29 Colon AGGRWNL (749) HT-29 Colon HGGRARL (750) HT-29 Colon RGGRSPS (751) HT-29 Colon RKPGGGR (752) HT-29 Colon EGGRTHW (753) HT-29 Colon GLG GEVGLGV (754) HT-29 Colon GLGAVGW (755) HT-29 Colon GGL PGGLVPG (756) HT-29 Colon VRGGLTG (757) HT-29 Colon RQKCGGL (758) HT-29 Colon RYGVGGL (759) HT-29 Colon GSS EMGSSRG (760) HT-29 Colon GSG AGSGFPF (761) HT-29 Colon GRGGSGY (762) HT-29 Colon GSV GSVSAGA (763) HT-29 Colon RGSVASA (764) HT-29 Colon DLGSVQH (765) HT-29 Colon HFIRGSV (766) HT-29 Colon GSVLGAL (767) HT-29 Colon GRV GTLGGRV (768) HT-29 Colon LGRVHVW (769) HT-29 Colon LVGRVKL (770) HT-29 Colon RWRSGRV (771) HT-29 Colon GRL RNPGRLA (772) HT-29 Colon PRGRLFD (773) HT-29 Colon GRLAVVA (774) HT-29 Colon LAQGRLA (775) HT-29 Colon GGMNGRL (776) HT-29 Colon GPS RSTLGPS (777) HT-29 Colon GVS GVSALSL (778) HT-29 Colon GGR KM-12C Colon RLS SRLSYYA (779) KM-12C Colon SRLSYYA KM-12C Colon RGV ARGVSAP (780) KM-12C Colon GRGVLAF (781) KM-12C Colon RGS MRGSGRN (782) KM-12C Colon RAV RDGRAVR (783) KM-12C Colon GRAVWMV (784) KM-12C Colon RAS KM-12C Colon GAG KM-12C Colon AVS KM-12C Colon LLS KM-12C Colon LLR KM-12C Colon LRV LRVPGGP (785) KM-12C Colon LRS AYYSLRS (786) KM-12C Colon AYYSLRS KM-12C Colon VLRSALQ (787) KM-12C Colon VYYALRS (788) KM-12C Colon VYYALRS KM-12C Colon VYYALRS KM-12C Colon VYYALRS KM-12C Colon VYYALRS KM-12C Colon VYYALRS KM-12C Colon VYYALRS KM-12C Colon RVS RYRVSVY (789) KM-12C Colon RSS KM-12C Colon AGS KM-12C Colon AGR KM-12C Colon AGL KM-12C Colon AGG AGGIWIR (790) KM-12C Colon GVR WQVSGVR (791) KM-12C Colon GVL GRGVLAF (792) KM-12C Colon GAV KM-12C Colon GLV KM-12C Colon GLR KM-12C Colon LVS HAELVSL (793) KM-12C Colon ARG ARGVSAP (794) KM-12C Colon RVARGDR (795) KM-12C Colon VMWVARG (796) KM-12C Colon ASL KM-12C Colon AAV AAVTVVR (797) KM-12C Colon AAS KM-12C Colon GGS KM-12C Colon GLG KM-12C Colon GGL TREGGLD (798) KM-12C Colon LGGGGLL (799) KM-12C Colon GSS KM-12C Colon GSG GSGHSFA (800) KM-12C Colon MRGSGRN (801) KM-12C Colon GSV RVGSVQW (802) KM-12C Colon EGTSGSV (803) KM-12C Colon GRV GRVPTVV (804) KM-12C Colon KM-12C Colon GRL ADGRLRY (805) KM-12C Colon GPS KM-12C Colon GVS ARGVSAP (806) KM-12C Colon RLS SW620-Colon RGV RGVKLGD (807) SW620-Colon RGS LRGSYVL (808) SW620-Colon RRGSLMF (809) SW620-Colon RGSVGPS (810) SW620-Colon RAV SW620-Colon RAS SRASDVT (811) SW620-Colon GAG SW620-Colon AVS SW620-Colon LLS AAKTLLS (812) SW620-Colon LLR SW620-Colon LRV SW620-Colon LRS RSYPLRS (813) SW620-Colon RVS YLGRRVS (814) SW620-Colon RSS RSSPVWT (815) SW620-Colon AGS DLRRAGS (816) SW620-Colon AGR SW620-Colon AGL GVAGLRW (817) SW620-Colon AGG RIDAGGG (818) SW620-Colon GVAGGAT (819) SW620-Colon GVR SW620-Colon GVL SW620-Colon GAV TAGGAVG (820) SW620-Colon WRLGAVG (821) SW620-Colon GLV SGLVAMV (822) SW620-Colon GLR VGLRDWG (823) SW620-Colon GVAGLRW (824) SW620-Colon LVS SW620-Colon ARG ARGIVRV (825) SW620-Colon ASL ASLHHRR (826) SW620-Colon AAV SW620-Colon AAS GAAASGY (827) SW620-Colon GGS SW620-Colon GGR SW620-Colon GLG LAIRGLG (828) SW620-Colon GGL GGLSNVV (829) SW620-Colon PPGGLKW (830) SW620-Colon GSS SW620-Colon GSG SW620-Colon GSV EGSVDAH (831) SW620-Colon RGSVGPS (832) SW620-Colon GRV SW620-Colon GRL LVYSGRL (833) SW620-Colon VEEGRLR (834) SW620-Colon GPS RGSVGPS (835) SW620-Colon GVS SPGVSGR (836) SW620-Colon RGV RVGRGVL (837) SF-268 CNS RGS SF-268 CNS RAV WIWRAVS (838) SF-268 CNS RAS SF-268 CNS GAG VTDGAGQ (839) SF-268 CNS AVS LGTAVSS (840) SF-268 CNS WIWRAVS (841) SF-268 CNS DTPSAVS (842) SF-268 CNS LLS GLLSAGI (843) SF-268 CNS LLR YLLRALG (844) SF-268 CNS LRV SF-268 CNS LRS LRSGSLG (845) SF-268 CNS PLRSVWS (846) SF-268 CNS RVS SF-268 CNS RSS ARSSIVR (847) SF-268 CNS AGS SF-268 CNS AGR SF-268 CNS AGL SF-268 CNS AGG AGGRLGL (848) SF-268 CNS AGGWRGR (849) SF-268 CNS GVR LVGRGVR (850) SF-268 CNS GVL DVVGVLK (851) SF-268 CNS RVGRGVL (852) SF-268 CNS GAV GAVTGYP (853) SF-268 CNS GLV WGLVRHA (854) SF-268 CNS GLR LGLRGGA (855) SF-268 CNS LVS SF-268 CNS ARG SF-268 CNS ASL IGASLLG (856) SF-268 CNS AAV AAVETGV (857) SF-268 CNS AAS SF-268 CNS GGS GLGGGGS (858) SF-268 CNS GGR EVLWGGR (859) SF-268 CNS AGGRLGL (860) SF-268 CNS GGRSKKV (861) SF-268 CNS GLG GLGGGGS (862) SF-268 CNS GGL SGGGGLG (863) SF-268 CNS GAYGGLL (864) SF-268 CNS GGLSRSN (865) SF-268 CNS GSS FGSSNRS (866) SF-268 CNS GSG SF-268 CNS GSV GSVSDRF (867) SF-268 CNS GRV SF-268 CNS GRL AGGRLGL (868) SF-268 CNS GPS WFKGPSV (869) SF-268 CNS GVS SF-268 CNS RLS SF-295 CNS RGV LSERRGV (870) SF-295 CNS ARGVAEY (871) SF-295 CNS SF-295 CNS RGS FDRGSLT (872) SF-295 CNS SF-295 CNS RAV SF-295 CNS RAS GRLRASL (873) SF-295 CNS SF-295 CNS GAG RDGRGAG (874) SF-295 CNS SF-295 CNS AVS GAVSVLA (875) SF-295 CNS TRGDAVS (876) SF-295 CNS SF-295 CNS LLS LLSPRGT (877) SF-295 CNS SF-295 CNS LLR LLRSHGV (878) SF-295 CNS SF-295 CNS LRV PLRVLKR (879) SF-295 CNS GRLRLRV (880) SF-295 CNS SF-295 CNS LRS LLRSHGV (881) SF-295 CNS VLRSGEL (882) SF-295 CNS VLRSIPS (883) SF-295 CNS VLRSIPS SF-295 CNS SF-295 CNS RVS GSMHRVS (884) SF-295 CNS YSIMRVS (885) SF-295 CNS SF-295 CNS RSS SF-295 CNS AGS RAGSRVQ (886) SF-295 CNS SF-295 CNS AGR RRDAGRM (887) SF-295 CNS GAGRGDR (888) SF-295 CNS SF-295 CNS AGL RWAGLVA (889) SF-295 CNS SF-295 CNS AGG QTLSAGG (890) SF-295 CNS LAGGWGS (891) SF-295 CNS SF-295 CNS GVR RHGVRSK (892) SF-295 CNS SF-295 CNS GVL SF-295 CNS GAV GAVSVLA (893) SF-295 CNS SF-295 CNS GLV RWAGLVA (894) SF-295 CNS SF-295 CNS GLR GRGLRTD (895) SF-295 CNS TLGGLRT (896) SF-295 CNS SF-295 CNS LVS ALVSVAG (897) SF-295 CNS SF-295 CNS ARG ARGVAEY (898) SF-295 CNS SF-295 CNS ASL GGASLTQ (899) SF-295 CNS GRLRASL (900) SF-295 CNS SNHTASL (901) SF-295 CNS SF-295 CNS AAV YADGAAV (902) SF-295 CNS SF-295 CNS AAS SF-295 CNS GGS SF-295 CNS GGR SF-295 CNS GLG LGGLGIH (903) SF-295 CNS SF-295 CNS GGL GGFTGGL (904) SF-295 CNS HIGLGGL (905) SF-295 CNS TRLGGLT (906) SF-295 CNS SF-295 CNS GSS SF-295 CNS GSG SF-295 CNS GSV VMPGSVV (907) SF-295 CNS SF-295 CNS GRV SF-295 CNS GRL GRLRASL (908) SF-295 CNS GRLYLGI (909) SF-295 CNS GRLRLRV (910) SF-295 CNS SF-295 CNS SF-295 CNS GPS SHCGPSN (911) SF-295 CNS SHCGPSN SF-295 CNS SF-295 CNS GVS SF-295 CNS RLS VRLSGRA (912) SNB-19 CNS RLSTFAG (913) SNB-19 CNS RGV SNB-19 CNS RGS ARGSLRV (914) SNB-19 CNS FSPRGSV (915) SNB-19 CNS RAV GGRLRAV (916) SNB-19 CNS RAS SNB-19 CNS GAG SNB-19 CNS AVS VLSAVSS (917) SNB-19 CNS LLS SNB-19 CNS LLR SNB-19 CNS LRV ARGSLRV (918) SNB-19 CNS LRS LRSYAWS (919) SNB-19 CNS RVS KGRVSAG (920) SNB-19 CNS RSS SNB-19 CNS AGS SNB-19 CNS AGR SNB-19 CNS AGL AGLTIGI (921) SNB-19 CNS AGG AWRHAGG (922) SNB-19 CNS WARAGGF (923) SNB-19 CNS GVR SNB-19 CNS GVL MGVLTAE (924) SNB-19 CNS FAGYGVL (925) SNB-19 CNS GAV RIFHGAV (926) SNB-19 CNS GLV EGLVVFE (927) SNB-19 CNS GLR REVPGLR (928) SNB-19 CNS LVS LVSVNGA (929) SNB-19 CNS HSLVSQP (930) SNB-19 CNS ARG ARGSLRV (931) SNB-19 CNS ASL SSVASLV (932) SNB-19 CNS AAV AAVWQMK (933) SNB-19 CNS QRAAVIV (934) SNB-19 CNS AAS SNB-19 CNS GGS PGGSDAA (935) SNB-19 CNS GGR GGRLRAV (936) SNB-19 CNS GLG SNB-19 CNS GGL LPCGGLA (937) SNB-19 CNS GSS GSSHDAL (938) SNB-19 CNS TQYYGSS (939) SNB-19 CNS GSG SNB-19 CNS GSV FSPRGSV (940) SNB-19 CNS GRV KGRVSAG (941) SNB-19 CNS QGRVNVK (942) SNB-19 CNS GRL GGRLRAV (943) SNB-19 CNS YDGRLAR (944) SNB-19 CNS GPS SNB-19 CNS GVS SNB-19 CNS RLS SNB-75 CNS RGV PQGRGVK (945) SNB-75 CNS RGS MVLRGSY (946) SNB-75 CNS RAV GGWARAV (947) SNB-75 CNS VRAVCLM (948) SNB-75 CNS RAS TRASRRG (949) SNB-75 CNS GAG LGAGEGD (950) SNB-75 CNS AVS IGAVSGW (951) SNB-75 CNS LLS LLSRRVG (952) SNB-75 CNS LELLSVV (953) SNB-75 CNS RLLSEGY (954) SNB-75 CNS LLR QLPGLLR (955) SNB-75 CNS YGESLLR (956) SNB-75 CNS LRV LRVYGEG (957) SNB-75 CNS LRS SNB-75 CNS RVS YRVSSGS (958) SNB-75 CNS RSS RSSSSTR (959) SNB-75 CNS AGS WAGSNYS (960) SNB-75 CNS AGR CAGRARR (961) SNB-75 CNS AGL IAGLAVV (962) SNB-75 CNS DGEGAGL (963) SNB-75 CNS AGG ALAGGGL (964) SNB-75 CNS GVR GVRRSLL (965) SNB-75 CNS GVL ADWGVLE (966) SNB-75 CNS GAV IGAVSGW (967) SNB-75 CNS GLV ASGLVVT (968) SNB-75 CNS GLR IGLRGEN (969) SNB-75 CNS LVS SNB-75 CNS ARG RRARGAC (970) SNB-75 CNS ASL YAASLMG (971) SNB-75 CNS AAV LTAAVMV (972) SNB-75 CNS AAS YAASLMG (973) SNB-75 CNS GGS RARTGGS (974) SNB-75 CNS VSGDGGS (975) SNB-75 CNS GGR FGGRSLS (976) SNB-75 CNS SLGGRTF (977) SNB-75 CNS GLG ARRGLGL (978) SNB-75 CNS GGL ALAGGGL (979) SNB-75 CNS FRALGGL (980) SNB-75 CNS FTRGGLS (981) SNB-75 CNS GSS SGSSVRY (982) SNB-75 CNS GSG SNB-75 CNS GSV WGSVAGI (983) SNB-75 CNS SGGDGSV (984) SNB-75 CNS GRV SNB-75 CNS GRL NEGRLGI (985) SNB-75 CNS YSGRLVM (986) SNB-75 CNS GPS DGPSGCS (987) SNB-75 CNS GVS SNB-75 CNS RLS U251 CNS RGV U251 CNS RGS RGSRTGP (988) U251 CNS RAV U251 CNS RAS U251 CNS GAG U251 CNS AVS U251 CNS LLS U251 CNS LLR U251 CNS LRV U251 CNS LRS U251 CNS RVS U251 CNS RSS U251 CNS AGS U251 CNS AGR U251 CNS AGL U251 CNS AGG U251 CNS GVR U251 CNS GVL U251 CNS GAV U251 CNS GLV U251 CNS GLR U251 CNS LVS U251 CNS ARG U251 CNS ASL U251 CNS AAV U251 CNS AAS U251 CNS GGS U251 CNS GGR U251 CNS GLG U251 CNS GGL U251 CNS GSS GSSACGA (989) U251 CNS GSG U251 CNS GSV U251 CNS GRV U251 CNS GRL U251 CNS GPS U251 CNS GVS U251 CNS RLS VRLSGRA (990) SF-539 CNS RLSTFAG (991) SF-539 CNS RGV SF-539 CNS RGS ARGSLRV (992) SF-539 CNS FSPRGSV (993) SF-539 CNS RAV GGRLRAV (994) SF-539 CNS RAS SF-539 CNS GAG SF-539 CNS AVS VLSAVSS (995) SF-539 CNS LLS SF-539 CNS LLR SF-539 CNS LRV ARGSLRV (996) SF-539 CNS LRS LRSYAWS (997) SF-539 CNS RVS KGRVSAG (998) SF-539 CNS RSS SF-539 CNS AGS SF-539 CNS AGR SF-539 CNS AGL AGLTIGI (999) SF-539 CNS AGG AWRHAGG (1000) SF-539 CNS WARAGGF (1001) SF-539 CNS GVR SF-539 CNS GVL MGVLTAE (1002) SF-539 CNS FAGYGVL (1003) SF-539 CNS GAV RIFHGAV (1004) SF-539 CNS GLV EGLVVFE (1005) SF-539 CNS GLR REVPGLR (1006) SF-539 CNS LVS LVSVNGA (1007) SF-539 CNS HSLVSQP (1008) SF-539 CNS ARG ARGSLRV (1009) SF-539 CNS ASL SSVASLV (1010) SF-539 CNS AAV AAVWQMK (1011) SF-539 CNS QRAAVIV (1012) SF-539 CNS AAS SF-539 CNS GGS SF-539 CNS GGR GGRLRAV (1013) SF-539 CNS GLG SF-539 CNS GGL LPCGGLA (1014) SF-539 CNS GSS GSSHDAL (1015) SF-539 CNS TQYYGSS (1016) SF-539 CNS GSG SF-539 CNS GSV FSPRGSV (1017) SF-539 CNS GRV KGRVSAG (1018) SF-539 CNS QGRVNVK (1019) SF-539 CNS GRL GGRLRAV (1020) SF-539 CNS YDGRLAR (1021) SF-539 CNS GPS SF-539 CNS GVS SF-539 CNS RLS SRLSYWQ (1022) LOX-IMVI Melanoma RGV FVGSRGV (1023) LOX-IMVI Melanoma SVDRGVI (1024) LOX-IMVI Melanoma RGS GRGSGGF (1025) LOX-IMVI Melanoma RAV LOX-IMVI Melanoma RAS LOX-IMVI Melanoma GAG IFGAGLR (1026) LOX-IMVI Melanoma AVS GWVAVSC (1027) LOX-IMVI Melanoma LLS LLSGVIL (1028) LOX-IMVI Melanoma GSTLLSR (1029) LOX-IMVI Melanoma LLR LOX-IMVI Melanoma LRV LOX-IMVI Melanoma LRS QWYSLRS (1030) LOX-IMVI Melanoma RVS TWIGRVS (1031) LOX-IMVI Melanoma RSS LOX-IMVI Melanoma AGS SVVLAGS (1032) LOX-IMVI Melanoma AGR LOX-IMVI Melanoma AGL IFGAGLR (1033) LOX-IMVI Melanoma AGG SAGGWCA (1034) LOX-IMVI Melanoma GVR RDGVRVG (1035) LOX-IMVI Melanoma VSRIGVR (1036) LOX-IMVI Melanoma GVRSMPV (1037) LOX-IMVI Melanoma GVL GGVLGSD (1038) LOX-IMVI Melanoma WGVLQLE (1039) LOX-IMVI Melanoma GAV HGGPGAV (1040) LOX-IMVI Melanoma GLV DSGLVGG (1041) LOX-IMVI Melanoma GLR IFGAGLR (1042) LOX-IMVI Melanoma RMGFGLR (1043) LOX-IMVI Melanoma LVS LOX-IMVI Melanoma ARG LOX-IMVI Melanoma ASL LOX-IMVI Melanoma AAV WLDAAVK (1044) LOX-IMVI Melanoma AAS IAASYRG (1045) LOX-IMVI Melanoma GGS ATIPGGS (1046) LOX-IMVI Melanoma DGGSLVV (1047) LOX-IMVI Melanoma FGGSGRG (1048) LOX-IMVI Melanoma GGR SPTGGRR (1049) LOX-IMVI Melanoma TWSTGGR (1050) LOX-IMVI Melanoma GLG LOX-IMVI Melanoma GGL SRSCGGL (1051) LOX-IMVI Melanoma GSS LOX-IMVI Melanoma GSG CPGSGII (1052) LOX-IMVI Melanoma FGGSGRG (1053) LOX-IMVI Melanoma GSV SGSVVQR (1054) LOX-IMVI Melanoma GRV TWIGRVS (1055) LOX-IMVI Melanoma GRL LOX-IMVI Melanoma GPS GPSWATV (1056) LOX-IMVI Melanoma GVS LOX-IMVI Melanoma RLS MALME-3M Melanoma RGV MALME-3M Melanoma RGS ARRGSGL (1057) MALME-3M Melanoma RAV RAVGYNA (1058) MALME-3M Melanoma LRAVEFL (1059) MALME-3M Melanoma RAS MALME-3M Melanoma GAG MALME-3M Melanoma AVS MALME-3M Melanoma LLS FEDLLSL (1060) MALME-3M Melanoma RWLSLLS (1061) MALME-3M Melanoma LLR MALME-3M Melanoma LRV HAPGLRV (1062) MALME-3M Melanoma LRS LRSSMML (1063) MALME-3M Melanoma RPKLRSV (1064) MALME-3M Melanoma RVS SRVSFHE (1065) MALME-3M Melanoma RSS LRSSMML (1066) MALME-3M Melanoma SSGGRSS (1067) MALME-3M Melanoma AGS MALME-3M Melanoma AGR VAGRVGI (1068) MALME-3M Melanoma AGL AGLALTV (1069) MALME-3M Melanoma AGG MALME-3M Melanoma GVR IGVRGAV (1070) MALME-3M Melanoma GVL LVRDGVL (1071) MALME-3M Melanoma GAV IGVRGAV (1072) MALME-3M Melanoma GLV HGLVTHN (1073) MALME-3M Melanoma GLR HAPGLRV (1074) MALME-3M Melanoma LVS MALME-3M Melanoma ARG VSSTARG (1075) MALME-3M Melanoma ASL MALME-3M Melanoma AAV RAAVIHT (1076) MALME-3M Melanoma AAS AASTRSL (1077) MALME-3M Melanoma GGS GWGGGSA (1078) MALME-3M Melanoma SSRGGSS (1079) MALME-3M Melanoma GGR SSGGRSS (1080) MALME-3M Melanoma GLG MALME-3M Melanoma GGL MALME-3M Melanoma GSS SSRGGSS (1081) MALME-3M Melanoma GSG ARRGSGL (1082) MALME-3M Melanoma GSV MALME-3M Melanoma GRV VAGRVGI (1083) MALME-3M Melanoma GRL EGRLMLA (1084) MALME-3M Melanoma GPS MALME-3M Melanoma GVS MALME-3M Melanoma RLS RLSSAPS (1085) M14 Melanoma RRLSYHS (1086) M14 Melanoma FLHMRLS (1087) M14 Melanoma RGV LARGVPP (1088) M14 Melanoma RGS LSRGSVA (1089) M14 Melanoma VWLRGST (1090) M14 Melanoma RAV M14 Melanoma RAS RGGQRAS (1091) M14 Melanoma GAG M14 Melanoma AVS AVSGRSL (1092) M14 Melanoma LLS GLLSSFS (1093) M14 Melanoma LLR RMGLLRQ (1094) M14 Melanoma LRV M14 Melanoma LRS RLHYLRS (1095) M14 Melanoma GGYWLRS (1096) M14 Melanoma RVS M14 Melanoma RSS NRSSHCG (1097) M14 Melanoma QRSSDLT (1098) M14 Melanoma AGS M14 Melanoma AGR AAGRSRI (1099) M14 Melanoma AGL M14 Melanoma AGG GRAGGNG (1100) M14 Melanoma GVR ANASGVR (1101) M14 Melanoma GVL WAHGVLS (1102) M14 Melanoma GAV M14 Melanoma GLV M14 Melanoma GLR SLYGLRW (1103) M14 Melanoma LVS M14 Melanoma ARG GNGGARG (1104) M14 Melanoma LARGVPP (1105) M14 Melanoma NWDARGR (1106) M14 Melanoma ASL ASLPVLD (1107) M14 Melanoma PPGASLY (1108) M14 Melanoma AAV AAVGGRV (1109) M14 Melanoma AAS AASSWAV (1110) M14 Melanoma GGS AFKTGGS (1111) M14 Melanoma GGR FEGGRSG (1112) M14 Melanoma RTWGGRM (1113) M14 Melanoma SARQGGR (lll4) M14 Melanoma AAVGGRV (1115) M14 Melanoma GLG M14 Melanoma GGL M14 Melanoma GSS ARHGSSV (1116) M14 Melanoma SNFYGSS (1117) M14 Melanoma GSG GSGQLIP (1118) M14 Melanoma GSV LSRGSVA (1119) M14 Melanoma GRV AEYGRVL (1120) M14 Melanoma RGRVLLP (1121) M14 Melanoma AAVGGRV (1122) M14 Melanoma GRL RGRLALL (1123) M14 Melanoma SGPGRLP (1124) M14 Melanoma TSGRLWV (1125) M14 Melanoma GPS M14 Melanoma GVS MVYSGVS (1126) M14 Melanoma RLS WRLSREG (1127) SK-MEL-2 Melanoma LLRRLSW (1128) SK-MEL-2 Melanoma RGV AARGVMV (1129) SK-MEL-2 Melanoma RGS ALARGSG (1130) SK-MEL-2 Melanoma NLRGSRS (1131) SK-MEL-2 Melanoma RAV RAVWRAS (1132) SK-MEL-2 Melanoma RAS RAVWRAS SK-MEL-2 Melanoma GAG GAGSFSS (1133) SK-MEL-2 Melanoma AVS SK-MEL-2 Melanoma LLS LLSSRRC (1134) SK-MEL-2 Melanoma LLSLDPG (1135) SK-MEL-2 Melanoma SSLLSSL (1136) SK-MEL-2 Melanoma LLR LLRPAHG (1137) SK-MEL-2 Melanoma LLRRLSW (1138) SK-MEL-2 Melanoma LRV SK-MEL-2 Melanoma LRS CMLRSAT (1139) SK-MEL-2 Melanoma SKAVLRS (1140) SK-MEL-2 Melanoma RVS SRVSNPS (1141) SK-MEL-2 Melanoma RSS CRRSSLL (1142) SK-MEL-2 Melanoma AGS GAGSFSS (1143) SK-MEL-2 Melanoma AGR SAAGRTF (1144) SK-MEL-2 Melanoma PAGRMLS (1145) SK-MEL-2 Melanoma AGL IAMAGLR (1146) SK-MEL-2 Melanoma AGG AGGFRFI (1147) SK-MEL-2 Melanoma GVR SGVRPVI (1148) SK-MEL-2 Melanoma GVL GVLSDRS (1149) SK-MEL-2 Melanoma GAV GAVTSAD (1150) SK-MEL-2 Melanoma GAVTSAD (1151) SK-MEL-2 Melanoma GAVNTPA (1152) SK-MEL-2 Melanoma GLV GGLVKRL (1153) SK-MEL-2 Melanoma EVASGLV (1154) SK-MEL-2 Melanoma GLR IAMAGLR (1155) SK-MEL-2 Melanoma GTHSGLR (1156) SK-MEL-2 Melanoma LVS LVSTSNR (1157) SK-MEL-2 Melanoma FSLVSFV (1158) SK-MEL-2 Melanoma ALVSSHV (1159) SK-MEL-2 Melanoma ARG AARGVMV (1160) SK-MEL-2 Melanoma ALARGSG (1161) SK-MEL-2 Melanoma ASL SK-MEL-2 Melanoma AAV LRYWAAV (1162) SK-MEL-2 Melanoma AAS FTRGAAS (1163) SK-MEL-2 Melanoma EWHAASG (1164) SK-MEL-2 Melanoma GGS FGGSMAP (1165) SK-MEL-2 Melanoma GGSLKWV (1166) SK-MEL-2 Melanoma GGR RGLQGGR (1167) SK-MEL-2 Melanoma TCGGRSY (1168) SK-MEL-2 Melanoma GLG GEALGLG (1169) SK-MEL-2 Melanoma PRGLGVG (1170) SK-MEL-2 Melanoma VGLGNSA (1171) SK-MEL-2 Melanoma GGL GGLVKRL (1172) SK-MEL-2 Melanoma GSS SK-MEL-2 Melanoma GSG GSGRALA (1173) SK-MEL-2 Melanoma GSV SK-MEL-2 Melanoma GRV SK-MEL-2 Melanoma GRL SRSGRLN (1174) SK-MEL-2 Melanoma GPS SK-MEL-2 Melanoma GVS SAGVSDS (1175) SK-MEL-2 Melanoma RLS PRLSDKS (1176) SK-MEL-28 Melanoma RGV GRGDRGV (1177) SK-MEL-28 Melanoma RGVSGRL (1178) SK-MEL-28 Melanoma RGS INRGSRE (1179) SK-MEL-28 Melanoma LRGSRQF (1180) SK-MEL-28 Melanoma LRGSVGR (1181) SK-MEL-28 Melanoma RAV GLWYRAV (1182) SK-MEL-28 Melanoma RVRAVLG (1183) SK-MEL-28 Melanoma RAVLELW (1184) SK-MEL-28 Melanoma RAS LVRASNG (1185) SK-MEL-28 Melanoma GAG SK-MEL-28 Melanoma AVS SK-MEL-28 Melanoma LLS SK-MEL-28 Melanoma LLR ASGTLLR (1186) SK-MEL-28 Melanoma LRV SK-MEL-28 Melanoma LRS SK-MEL-28 Melanoma RVS GSGVRVS (1187) SK-MEL-28 Melanoma RSS VGSTRSS (1188) SK-MEL-28 Melanoma AGS RAGSRYI (1189) SK-MEL-28 Melanoma AGR SK-MEL-28 Melanoma AGL SK-MEL-28 Melanoma AGG SK-MEL-28 Melanoma GVR VGVRFSR (1190) SK-MEL-28 Melanoma GSGVRVS (1191) SK-MEL-28 Melanoma GVL IGVLASA (1192) SK-MEL-28 Melanoma GAV SK-MEL-28 Melanoma GLV GLVARVR (1193) SK-MEL-28 Melanoma GLR SK-MEL-28 Melanoma LVS SK-MEL-28 Melanoma ARG SK-MEL-28 Melanoma ASL SK-MEL-28 Melanoma AAV SK-MEL-28 Melanoma AAS SK-MEL-28 Melanoma GGS LLGIGGS (1194) SK-MEL-28 Melanoma QLGGSFR (1195) SK-MEL-28 Melanoma GGR LFRWGGR (1196) SK-MEL-28 Melanoma GLG SK-MEL-28 Melanoma GGL RFSGGLQ (1197) SK-MEL-28 Melanoma GSS VGSSHGL (1198) SK-MEL-28 Melanoma GSG SVRVGSG (1199) SK-MEL-28 Melanoma GSV GVNGSVS (1200) SK-MEL-28 Melanoma LRGSVGR (1201) SK-MEL-28 Melanoma GRV HVKNGRV (1202) SK-MEL-28 Melanoma GRL FQRSGRL (1203) SK-MEL-28 Melanoma HGRLAFG (1204) SK-MEL-28 Melanoma RGVSGRL (1205) SK-MEL-28 Melanoma GPS SK-MEL-28 Melanoma GVS RGVSGRL (1206) SK-MEL-28 Melanoma RLS SK-MEL-5 Melanoma RGV FGIGRGV (1207) SK-MEL-5 Melanoma RGS SK-MEL-5 Melanoma RAV SK-MEL-5 Melanoma RAS SK-MEL-5 Melanoma GAG SK-MEL-5 Melanoma AVS GVVQAVS (1208) SK-MEL-5 Melanoma LSAVSVK (1209) SK-MEL-5 Melanoma LLS LYLLSSA (1210) SK-MEL-5 Melanoma LIGGLLS (1211) SK-MEL-5 Melanoma LLR LLRRGIG (1212) SK-MEL-5 Melanoma LRV SK-MEL-5 Melanoma LRS FLRSLSL (1213) SK-MEL-5 Melanoma RVS VRVSGLT (1214) SK-MEL-5 Melanoma RSS SK-MEL-5 Melanoma AGS AGSVDLV (1215) SK-MEL-5 Melanoma AGR GFVAGRT (1216) SK-MEL-5 Melanoma AGL SK-MEL-5 Melanoma AGG SK-MEL-5 Melanoma GVR SK-MEL-5 Melanoma GVL SK-MEL-5 Melanoma GAV TRGAVFG (1217) SK-MEL-5 Melanoma GLV IYGGLVI (1218) SK-MEL-5 Melanoma GLR PTGEGLR (1219) SK-MEL-5 Melanoma LVS SK-MEL-5 Melanoma ARG SK-MEL-5 Melanoma ASL KVSVASL (1220) SK-MEL-5 Melanoma RYSMASL (1221) SK-MEL-5 Melanoma AAV SK-MEL-5 Melanoma AAS ANAASSP (1222) SK-MEL-5 Melanoma GGS PGGSRHA (1223) SK-MEL-5 Melanoma GGSPGVW (1224) SK-MEL-5 Melanoma GGR SK-MEL-5 Melanoma GLG SK-MEL-5 Melanoma GGL IYGGLVI (1225) SK-MEL-5 Melanoma LIGGLLS (1226) SK-MEL-5 Melanoma GSS SK-MEL-5 Melanoma GSG ACGSGLD (1227) SK-MEL-5 Melanoma GSV AGSVDLV (1228) SK-MEL-5 Melanoma TLGSVRV (1229) SK-MEL-5 Melanoma GRV HVRGRVA (1230) SK-MEL-5 Melanoma IDLGRVN (1231) SK-MEL-5 Melanoma GRL GRLDAFG (1232) SK-MEL-5 Melanoma GPS WVGPSGG (1233) SK-MEL-5 Melanoma GVS SK-MEL-5 Melanoma GSS UACC 257 Melanoma RLS DLRLSFP (1234) UACC 257 Melanoma SARLSHV (1235) UACC 257 Melanoma RGV VMDRGVA (1236) UACC 257 Melanoma RGS RGSLLWA (1237) UACC 257 Melanoma RGSPLTK (1238) UACC 257 Melanoma RAV UACC 257 Melanoma RAS RASIGIE (1239) UACC 257 Melanoma VHSLRAS (1240) UACC 257 Melanoma GAG UACC 257 Melanoma AVS UACC 257 Melanoma LLS AWLLSGR (1241) UACC 257 Melanoma LLR UACC 257 Melanoma LRV UACC 257 Melanoma LRS LWLRSRE (1242) UACC 257 Melanoma RVS VTRIRVS (1243) UACC 257 Melanoma RSS NSQRSSV (1244) UACC 257 Melanoma AGS AATRAGS (1245) UACC 257 Melanoma AGR UACC 257 Melanoma AGL UACC 257 Melanoma AGG UACC 257 Melanoma GVR TDGVRAF (1246) UACC 257 Melanoma GVL FAASGVL (1247) UACC 257 Melanoma GVLEGRR (1248) UACC 257 Melanoma GAV EADPGAV (1249) UACC 257 Melanoma DGAVILH (1250) UACC 257 Melanoma RDGAVNL (1251) UACC 257 Melanoma GLV UACC 257 Melanoma GLR GLRPHGA (1252) UACC 257 Melanoma TSRGLRL (1253) UACC 257 Melanoma LVS RMLVSSF (1254) UACC 257 Melanoma ARG DVIARGW (1255) UACC 257 Melanoma UACC 257 Melanoma ASL UACC 257 Melanoma AAV TLTAAVF (1256) UACC 257 Melanoma GWLNAAV (1257) UACC 257 Melanoma AAS FAASGVL (1258) UACC 257 Melanoma GGS GGSKGSA (1259) UACC 257 Melanoma AVALGGS (1260) UACC 257 Melanoma GGR HGGRYRH (1261) UACC 257 Melanoma SGVGGRY (1262) UACC 257 Melanoma GLG UACC 257 Melanoma GGL SGGLAVA (1263) UACC 257 Melanoma GSG UACC 257 Melanoma GSV UACC 257 Melanoma GRV UACC 257 Melanoma GRL GRLAKSI (1264) UACC 257 Melanoma GPS AGPSRGP (1265) UACC 257 Melanoma UACC 257 Melanoma GVS UACC 257 Melanoma RLS GLMRLSH (1266) UACC62 Melanoma VRVGRLS (1267) UACC62 Melanoma TGRLSAA (1268) UACC62 Melanoma RGV SLRGVRV (1269) UACC62 Melanoma DNCERGV (1270) UACC62 Melanoma TTQLRGV (1271) UACC62 Melanoma RGS GVIGRGS (1272) UACC62 Melanoma LAGMRGS (1273) UACC62 Melanoma RAV VRPRAVL (1274) UACC62 Melanoma PPRAVTN (1275) UACC62 Melanoma RAS WRARASP (1276) UACC62 Melanoma GAG UACC62 Melanoma AVS UACC62 Melanoma LLS FGRLLSP (1277) UACC62 Melanoma LLR PSLLRGF (1278) UACC62 Melanoma LRV RDLRVHL (1279) UACC62 Melanoma LRVSNPR (1280) UACC62 Melanoma LRVDQLY (1281) UACC62 Melanoma LRS HRLRSMS (1282) UACC62 Melanoma RVS LRVSNPR (1283) UACC62 Melanoma RSS UACC62 Melanoma AGS PGFMAGS (1284) UACC62 Melanoma AGR AGRGISQ (1285) UACC62 Melanoma RAGRDAP (1286) UACC62 Melanoma RAGRGFE (1287) UACC62 Melanoma AGL UACC62 Melanoma AGG HQAGGVT (1288) UACC62 Melanoma GVR SLRGVRV (1289) UACC62 Melanoma GVL DWVGVLM (1290) UACC62 Melanoma GTLGVLS (1291) UACC62 Melanoma GVLLWRP (1292) UACC62 Melanoma GAV UACC62 Melanoma GLV UACC62 Melanoma GLR GLREAHV (1293) UACC62 Melanoma LVS UACC62 Melanoma ARG AARGELR (1294) UACC62 Melanoma ASL AASLRGT (1295) UACC62 Melanoma AAV PVGAAVA (1296) UACC62 Melanoma AAS AASLRGT (1297) UACC62 Melanoma GGS UACC62 Melanoma GGR UACC62 Melanoma GLG UACC62 Melanoma GGL UACC62 Melanoma GSS UACC62 Melanoma GSG SNPGSGS (1298) UACC62 Melanoma GSV UACC62 Melanoma GRV GRVRETP (1299) UACC62 Melanoma UACC62 Melanoma GRL FGRLLSP (1300) UACC62 Melanoma VRVGRLS (1301) UACC62 Melanoma TGRLSAA (1302) UACC62 Melanoma VGRLQTT (1303) UACC62 Melanoma GPS DGPSCVI (1304) UACC62 Melanoma UACC62 Melanoma GVS UACC62 Melanoma RLS IGROV1 Ovarian RGV IGROV1 Ovarian RGS IGROV1 Ovarian RAV RFSSRAV (1305) IGROV1 Ovarian RAS HAGSRAS (1306) IGROV1 Ovarian GAG GAGLGVS (1307) IGROV1 Ovarian LLGAGTP (1308) IGROV1 Ovarian AVS IGROV1 Ovarian LLS LLSILKA (1309) IGROV1 Ovarian GLLSGGT (1310) IGROV1 Ovarian LLR IGROV1 Ovarian LRV LSVLRVL (1311) IGROV1 Ovarian LRS SRYTLRS (1312) IGROV1 Ovarian RVS IGROV1 Ovarian RSS LFHTRSS (1313) IGROV1 Ovarian VARSSFR (1314) IGROV1 Ovarian AGS CTAGSVS (1315) IGROV1 Ovarian RAAGSAG (1316) IGROV1 Ovarian HAGSRAS (1317) IGROV1 Ovarian AGR IGROV1 Ovarian AGL GAGLGVS (1318) IGROV1 Ovarian PTGAGLL (1319) IGROV1 Ovarian ASYAGLV (2) IGROV1 Ovarian (1320) AGG AGGFGVL (1321) IGROV1 Ovarian NMAGGQE (1322) IGROV1 Ovarian LRAGGSY (1323) IGROV1 Ovarian YLAGGKA (1324) IGROV1 Ovarian GVR PYYNGVR (1325) IGROV1 Ovarian GVL AGGFGVL (1326) IGROV1 Ovarian LIGGVLH (1327) IGROV1 Ovarian GAV IGROV1 Ovarian GLV DGLVPVA (1328) IGROV1 Ovarian GLVASMP (1329) IGROV1 Ovarian ASYAGLV (2) IGROV1 Ovarian (1330) GLR IGROV1 Ovarian LVS LVRLVSL (1331) IGROV1 Ovarian ARG IGROV1 Ovarian ASL VLASLSG (1332) IGROV1 Ovarian AAV IGROV1 Ovarian AAS IGROV1 Ovarian GGS GSITGGS (1333) IGROV1 Ovarian LRAGGSY (1334) IGROV1 Ovarian TGGSLLG (1335) IGROV1 Ovarian DEGGSRW (1336) IGROV1 Ovarian GGR IGROV1 Ovarian GLG GAGLGVS (1337) IGROV1 Ovarian GGL IGROV1 Ovarian GSS WGSSAVK (1338) IGROV1 Ovarian QGSSNSV (1339) IGROV1 Ovarian GSG IGROV1 Ovarian GSV CTAGSVS (1340) IGROV1 Ovarian SVTGSVG (1341) IGROV1 Ovarian GRV SPGRVAD (1342) IGROV1 Ovarian GRL IGROV1 Ovarian GPS DAVRGPS (1343) IGROV1 Ovarian GVS GAGLGVS (1344) IGROV1 Ovarian GVSGTVS (1345) IGROV1 Ovarian SGVSISC (1346) IGROV1 Ovarian RLS RRLSYHS (65) OVCAR-3 Ovarian (1347) RGV OVCAR-3 Ovarian RGS OVCAR-3 Ovarian RAV OVCAR-3 Ovarian RAS OVCAR-3 Ovarian GAG OVCAR-3 Ovarian AVS OVCAR-3 Ovarian LLS OVCAR-3 Ovarian LLR OVCAR-3 Ovarian LRV OVCAR-3 Ovarian LRS RREGLRS (10) OVCAR-3 Ovarian (1348) RVS ERVSAAV (1349) OVCAR-3 Ovarian RSS OVCAR-3 Ovarian AGS AGSMMEF (1350) OVCAR-3 Ovarian AGR OVCAR-3 Ovarian AGL OVCAR-3 Ovarian AGG OVCAR-3 Ovarian GVR OVCAR-3 Ovarian GVL RHGPGVL (1351) OVCAR-3 Ovarian GAV OVCAR-3 Ovarian GLV OVCAR-3 Ovarian GLR GLRRDNG (1352) OVCAR-3 Ovarian RREGLRS (10) OVCAR-3 Ovarian (1353) LVS OVCAR-3 Ovarian ARG OVCAR-3 Ovarian ASL OVCAR-3 Ovarian AAV ERVSAAV (1354) OVCAR-3 Ovarian AAS VAASVRE (1355) OVCAR-3 Ovarian GGS OVCAR-3 Ovarian GGR OVCAR-3 Ovarian GLG OVCAR-3 Ovarian GGL OVCAR-3 Ovarian GSS OVCAR-3 Ovarian GSG OVCAR-3 Ovarian GSV PWYDGSV (1356) OVCAR-3 Ovarian GRV GRVTLES (1357) OVCAR-3 Ovarian GRL OVCAR-3 Ovarian GPS OVCAR-3 Ovarian GVS OVCAR-3 Ovarian RLS GRLSRAP (1358) OVCAR-4 Ovarian SRLSYCN (1359) OVCAR-4 Ovarian RGV OVCAR-4 Ovarian RGS QARGSWL (1360) OVCAR-4 Ovarian FVPRGSY (1361) OVCAR-4 Ovarian RAV AALLRAV (1362) OVCAR-4 Ovarian RAS LAGRASE (1363) OVCAR-4 Ovarian GAG AAGAGWR (1364) OVCAR-4 Ovarian ADLGAGW (1365) OVCAR-4 Ovarian ADLGAGW (1366) OVCAR-4 Ovarian GGAGRGA (1367) OVCAR-4 Ovarian AVS DVWVAVS (1368) OVCAR-4 Ovarian LLS OVCAR-4 Ovarian LLR AALLRAV (1369) OVCAR-4 Ovarian LRV NLRVGAE (1370) OVCAR-4 Ovarian LRS NCYSLRS (1371) OVCAR-4 Ovarian RVS LAGSRVS (1372) OVCAR-4 Ovarian RSS OVCAR-4 Ovarian AGS SGPAGSF (1373) OVCAR-4 Ovarian LAGSRVS (1374) OVCAR-4 Ovarian AGR GGAGRGA (1375) OVCAR-4 Ovarian LAGRASE (1376) OVCAR-4 Ovarian VAGRLQM (1377) OVCAR-4 Ovarian AGL WGAGLDA (1378) OVCAR-4 Ovarian WGAGLDA (1379) OVCAR-4 Ovarian AGG AGRGAGG (1380) OVCAR-4 Ovarian GVR EAGVRLN (1381) OVCAR-4 Ovarian GVL OVCAR-4 Ovarian GAV MQLRGAV (1382) OVCAR-4 Ovarian GLV GGPGLVM (1383) OVCAR-4 Ovarian QGLVRGG (1384) OVCAR-4 Ovarian GLR PGLRGPA (1385) OVCAR-4 Ovarian PGLRGPA (1386) OVCAR-4 Ovarian LVS GRMLVSG (1387) OVCAR-4 Ovarian ARG ESARGAL (1388) OVCAR-4 Ovarian QARGSWL (1389) OVCAR-4 Ovarian ASL OVCAR-4 Ovarian AAV OVCAR-4 Ovarian AAS OVCAR-4 Ovarian GGS GGGSGGG (1390) OVCAR-4 Ovarian NNVGGSS (1391) OVCAR-4 Ovarian GGR GGRVLGQ (1392) OVCAR-4 Ovarian GGRVRGG (1393) OVCAR-4 Ovarian GGRVRGG (1394) OVCAR-4 Ovarian WYGGRGN (1395) OVCAR-4 Ovarian GLG CVGLGCH (1396) OVCAR-4 Ovarian GGL OVCAR-4 Ovarian GSS NNVGGSS (1397) OVCAR-4 Ovarian GSG FMTYGSG (1398) OVCAR-4 Ovarian GGGSGGG (1399) OVCAR-4 Ovarian WDQGSGY (1400) OVCAR-4 Ovarian GSV GSVLMRG (1401) OVCAR-4 Ovarian GRV GGRVLGQ (1402) OVCAR-4 Ovarian GGRVRGG (1403) OVCAR-4 Ovarian GGRVRGG (1404) OVCAR-4 Ovarian YMYHGRV (1405) OVCAR-4 Ovarian GRL GRLSRAP (1406) OVCAR-4 Ovarian VAGRLQM (1407) OVCAR-4 Ovarian APGRLGP (1408) OVCAR-4 Ovarian APGRLGP (1409) OVCAR-4 Ovarian GPS RDLAGPS (1410) OVCAR-4 Ovarian GVS OVCAR-4 Ovarian RLS RLSGAGD (1411) OVCAR-5 Ovarian RGV LQRGVAR (1412) OVCAR-5 Ovarian RGS OVCAR-5 Ovarian RAV RAVGRQL (1413) OVCAR-5 Ovarian SRAVIRL (1414) OVCAR-5 Ovarian RAS VRASSKR (1415) OVCAR-5 Ovarian GAG DGAGSLR (1416) OVCAR-5 Ovarian SVSGAGS (1417) OVCAR-5 Ovarian AVS OVCAR-5 Ovarian LLS TTLLSRQ (1418) OVCAR-5 Ovarian VAELLSM (1419) OVCAR-5 Ovarian LLR OVCAR-5 Ovarian LRV LPGRLRV (1420) OVCAR-5 Ovarian LRS LKAGLRS (1421) OVCAR-5 Ovarian RVS HRVSESV (1422) OVCAR-5 Ovarian RSS YYGERSS (1423) OVCAR-5 Ovarian AGS DGAGSLR (1424) OVCAR-5 Ovarian SVSGAGS (1425) OVCAR-5 Ovarian AGSVYSV (1426) OVCAR-5 Ovarian AGR OVCAR-5 Ovarian AGL SAGLLPS (1427) OVCAR-5 Ovarian LKAGLRS (1428) OVCAR-5 Ovarian AGG RRAGGSV (1429) OVCAR-5 Ovarian GVR SWAGVRF (1430) OVCAR-5 Ovarian GVL OVCAR-5 Ovarian GAV IYPGAVL (1431) OVCAR-5 Ovarian GLV OVCAR-5 Ovarian GLR LKAGLRS (1432) OVCAR-5 Ovarian LVS SLVSPRT (1433) OVCAR-5 Ovarian ARG OVCAR-5 Ovarian ASL OVCAR-5 Ovarian AAV HAAVEPS (1434) OVCAR-5 Ovarian TAAAVLL (1435) OVCAR-5 Ovarian AAS OVCAR-5 Ovarian GGS FHFGGSG (1436) OVCAR-5 Ovarian GEGGSGG (1437) OVCAR-5 Ovarian RRAGGSV (1438) OVCAR-5 Ovarian GGR ALPGGGR (1439) OVCAR-5 Ovarian YVGGRLR (1440) OVCAR-5 Ovarian GLG GKGMGLG (1441) OVCAR-5 Ovarian SLGLGGL (1442) OVCAR-5 Ovarian GGL DGGLNDC (1443) OVCAR-5 Ovarian LGGLGLS (1444) OVCAR-5 Ovarian GSS OVCAR-5 Ovarian GSG FHFGGSG (1445) OVCAR-5 Ovarian GEGGSGG (1446) OVCAR-5 Ovarian GSV RRAGGSV (1447) OVCAR-5 Ovarian SGAGSVS (1448) OVCAR-5 Ovarian AGSVYSV (1449) OVCAR-5 Ovarian GRV GRVTWRS (1450) OVCAR-5 Ovarian GRL LPGRLRV (1451) OVCAR-5 Ovarian YVGGRLR (1452) OVCAR-5 Ovarian GPS GPSSAVE (1453) OVCAR-5 Ovarian GVS OVCAR-5 Ovarian RLS RRLSYRE (28) OVCAR-8 Ovarian (1454) RGV OVCAR-8 Ovarian RGS OVCAR-8 Ovarian RAV HTRAVSE (1455) OVCAR-8 Ovarian NVSRAVG (1456) OVCAR-8 Ovarian RAS PRHRASQ (1457) OVCAR-8 Ovarian GAG LGAGMIA (1458) OVCAR-8 Ovarian AVS AVSLVVL (1459) OVCAR-8 Ovarian HTRAVSE (1460) OVCAR-8 Ovarian LLS OVCAR-8 Ovarian LLR OVCAR-8 Ovarian LRV ELGLRVP (1461) OVCAR-8 Ovarian LRS OVCAR-8 Ovarian RVS OVCAR-8 Ovarian RSS GRSSVSD (1462) OVCAR-8 Ovarian AGS YAGSGQL (2) OVCAR-8 Ovarian (1463) AGR AGRFGAR (1464) OVCAR-8 Ovarian AGL AIMGAGL (1465) OVCAR-8 Ovarian AGG OVCAR-8 Ovarian GVR THVGGVR (1466) OVCAR-8 Ovarian GVL GVLTRGN (1467) OVCAR-8 Ovarian GAV OVCAR-8 Ovarian GLV OVCAR-8 Ovarian GLR ELGLRVP (1468) OVCAR-8 Ovarian GLGLRLG (1469) OVCAR-8 Ovarian LVS IDLVSPG (1470) OVCAR-8 Ovarian ARG OVCAR-8 Ovarian ASL OVCAR-8 Ovarian AAV OVCAR-8 Ovarian AAS OVCAR-8 Ovarian GGS GGSTVPQ (1471) OVCAR-8 Ovarian GGR OVCAR-8 Ovarian GLG GLGLRLG (1472) OVCAR-8 Ovarian GGL TATGGLL (1473) OVCAR-8 Ovarian GSS GSNGSSH (3) OVCAR-8 Ovarian (1474) GSG LQGSGAY (2) OVCAR-8 Ovarian (1475) LQHLGSG (1476) OVCAR-8 Ovarian GSV OVCAR-8 Ovarian GRV OVCAR-8 Ovarian GRL OVCAR-8 Ovarian GPS GPSVLDI (1477) OVCAR-8 Ovarian GVS GATGVSS (1478) OVCAR-8 Ovarian RLS TRLSFRH (1479) SK-OV-3-3 Ovarian RGV FLRGVEL (1480) SK-OV-3-3 Ovarian RGS NSVRGSR (1481) SK-OV-3-3 Ovarian RAV NRAVLSA (1482) SK-OV-3-3 Ovarian RAS LIGRASM (1483) SK-OV-3-3 Ovarian GAG RVGAGAF (1484) SK-OV-3-3 Ovarian AVS WISAVSK (1485) SK-OV-3-3 Ovarian SAVSESP (1486) SK-OV-3-3 Ovarian LLS SK-OV-3-3 Ovarian LLR SK-OV-3-3 Ovarian LRV RVGTLRV(4) SK-OV-3-3 Ovarian (1487) LRS SK-OV-3-3 Ovarian RVS RVSGDGK (1488) SK-OV-3-3 Ovarian RSGRVSN (1489) SK-OV-3-3 Ovarian RVSNEAL (1490) SK-OV-3-3 Ovarian RVSSDPI (1491) SK-OV-3-3 Ovarian RSS VRSSGVL (1492) SK-OV-3-3 Ovarian AGS SGWFAGS (1493) SK-OV-3-3 Ovarian AGR SK-OV-3-3 Ovarian AGL AGLGLLD (1494) SK-OV-3-3 Ovarian SAAGLAR (1495) SK-OV-3-3 Ovarian AGG SK-OV-3-3 Ovarian GVR FAGAGVR (1496) SK-OV-3-3 Ovarian VRLTGVR (4) SK-OV-3-3 Ovarian (1497) GVL VRSSGVL (1498) SK-OV-3-3 Ovarian GAV RPWGAVA (1499) SK-OV-3-3 Ovarian GLV PVSDGLV (1500) SK-OV-3-3 Ovarian GLR NKGGLRQ (1501) SK-OV-3-3 Ovarian LVS GGFLLVS (1502) SK-OV-3-3 Ovarian LVPLVSG (1503) SK-OV-3-3 Ovarian ARG ARGGESA (1504) SK-OV-3-3 Ovarian MSARGIL (1505) SK-OV-3-3 Ovarian ASL ASLVARN (1506) SK-OV-3-3 Ovarian AAV RVEAAVP (1507) SK-OV-3-3 Ovarian AAS RALGAAS (1508) SK-OV-3-3 Ovarian GGS SK-OV-3-3 Ovarian GGR ASEGGRA (1509) SK-OV-3-3 Ovarian IGGRWVV (1510) SK-OV-3-3 Ovarian GLG AGLGLLD (1511) SK-OV-3-3 Ovarian GGL LGGLSER (1512) SK-OV-3-3 Ovarian NKGGLRQ (1513) SK-OV-3-3 Ovarian GSS LVGSSRV (1514) SK-OV-3-3 Ovarian YTGSSPS (1515) SK-OV-3-3 Ovarian GSG SK-OV-3-3 Ovarian GSV GSVLPVL (1516) SK-OV-3-3 Ovarian KGDGSVR (1517) SK-OV-3-3 Ovarian GSVSHRR (1518) SK-OV-3-3 Ovarian RLWGSVV (1519) SK-OV-3-3 Ovarian GRV MQGRVIV (1520) SK-OV-3-3 Ovarian RSGRVSN (1521) SK-OV-3-3 Ovarian GRL LEVGRLF (1522) SK-OV-3-3 Ovarian GPS SQFGPSF (3) SK-OV-3-3 Ovarian (1523) GVS ATLDGVS (1524) SK-OV-3-3 Ovarian RLS RLSWTVL (1525) PC3 Prostate RGV LRFRRGV (1526) PC3 Prostate RGS ARGRGSQ (1527) PC3 Prostate VLRGSTP (1528) PC3 Prostate RAV PC3 Prostate RAS ARLRASR (1529) PC3 Prostate GAG RIGAGHR (1530) PC3 Prostate AVS PC3 Prostate LLS WLLSSEI (1531) PC3 Prostate LLR PC3 Prostate LRV GGLRVGG (1532) PC3 Prostate GLRVYEP (1533) PC3 Prostate LRS YLRSAGM (1534) PC3 Prostate RVS RVSRAGG (1535) PC3 Prostate RSS PC3 Prostate AGS PC3 Prostate AGR AGRPGGY (1536) PC3 Prostate AGL YGALAGL (1537) PC3 Prostate AGG RVSRAGG (1538) PC3 Prostate SHTAGGG (1539) PC3 Prostate AGGVRDL (1540) PC3 Prostate RPAGGRT (1541) PC3 Prostate GVR GGVRLGG (1542) PC3 Prostate AGGVRDL (1543) PC3 Prostate GVL GVLGCDG (1544) PC3 Prostate GAV CGAVAEW (1545) PC3 Prostate GLV GDCGLVG (1546) PC3 Prostate GLR GGLRVGG (1547) PC3 Prostate GLRVYEP (1548) PC3 Prostate LVS PC3 Prostate ARG ARGRGSQ (1549) PC3 Prostate ASL PC3 Prostate AAV PC3 Prostate AAS PC3 Prostate GGS PC3 Prostate GGR GGRELKA (1550) PC3 Prostate GGGRRAL (1551) PC3 Prostate RPAGGRT (1552) PC3 Prostate GLG PC3 Prostate GGL GGLKVWR (1553) PC3 Prostate GGLRVGG (1554) PC3 Prostate GGLPVQM (1555) PC3 Prostate RQDGGLY (1556) PC3 Prostate GSS YATLGSS (1557) PC3 Prostate GSG SGSGCVF (1558) PC3 Prostate VSGSGTA (1559) PC3 Prostate GSV VGSVKAS (1560) PC3 Prostate ATGSGSV (1561) PC3 Prostate GRV PC3 Prostate GRL PTSGRLV (1562) PC3 Prostate GPS LACRGPS (1563) PC3 Prostate RGPSQVL (1564) PC3 Prostate GVS PC3 Prostate RLS TLGRLSS (1565) DU-145 Prostate RGV AGDRGVA (1566) DU-145 Prostate RGS DU-145 Prostate RAV LPRRAVF (1567) DU-145 Prostate RAS RASCVWR (6) DU-145 Prostate (1568) FSKMRAS (1569) DU-145 Prostate GAG DYVGAGT (1570) DU-145 Prostate AVS DU-145 Prostate LLS DU-145 Prostate LLR ARLLRGG (1571) DU-145 Prostate LLRSVGY (1572) DU-145 Prostate LRV DU-145 Prostate LRS HLRSGFS (1573) DU-145 Prostate LLRSVGY (1574) DU-145 Prostate RVS DU-145 Prostate RSS DU-145 Prostate AGS DU-145 Prostate AGR AGRPDGV (1575) DU-145 Prostate AGL DENRAGL (1576) DU-145 Prostate AGG AWAGGDM (1577) DU-145 Prostate LNAGGSG (1578) DU-145 Prostate GVR DU-145 Prostate GVL DU-145 Prostate GAV NMGAVGS (1579) DU-145 Prostate PIGAVMN (1580) DU-145 Prostate GLV LTGGLVF (1581) DU-145 Prostate CGEGLVV (1582) DU-145 Prostate GLR SDLGLRR (1583) DU-145 Prostate LVS HADVLVS (1584) DU-145 Prostate ARG FSNARGY (1585) DU-145 Prostate ASL DU-145 Prostate AAV AAVWWAA (1586) DU-145 Prostate AAS DU-145 Prostate GGS LNAGGSG (1587) DU-145 Prostate GGSAWWG (1588) DU-145 Prostate VYGWGGS (1589) DU-145 Prostate GGR GGRLLRA (1590) DU-145 Prostate LGGRTIS (1591) DU-145 Prostate GLG YLGLGGL (1592) DU-145 Prostate GGL SITRGGL (1593) DU-145 Prostate LTGGLVF (1594) DU-145 Prostate LGGLGLY (1595) DU-145 Prostate GSS GSSELSR (1596) DU-145 Prostate GSG GSGGANL (1597) DU-145 Prostate VDGSGDD (1598) DU-145 Prostate GSV RSLGSVG (1599) DU-145 Prostate GRV GRVKPGA (1600) DU-145 Prostate GRL GGRLLRA (1601) DU-145 Prostate GRLWYVA (1602) DU-145 Prostate TLGRLSS (1603) DU-145 Prostate GPS DU-145 Prostate GVS GVSGLSR (1604) DU-145 Prostate YGVSRLL (1605) DU-145 Prostate RLS SRLSYRA (1606) 786-0 Renal RGV IHRGVWG (1607) 786-0 Renal RGS YFRARGS (1608) 786-0 Renal RAV 786-0 Renal RAS 786-0 Renal GAG GAGRFPH (1609) 786-0 Renal SGAGAAF (1610) 786-0 Renal VDVGGAG (1611) 786-0 Renal AVS ASAGAVS (1612) 786-0 Renal LLS 786-0 Renal LLR 786-0 Renal LRV 786-0 Renal LRS ARYSLRS (1613) 786-0 Renal RLRSYVA (1614) 786-0 Renal SRKGLRS (1615) 786-0 Renal RVS SVTGRVS (1616) 786-0 Renal RSS 786-0 Renal AGS AGSAFWA (1617) 786-0 Renal DQQEAGS (1618) 786-0 Renal FAAGAGS (1619) 786-0 Renal AGR GAGRFPH (1620) 786-0 Renal AGL 786-0 Renal AGG GAGGVDV (1621) 786-0 Renal GVR 786-0 Renal GVL 786-0 Renal GAV ASAGAVS (1622) 786-0 Renal GLV RRDGLVE (1623) 786-0 Renal GLR SRKGLRS (1624) 786-0 Renal LVS GDATLVS (1625) 786-0 Renal GDATLVS (1626) 786-0 Renal ARG YFRARGS (1627) 786-0 Renal ASL 786-0 Renal AAV 786-0 Renal AAS 786-0 Renal GGS 786-0 Renal GGR 786-0 Renal GLG DRGLGMS (1628) 786-0 Renal GGL 786-0 Renal GSS 786-0 Renal GSG GSGYFIT (1629) 786-0 Renal GSV 786-0 Renal GRV SVTGRVS (1630) 786-0 Renal GRL 786-0 Renal GPS VGPSVHL (1631) 786-0 Renal GVS 786-0 Renal RLS A498 Renal RGV EGVRGVF (1632) A498 Renal GDRGVRG (1633) A498 Renal MRGVARK (1634) A498 Renal RGS A498 Renal RAV KRAVGRM (1635) A498 Renal RAS DRASSWA (1636) A498 Renal GAG LQGAGIH (1637) A498 Renal AVS A498 Renal LLS A498 Renal LLR WLLRGFG (1638) A498 Renal LRV A498 Renal LRS ASPPLRS (1639) A498 Renal RVS RVSSETF (1640) A498 Renal RSS A498 Renal AGS ARAGSTF (1641) A498 Renal AGR TFAGRSL (1642) A498 Renal AGL A498 Renal AGG YAAGGST (1643) A498 Renal GVR EGVRGVF (1644) A498 Renal GDRGVRG (1645) A498 Renal GVL PGVLREP (1646) A498 Renal GAV A498 Renal GLV A498 Renal GLR GLRDGVE (1647) A498 Renal LVS A498 Renal ARG FPARGED (1648) A498 Renal ASL MLGSASL (1649) A498 Renal AAV A498 Renal AAS A498 Renal GGS HGGSNDR (1650) A498 Renal YAAGGST (1651) A498 Renal GGR QGGRSGV (1652) A498 Renal WTVGGRV (1653) A498 Renal GLG A498 Renal GGL A498 Renal GSS VKGSSMR (1654) A498 Renal GSG A498 Renal GSV A498 Renal GRV FVGRVGE (1655) A498 Renal GRVGRDG (1656) A498 Renal SVSRGRV (1657) A498 Renal WTVGGRV (1658) A498 Renal GRL GFGRLLW (1659) A498 Renal GPS AAYWGPS (1660) A498 Renal GVS MDGVSTE (1661) A498 Renal VYWWGVS (1662) A498 Renal RLS RLSMASR (1663) ACHN Renal GRLSFGV (1664) ACHN Renal RGV GLSRGVL (1665) ACHN Renal RGS LRGSHVA (1666) ACHN Renal NMGRGSL (1667) ACHN Renal SVVRRGS (1668) ACHN Renal RAV ACHN Renal RAS ACHN Renal GAG VMGAGVQ (1669) ACHN Renal AVS ACHN Renal LLS ACHN Renal LLR PLLRQQL (1670) ACHN Renal LRV SNGLRVV (1671) ACHN Renal LRS LRSMAVM (1672) ACHN Renal VDLRSAF (1673) ACHN Renal RVS FRVSLGY (1674) ACHN Renal RSS RSSYAPP (1675) ACHN Renal AGS FPGSAGS (1676) ACHN Renal AGR FAGRAPR (1677) ACHN Renal AGL ACHN Renal AGG FIAGGVG (1678) ACHN Renal LIHAGGQ (1679) ACHN Renal RAGGGAP (1680) ACHN Renal TWHAGGI (1681) ACHN Renal GVR GVRSITL (1682) ACHN Renal GVL GLSRGVL (1683) ACHN Renal GAV RVVGAVL (1684) ACHN Renal GLV ACHN Renal GLR FGLRMSN (1685) ACHN Renal LGLRGWT (1686) ACHN Renal AFFMGLR (1687) ACHN Renal SNGLRVV (1688) ACHN Renal LVS ACHN Renal ARG ARGTMTG (1689) ACHN Renal RPARGAF (1690) ACHN Renal ASL ASLPMLH (1691) ACHN Renal AAV ACHN Renal AAS ACHN Renal GGS GGSVEGQ (1692) ACHN Renal GGR LGGRQES (1693) ACHN Renal NGGRVLS (1694) ACHN Renal GLG ACHN Renal GGL PIGGLFG (1695) ACHN Renal AECCGGL (1696) ACHN Renal SEQRGGL (1697) ACHN Renal GSS DRFGSSA (1698) ACHN Renal GSG GHGSGSR (1699) ACHN Renal GSV GGSVEGQ (1700) ACHN Renal GSVVSSW (1701) ACHN Renal GRV NGGRVLS (1702) ACHN Renal GRL GRLMPGG (1703) ACHN Renal TWGRLGL (1704) ACHN Renal AVHSGRL (1705) ACHN Renal GRLSFGV (1706) ACHN Renal GPS PQGPSSV (1707) ACHN Renal GVS ACHN Renal RLS AGWRLSQ (1708) CAIK-1 Renal RGV CAIK-1 Renal RGS RVDRGSL (1709) CAIK-1 Renal RAV RAVCEWD (1710) CAIK-1 Renal RAVERVA (1711) CAIK-1 Renal RAS AVFRASR (1712) CAIK-1 Renal GAG GAGSSVW (1713) CAIK-1 Renal GAGSSVW (1714) CAIK-1 Renal AVS CAIK-1 Renal LLS CAIK-1 Renal LLR WLLRSWS (1715) CAIK-1 Renal LRV RKEALRV (1716) CAIK-1 Renal RLRVSVR (1717) CAIK-1 Renal LRS LRPGLRS (1718) CAIK-1 Renal QRYHLRS (13) CAIK-1 Renal (1719) WLLRSWS (1720) CAIK-1 Renal RVS GRERVSH (2) CAIK-1 Renal (1721) RVSVRLR (1722) CAIK-1 Renal RSS CAIK-1 Renal AGS GAGSSVW (1723) CAIK-1 Renal GAGSSVW (1724) CAIK-1 Renal AGR CAIK-1 Renal AGL AGLWPWN (1725) CAIK-1 Renal AGG CAIK-1 Renal GVR GVRGGGD (1726) CAIK-1 Renal GVL CAIK-1 Renal GAV CAIK-1 Renal GLV GLVRRVV (1727) CAIK-1 Renal GLR LRPGLRS (1728) CAIK-1 Renal LVS CAIK-1 Renal ARG CAIK-1 Renal ASL CAIK-1 Renal AAV CAIK-1 Renal AAS WAHAASY (1729) CAIK-1 Renal GGS CAIK-1 Renal GGR DGGGRVG (1730) CAIK-1 Renal VGVMGGR (1731) CAIK-1 Renal VYGGRSE (1732) CAIK-1 Renal GLG TICLGLG (1733) CAIK-1 Renal GGL CAIK-1 Renal GSS GAGSSVW (1734) CAIK-1 Renal GAGSSVW (1735) CAIK-1 Renal GSG CAIK-1 Renal GSV DHVSGSV (1736) CAIK-1 Renal GRV DGGGRVG (1737) CAIK-1 Renal GRL GEGRLCG (1738) CAIK-1 Renal GVAIGRL (1739) CAIK-1 Renal GPS CAIK-1 Renal GVS FGVSQVH (1740) CAIK-1 Renal GGVSRMR (1741) CAIK-1 Renal GGL RXF393 Renal RLS GRIRLSF (1742) RXF393 Renal RGV RGVNYRS (1743) RXF393 Renal TEGTRGV (1744) RXF393 Renal RGS GYARGSG (1745) RXF393 Renal GVWLRGS (1746) RXF393 Renal RAV AARAVWG (1747) RXF393 Renal RAS RASYYGV (1748) RXF393 Renal GAG GAGVEYF (1749) RXF393 Renal AVS RXF393 Renal LLS LLLLSGS (1750) RXF393 Renal VLLSAGL (1751) RXF393 Renal LLR TGLLRLY (1752) RXF393 Renal LRV RXF393 Renal LRS LRSSLVS (1753) RXF393 Renal RVS RXF393 Renal RSS LRSSLVS (1754) RXF393 Renal PRSSGPM (1755) RXF393 Renal AGS RXF393 Renal AGR TAGRLEV (1756) RXF393 Renal AGL AGLEDLG (1757) RXF393 Renal MPAGLGV (1758) RXF393 Renal VLLSAGL (1759) RXF393 Renal AGG RXF393 Renal GVR GVRWNWS (1760) RXF393 Renal TRDGVRW (1761) RXF393 Renal GVL RXF393 Renal GAV RXF393 Renal GLV RAHGLVC (1762) RXF393 Renal GLR LGSSGLR (1763) RXF393 Renal LVS LLVSLSS (1764) RXF393 Renal LRSSLVS (1765) RXF393 Renal LVSTRWA (1766) RXF393 Renal LVSYSAV (1767) RXF393 Renal ARG GYARGSG (1768) RXF393 Renal ASL LGASLLV (1769) RXF393 Renal AAV GTGAAVF (1770) RXF393 Renal AAVGTAL (1771) RXF393 Renal AAS VSAASSV (1772) RXF393 Renal GGS RGGSPPV (1773) RXF393 Renal GGR VPPSGGR (1774) RXF393 Renal GLG GLGSCAP (1775) RXF393 Renal MPAGLGV (1776) RXF393 Renal GSS MPGSSRP (1777) RXF393 Renal GSSLSRP (1778) RXF393 Renal RLGSSGL (1779) RXF393 Renal GSG GYARGSG (1780) RXF393 Renal GSV RXF393 Renal GRV RXF393 Renal GRL SGRLWVG (1781) RXF393 Renal TAGRLEV (1782) RXF393 Renal GPS GPSFDAK (1783) RXF393 Renal GVS ACTGVSR (1784) RXF393 Renal RLS SN12C Renal RGV LGMGRGV (1785) SN12C Renal RGS MLGRGSV (1786) SN12C Renal RAV SN12C Renal RAS PRASSTG (1787) SN12C Renal RASCFWD (1788) SN12C Renal RASCFWD (1789) SN12C Renal GAG SN12C Renal AVS SN12C Renal LLS FLLLSHR (1790) SN12C Renal LLSVTSX (1791) SN12C Renal LLR PLLREVG (1792) SN12C Renal LRV LRVGHAG (1793) SN12C Renal NELRVCR (1794) SN12C Renal LRS MRYELRS (1795) SN12C Renal RVS RVSVWWA (1796) SN12C Renal FAQRRVS (1797) SN12C Renal RSS SHHRSSI (1798) SN12C Renal AGS CMAGSQD (1799) SN12C Renal RYGTAGS (1800) SN12C Renal SAGSHPA (1801) SN12C Renal PNSAGSV (1802) SN12C Renal AGR KMRIAGR (1803) SN12C Renal MERVAGR (1804) SN12C Renal AGL WAGLSRP (1805) SN12C Renal AGG SN12C Renal GVR GAHGVRL (1806) SN12C Renal RVPTGVR (1807) SN12C Renal GVL SN12C Renal GAV RGAVREM (1808) SN12C Renal GLV SN12C Renal GLR FDPGGLR (1809) SN12C Renal LVS ILSDLVS (1810) SN12C Renal ARG LLNPARG (1811) SN12C Renal ASL SN12C Renal AAV WWAAVPG (1812) SN12C Renal AAS KAASTED (1813) SN12C Renal SYMGAAS (1814) SN12C Renal GGS GGSIDCC (1815) SN12C Renal GPGGSKR (1816) SN12C Renal AFGGGSM (1817) SN12C Renal GGR PEGGRRP (1818) SN12C Renal GLG SN12C Renal GGL GGLEQDG (1819) SN12C Renal FDPGGLR (1820) SN12C Renal GSS LFGSSVS (1821) SN12C Renal WDGSSVS (1822) SN12C Renal GSG SN12C Renal GSV PNSAGSV (1823) SN12C Renal MLGRGSV (1824) SN12C Renal GRV SN12C Renal GRL TRRGRLD (1825) SN12C Renal GPS SN12C Renal GVS GVSISDG (1826) SN12C Renal GVSIYDL (1827) SN12C Renal RLS ARLSLEL (1828) TK-10 Renal RLRLSSW (1829) TK-10 Renal RRLSSIA (1830) TK-10 Renal SRLSYRT (1831) TK-10 Renal RGV TK-10 Renal RGS ARGSWRE (1832) TK-10 Renal RAV VRLRAVF (1833) TK-10 Renal RAS RASRIGL (1834) TK-10 Renal GAG GAGTSEG (1835) TK-10 Renal AVS TK-10 Renal LLS LLSTVWV (1836) TK-10 Renal ELRRLLS (1837) TK-10 Renal LLR LLRGLRP (1838) TK-10 Renal SLLRRLE (1839) TK-10 Renal LRV LRVSRGL (1840) TK-10 Renal TLGLRVP (1841) TK-10 Renal FVARLRV (1842) TK-10 Renal LRS GVYWLRS (1843) TK-10 Renal SFWWLRS (1844) TK-10 Renal TRYSLRS (1845) TK-10 Renal RVS LRVSRGL (1846) TK-10 Renal RSS RSSSGSG (1847) TK-10 Renal TRSSLTH (1848) TK-10 Renal TGRSSFW (1849) TK-10 Renal AGS TK-10 Renal AGR NAGRGAS (1850) TK-10 Renal AGL HAGLLVV (1851) TK-10 Renal AGG TK-10 Renal GVR HTYGVRF (1852) TK-10 Renal GVL TK-10 Renal GAV GAVRSVM (1853) TK-10 Renal VLVEGAV (1854) TK-10 Renal GLV TK-10 Renal GLR LLRGLRP (1855) TK-10 Renal TLGLRVP (1856) TK-10 Renal LVS TK-10 Renal ARG ARGSWRE (1857) TK-10 Renal ASL TK-10 Renal AAV GLWAAVL (1858) TK-10 Renal AAS GWTMAAS (1859) TK-10 Renal GGS LYMGGSH (1860) TK-10 Renal GGR GVGGRQS (1861) TK-10 Renal GLG RRGLGDA (1862) TK-10 Renal GGL TGGLHWY (1863) TK-10 Renal GSS GSGSSSR (1864) TK-10 Renal GSSTLQW (1865) TK-10 Renal GSG RSSSGSG (1866) TK-10 Renal GSV DELGSVQ (1867) TK-10 Renal GRV TK-10 Renal GRL GRLRPFS (1868) TK-10 Renal PRLGRLL (1869) TK-10 Renal GPS TK-10 Renal GVS VGVSQEW (1870) TK-10 Renal DGVSPLW (1871) TK-10 Renal RLS UO31 Renal RGV UO31 Renal RGS PRGSLFA (1872) UO31 Renal VIVRGSL (1873) UO31 Renal RAV GDRAVGL (1874) UO31 Renal VHKRAVL (1875) UO31 Renal RAS UO31 Renal GAG GGAGSRR (1876) UO31 Renal AVS UO31 Renal LLS RLETLLS (1877) UO31 Renal LLR LLRAGVR (1878) UO31 Renal LRV PAILRVR (1879) UO31 Renal GDLRVSV (1880) UO31 Renal LRS UO31 Renal RVS GDLRVSV (1881) UO31 Renal RSS UO31 Renal AGS GGAGSRR (1882) UO31 Renal AGSVTEQ (1883) UO31 Renal SSSLAGS (1884) UO31 Renal AGR RSWNAGR (1885) UO31 Renal AGL AGLPHRF (1886) UO31 Renal RNSRAGL (1887) UO31 Renal AGG RRSGAGG (1888) UO31 Renal AGGPSSY (1889) UO31 Renal GVR TGVRNSP (1890) UO31 Renal LLRAGVR (1891) UO31 Renal GVL UO31 Renal GAV UO31 Renal GLV UO31 Renal GLR UO31 Renal LVS ALVSTIL (1892) UO31 Renal ARG ARGRDEG (1893) UO31 Renal ASL ASLSVVI (1894) UO31 Renal AAV UO31 Renal AAS UO31 Renal GGS GGSRGYR (1895) UO31 Renal YWGGSVP (1896) UO31 Renal GGR GGRPVER (1897) UO31 Renal GGRSQEG (1898) UO31 Renal PGGGRGR (1899) UO31 Renal GLG UO31 Renal GGL UO31 Renal GSS FSLGSSP (1900) UO31 Renal GSG UO31 Renal GSV GSVFGTP (1901) UO31 Renal AGSVTEQ (1902) UO31 Renal YWGGSVP (1903) UO31 Renal GRV LSGRVIV (1904) UO31 Renal LSTPGRV (1905) UO31 Renal GRL UO31 Renal GPS AGGPSSY (1906) UO31 Renal UO31 Renal GVS UO31 Renal RLS MCF-7 Breast RGV MCF-7 Breast RGS RVMRGSL (1907) MCF-7 Breast RAV MCF-7 Breast RAS RASCVWA (1908) MCF-7 Breast GAG MCF-7 Breast AVS MCF-7 Breast LLS QLLSQVY (1909) MCF-7 Breast LLR MCF-7 Breast LRV MCF-7 Breast LRS ERYYLRS (1910) MCF-7 Breast GLVKLRS (1911) MCF-7 Breast RVS MCF-7 Breast RSS MCF-7 Breast AGS GRLAAGS (1912) MCF-7 Breast AGR MCF-7 Breast AGL MCF-7 Breast AGG MCF-7 Breast GVR MCF-7 Breast GVL MCF-7 Breast GAV MCF-7 Breast GLV GLVKLRS (1913) MCF-7 Breast GLR MCF-7 Breast LVS LWFELVS (1914) MCF-7 Breast ARG MCF-7 Breast ASL MCF-7 Breast AAV MCF-7 Breast AAS IGAASWF (1915) MCF-7 Breast GGS MCF-7 Breast GGR GGRRGTS (1916) MCF-7 Breast RDLGGRW (1917) MCF-7 Breast GLG MCF-7 Breast GGL WRGGLDR (1918) MCF-7 Breast GSS GRWTGSS (1919) MCF-7 Breast SYWVGSS (1920) MCF-7 Breast GSG MCF-7 Breast GSV MCF-7 Breast GRV MCF-7 Breast GRL GRLAAGS (1921) MCF-7 Breast GPS MCF-7 Breast GVS AKAGVSR (1922) MCF-7 Breast RLS LRLSGHD (1923) NCI/ADR-RES Breast RGV RGVGAKA (1924) NCI/ADR-RES Breast LRGVYVA (1925) NCI/ADR-RES Breast RGS NCI/ADR-RES Breast RAV NCI/ADR-RES Breast RAS NCI/ADR-RES Breast GAG NCI/ADR-RES Breast AVS GTPAVSY (1926) NCI/ADR-RES Breast LLS FLLSRSA (1927) NCI/ADR-RES Breast AGLLSDV (1928) NCI/ADR-RES Breast LLR NCI/ADR-RES Breast LRV LRVGXPG (1929) NCI/ADR-RES Breast LRS NCI/ADR-RES Breast RVS RVSGSPV (1930) NCI/ADR-RES Breast RSS RSSIDVG (1931) NCI/ADR-RES Breast AGS NCI/ADR-RES Breast AGR AGRRLRD (1932) NCI/ADR-RES Breast AGL WRLAGLG (1933) NCI/ADR-RES Breast PTVSAGL (1934) NCI/ADR-RES Breast AGLLSDV (1935) NCI/ADR-RES Breast AGG NCI/ADR-RES Breast GVR NCI/ADR-RES Breast GVL TLGVLVT (1936) NCI/ADR-RES Breast GAV NCI/ADR-RES Breast GLV NCI/ADR-RES Breast GLR NCI/ADR-RES Breast LVS GDRRLVS (1937) NCI/ADR-RES Breast LMLVSGK (1938) NCI/ADR-RES Breast ARG DVHARGD (1939) NCI/ADR-RES Breast ASL NCI/ADR-RES Breast AAV NCI/ADR-RES Breast AAS NCI/ADR-RES Breast GGS REGGSDT (1940) NCI/ADR-RES Breast GGR GGRRVVV (1941) NCI/ADR-RES Breast NVGGGRF (1942) NCI/ADR-RES Breast GLG GLGALRW (1943) NCI/ADR-RES Breast LGLSGLG (1944) NCI/ADR-RES Breast RGLGRPV (1945) NCI/ADR-RES Breast GGL NCI/ADR-RES Breast GSS GSSGLLA (1946) NCI/ADR-RES Breast LGSSSHI (1947) NCI/ADR-RES Breast GSG IGSGVGV (1948) NCI/ADR-RES Breast GSV KGSVLML (1949) NCI/ADR-RES Breast VPSGSVR (1950) NCI/ADR-RES Breast GRV NCI/ADR-RES Breast GRL GYLGRLP (1951) NCI/ADR-RES Breast AVYVGRL (1952) NCI/ADR-RES Breast GPS NCI/ADR-RES Breast GVS NCI/ADR-RES Breast RLS LGGRLSL (1953) MDA-MB-231 Breast RGV RGVGKTK (1954) MDA-MB-231 Breast LGGARGV (1955) MDA-MB-231 Breast HAWDRGV (1956) MDA-MB-231 Breast DWGSRGV (1957) MDA-MB-231 Breast RGS PYRRGSC (1958) MDA-MB-231 Breast ALNRGSR (3) MDA-MB-231 Breast (1959) RAV MDA-MB-231 Breast RAS MDA-MB-231 Breast GAG TFRGAGV (1960) MDA-MB-231 Breast AVS MDA-MB-231 Breast LLS LLSAARF (1961) MDA-MB-231 Breast LLR MDA-MB-231 Breast LRV MDA-MB-231 Breast LRS MRPGLRS (1962) MDA-MB-231 Breast RVS PRVSALV (1963) MDA-MB-231 Breast VRVSLNS (1964) MDA-MB-231 Breast RSS GRSSAGP (1965) MDA-MB-231 Breast AGS LHAGSSV (1966) MDA-MB-231 Breast VVMIAGS (1967) MDA-MB-231 Breast AGR DTPAGRL (1968) MDA-MB-231 Breast VGAGRFT (1969) MDA-MB-231 Breast AGL MDA-MB-231 Breast AGG AGGTDRT (1970) MDA-MB-231 Breast FISAGGW (1971) MDA-MB-231 Breast TIPAGGG (1972) MDA-MB-231 Breast VGRAGGL (1973) MDA-MB-231 Breast GVR MDA-MB-231 Breast GVL MDA-MB-231 Breast GAV MDA-MB-231 Breast GLV NPGLVWN (1974) MDA-MB-231 Breast LGLVHWV (1975) MDA-MB-231 Breast GLR MRPGLRS (1976) MDA-MB-231 Breast LVS MDA-MB-231 Breast ARG ARGNVRF (1977) MDA-MB-231 Breast LGGARGV (1978) MDA-MB-231 Breast ASL FRAASLL (1979) MDA-MB-231 Breast AAV MDA-MB-231 Breast AAS AASVGVA (1980) MDA-MB-231 Breast FRAASLL (1981) MDA-MB-231 Breast GGS PVFRGGS (1982) MDA-MB-231 Breast SGGSVGF (1983) MDA-MB-231 Breast VRANGGS (1984) MDA-MB-231 Breast GGR FHIWGGR (1985) MDA-MB-231 Breast LGGRLSL (1986) MDA-MB-231 Breast SGGRFVP (1987) MDA-MB-231 Breast GLG MDA-MB-231 Breast GGL GGGLPVD (1988) MDA-MB-231 Breast LSLRGGL (1989) MDA-MB-231 Breast VGRAGGL (1990) MDA-MB-231 Breast GSS ANGSSKK (1991) MDA-MB-231 Breast DFTLGSS (1992) MDA-MB-231 Breast LHAGSSV (1993) MDA-MB-231 Breast GSG MDA-MB-231 Breast GSV NSGSVVS (1994) MDA-MB-231 Breast SGGSVGF (1995) MDA-MB-231 Breast WSISGSV (1996) MDA-MB-231 Breast GRV MDA-MB-231 Breast GRL DTPAGRL (1997) MDA-MB-231 Breast LGGRLSL (1998) MDA-MB-231 Breast GPS MDA-MB-231 Breast GVS AVGVSAA (1999) MDA-MB-231 Breast SGVSNPG (2000) MDA-MB-231 Breast FGVSGGS (2001) MDA-MB-231 Breast ESATGVS (2002) MDA-MB-231 Breast AAIVGVS (2003) MDA-MB-231 Breast RLS MDA-MB-435-Breast RGV MDA-MB-435-Breast RGS LRSGRGS (2004) MDA-MB-435-Breast LRSGRGS (2005) MDA-MB-435-Breast RGRGSTL (2006) MDA-MB-435-Breast RGSPAAA (2007) MDA-MB-435-Breast SRGSYGS (2008) MDA-MB-435-Breast MDA-MB-435-Breast RAV MDA-MB-435-Breast RAS MDA-MB-435-Breast GAG GVGGGAG (2009) MDA-MB-435-Breast MDA-MB-435-Breast AVS MDA-MB-435-Breast LLS MDA-MB-435-Breast LLR MDA-MB-435-Breast LRV MDA-MB-435-Breast LRS LRSGRGS (49) MDA-MB-435-Breast (2010) RVS MDA-MB-435-Breast RSS MDA-MB-435-Breast AGS MDA-MB-435-Breast AGR MDA-MB-435-Breast AGL MDA-MB-435-Breast AGG AGGGGYH (2011) MDA-MB-435-Breast GAGGGVG (2012) MDA-MB-435-Breast YRALAGG (2) MDA-MB-435-Breast (2013) MDA-MB-435-Breast GVR MDA-MB-435-Breast GVL MDA-MB-435-Breast GAV MDA-MB-435-Breast GLV MDA-MB-435-Breast GLR MDA-MB-435-Breast LVS MDA-MB-435-Breast ARG MDA-MB-435-Breast ASL LYVDASL (2014) MDA-MB-435-Breast AAV MDA-MB-435-Breast AAS MDA-MB-435-Breast GGS MDA-MB-435-Breast GGR MDA-MB-435-Breast GLG MDA-MB-435-Breast GGL MDA-MB-435-Breast GSS MDA-MB-435-Breast GSG GEGSGSA (2015) MDA-MB-435-Breast GSV MDA-MB-435-Breast GRV MDA-MB-435-Breast GRL MDA-MB-435-Breast GPS MDA-MB-435-Breast GVS MDA-MB-435-Breast RLS BT-549 Breast RGV RVRGVLD (2016) BT-549 Breast SMRGVLS (2017) BT-549 Breast EAGPRGV (2018) BT-549 Breast RGS CRGSIGA (2019) BT-549 Breast PLQRGSG (2020) BT-549 Breast RGSRWSS (2021) BT-549 Breast RGSYVER (2022) BT-549 Breast RAV TYCDRAV (2023) BT-549 Breast RAS LGVRASP (2024) BT-549 Breast WRASPGM (2025) BT-549 Breast PRASDIL (2026) BT-549 Breast GAG RVGAGWP (2027) BT-549 Breast AVS BT-549 Breast LLS LLSRAQA (2028) BT-549 Breast LLR BT-549 Breast LRV SALRVGL (2029) BT-549 Breast VGLRVRF (2030) BT-549 Breast LRS YGLRSLV (2031) BT-549 Breast RVS TRVSGSG (2032) BT-549 Breast RSS VRRSSKF (2033) BT-549 Breast AGS BT-549 Breast AGR BT-549 Breast AGL TFAGLAQ (2034) BT-549 Breast AGG BT-549 Breast GVR LGVRASP (2035) BT-549 Breast LGVRLAS (2036) BT-549 Breast PWGAGVR (2037) BT-549 Breast GVL GVLTIGA (2038) BT-549 Breast RVRGVLD (2039) BT-549 Breast IGWGVLG (2040) BT-549 Breast SMRGVLS (2041) BT-549 Breast GAV GAVLTSC (2042) BT-549 Breast GLV GLVSTLI (2043) BT-549 Breast GLVGWGI (2044) BT-549 Breast GLR VGLRCSV (2045) BT-549 Breast VGLRVRF (2046) BT-549 Breast YGLRSLV (2047) BT-549 Breast LVS GLVSTLI (2048) BT-549 Breast ARG PRGMARG (2049) BT-549 Breast ASL BT-549 Breast AAV BT-549 Breast AAS BT-549 Breast GGS RGGSDEA (2050) BT-549 Breast GGR AEDSGGR (2051) BT-549 Breast GGRCGAE (2052) BT-549 Breast GLG BT-549 Breast GGL GGLMPRY (2053) BT-549 Breast GSS GSSVSLG (2054) BT-549 Breast GSG GSGRQLP (2055) BT-549 Breast RKGSGTA (2056) BT-549 Breast TRVSGSG (2057) BT-549 Breast GSV GSGSVRT (2058) BT-549 Breast GRV DDGRVHR (2059) BT-549 Breast DLVGRVR (2060) BT-549 Breast GRL WGRLEST (2061) BT-549 Breast GPS MGPSARW (2062) BT-549 Breast GVS ISGVSDD (2063) BT-549 Breast RLS GHSERLS (2064) T-47D Breast RGV ERGVFVY (2065) T-47D Breast TRGVIGG (2066) T-47D Breast RGS RGSFGLG (2067) T-47D Breast RAV PFHRRAV (2068) T-47D Breast RAS T-47D Breast GAG VGIGAGG (2) T-47D Breast (2069) AVS AVSLAWQ (2070) T-47D Breast FPAVSTE (2071) T-47D Breast LLS T-47D Breast LLR T-47D Breast LRV T-47D Breast LRS SGARLRS (2072) T-47D Breast RVS T-47D Breast RSS SHRSSTG (2073) T-47D Breast AGS SRLRAGS (2074) T-47D Breast AGR SFAGRIL (2075) T-47D Breast AGL T-47D Breast AGG RVAAGGL (2076) T-47D Breast VGIGAGG (2077) T-47D Breast VGIGAGG (2078) T-47D Breast GVR T-47D Breast GVL T-47D Breast GAV QKPGAVG (2079) T-47D Breast LGYYGAV (2080) T-47D Breast GLV LPLGLVS (2081) T-47D Breast LGLVFTR (2082) T-47D Breast GLR T-47D Breast LVS LPLGLVS (2083) T-47D Breast NSKPLVS (2084) T-47D Breast ARG TNRFARG (2085) T-47D Breast ASL LASLARP (2086) T-47D Breast AAV LGGAAVR (2087) T-47D Breast AAS AASPHPG (2088) T-47D Breast GGS LSKGGSE (2089) T-47D Breast GGR T-47D Breast GLG GLGRSVN (2090) T-47D Breast PGLGYAL (2091) T-47D Breast RGSFGLG (2092) T-47D Breast GGL GRDWGGL (2093) T-47D Breast RVAAGGL (2094) T-47D Breast GSS TVGSSLG (2095) T-47D Breast GSG T-47D Breast GSV T-47D Breast GRV GRVDPVD (2096) T-47D Breast GRL SLYRGRL (2097) T-47D Breast GPS T-47D Breast GVS VALGVSS (2098) T-47D Breast RLS VSVTRLS (2099) HS 578 T Breast RGV HS 578 T Breast RGS AGATRGS (2100) HS 578 T Breast RRGSVAE (2101) HS 578 T Breast FRFVRGS (2102) HS 578 T Breast TRGSGAG (2103) HS 578 T Breast RAV GARAVAP (2104) HS 578 T Breast RAS HS 578 T Breast GAG TRGSGAG (2105) HS 578 T Breast AVS EAVSGRR (2106) HS 578 T Breast LLS HS 578 T Breast LLR HS 578 T Breast LRV HS 578 T Breast LRS HS 578 T Breast RVS PVRRVSS (2107) HS 578 T Breast IRVSAVV (2108) HS 578 T Breast RSS HVRSSYA (2109) HS 578 T Breast RVRSSLA (2110) HS 578 T Breast AGS TAAGSSF (2111) HS 578 T Breast GAGSGRT (2112) HS 578 T Breast PAVAGST (2113) HS 578 T Breast AGR AGRHLDA (2114) HS 578 T Breast DRQLAGR (2115) HS 578 T Breast AGL HS 578 T Breast AGG HS 578 T Breast GVR LGVREVG (2116) HS 578 T Breast VAVGVRS (2117) HS 578 T Breast GVL SFGVLSG (2118) HS 578 T Breast GAV TSGAVAP (2119) HS 578 T Breast GLV HS 578 T Breast GLR GLREVQD (2120) HS 578 T Breast LVS SLVSERA (2121) HS 578 T Breast SVHLVSG (2122) HS 578 T Breast ARG TQVEARG (2123) HS 578 T Breast ASL HS 578 T Breast AAV HS 578 T Breast AAS HS 578 T Breast GGS HS 578 T Breast GGR GGRPTVT (2124) HS 578 T Breast VVGGRRT (2125) HS 578 T Breast GLG HS 578 T Breast GGL GVGGLSS (2126) HS 578 T Breast GSS TAAGSSF (2127) HS 578 T Breast GSG TRGSGAG (2128) HS 578 T Breast GSV RRGSVAE (2129) HS 578 T Breast GSVLHVS (2130) HS 578 T Breast GRV SGRVFRF (2131) HS 578 T Breast GRL HS 578 T Breast GPS HS 578 T Breast GVS WSATGVS (2132) HS 578 T Breast

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

-   Arap et al., Nature Med. 8, 121-127, 2002. -   Arap et al., Science, 279:377-80, 1998. -   Blower et al., Pharmacogenomics J., 2:259-271, 2002. -   Brown, Oncol. Res., 1997; 9:213-5, 1997. -   Giordano et al., Nat. Med., 7:1249-1253, 2001. -   Hafner et al., Clin. Chem., 50:490-499, 2004. -   Holbeck, Eur. J. Cancer, 40:785-793, 2004. -   Kolonin et al., Cancer Res., 66(1):1-7, 2006. -   Kolonin et al., Curr. Opin. Chem. Biol., 5:308-13, 2001. -   Kolonin et al., Nat. Med., 6:625-632, 2004. -   Kolonin et al., Proc. Natl. Acad. Sci. USA, 99:13055-13060, 2002. -   Maihle and Lafky, Trends Cell Biol., 12:160-161, 2002. -   Monks et al., J. Natl. Cancer Inst., 1991; 83:757-66, 1991. -   Myers et al., Electrophoresis, 18:647-653, 1997. -   Nishizuka et al., Proc. Natl. Acad. Sci. USA, 100:14229-14234, 2003. -   Pasqualini and Ruoslahti, Nature, 380:364-366, 1996. -   Pasqualini et al., Cancer Res., 60:722-727, 2000. -   Pasqualini et al., In: Phage Display, A Laboratory Manual, Barbas et     al. (Eds.), NY, Cold Spring Harbor Laboratory Press, 22:1-24, 2001. -   Rabow et al., J. Med. Chem., 45:818-40, 2002. -   Scherf et al., Nat. Genet., 24:236-244, 2000. -   Szakacs et al., Cancer Cell, 6:129-37, 2004. -   Vogelstein and Kinzler, Nat. Med., 10:789-799, 2004. -   Walloyist et al., Bioinformatics, 19:2212-24, 2003. -   Wallqvist et al., Mol. Cancer Ther., 1:311-20, 2002. -   Weinstein et al., Science, 275:343-349, 1997. -   Zaharevitz et al., J. Mol. Graph. Model, 30:297-303, 2002. -   Zurita et al., Cancer Res., 2004:64:435-9, 2004. 

1.-31. (canceled)
 32. A method of targeting a therapeutic agent or an imaging agent to an EphA5 receptor positive cancer cell in a subject, the method comprising administering to the subject a pharmaceutical composition comprising: a) the EphA5 cell targeting moiety; and b) the therapeutic agent or the imaging agent.
 33. The method of claim 32, wherein an EphA5 receptor is on a surface of the cancer cell.
 34. The method of claim 32, wherein the subject is a human.
 35. The method of claim 32, wherein the EphA5 cell targeting moiety comprises a peptide.
 36. The method of claim 35, wherein the peptide is covalently modified.
 37. The method of claim 35, wherein the peptide is cyclic.
 38. The method of claim 32, wherein the EphA5 cell targeting moiety comprises an antibody.
 39. The method of claim 38, wherein the antibody is specific for EphA5 receptor only when upregulated on a surface of the cancer cell.
 40. The method of claim 32, wherein the therapeutic agent or the imaging agent comprises a radioisotope.
 41. The method of claim 40,wherein the radioisotope is ²¹³Bi, ¹⁰³Pd, ¹³³Xe, ¹³¹I, ⁶⁸Ge, ⁵⁷Co, ⁶⁵Zn, ⁸⁵Sr, ³²P, ³⁵S, ⁹⁰Y, ¹⁵³Sm, ¹⁵³Gd, ¹⁶⁹Yb, ⁵¹Cr, ⁵⁴Mn, ⁷⁵Se, ¹¹³Sn, ¹¹⁷Sn, ¹⁸⁶Re, ¹⁶⁶Ho or ¹⁸⁸Re.
 42. The method of claim 32, wherein the therapeutic agent is a polypeptide capable of inducing cell death in the cell.
 43. The method of claim 32, wherein the therapeutic agent is an immunotherapeutic agent.
 44. The method of claim 32, Wherein the therapeutic agent is a chemotherapeutic agent.
 45. The method of claim 32, wherein the EphA5 cell targeting moiety is directly coupled to the therapeutic agent or the imaging agent.
 46. A method of treating an EphA5 receptor positive cancer cell in a subject, the method comprising administering a pharmaceutical composition comprising: a) an EphA5 cell targeting moiety; and b) a therapeutic agent or an imaging agent, to the subject.
 47. The method of claim 46, wherein an EphA5 receptor is on a surface of the cancer cell.
 48. The method of claim 46, wherein the subject is a human.
 49. The method of claim 46, wherein the EphA5 cell targeting moiety comprises a peptide.
 50. The method of claim 49, wherein the peptide is covalently modified.
 51. The method of claim 50, wherein the peptide is cyclic.
 52. The method of claim 46, wherein the EphA5 cell targeting moiety comprises an antibody.
 53. The method of claim 52, wherein the antibody is specific for an EphA5 receptor only when upregulated on a surface of the cancer cell.
 54. The method of claim 46, wherein the therapeutic agent or imaging agent comprises a radioisotope.
 55. The method of claim 54,wherein the radioisotope is ²¹³Bi, ¹⁰³Pd, ¹³³Xe, ¹³¹I, ⁶⁸Ge, ⁵⁷Co, ⁶⁵Zn, ⁸⁵Sr, ³²P, ³⁵S, ⁹⁰Y, ¹⁵³Sm, ¹⁵³Gd, ¹⁶⁹Yb, ⁵¹Cr, ⁵⁴Mn, ⁷⁵Se, ¹¹³Sn, ¹¹⁷Sn, ¹⁸⁶Re, ¹⁶⁶Ho or ¹⁸⁸Re.
 56. The method of claim 46, wherein the therapeutic agent is a polypeptide capable of inducing cell death in the cell.
 57. The method of claim 46, wherein the therapeutic agent is an immunotherapeutic agent.
 58. The method of claim 46, wherein the therapeutic agent is a chemotherapeutic agent.
 59. The method of claim 46, wherein the EphA5 cell targeting moiety is directly coupled to the therapeutic agent or the imaging agent. 